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                                                          Abstract 
A training set of eleven known anthracyclines were picked from literature and  
some of their physiochemical parameters were calculated using semi-
empirical quantum mechanical methods and correlated with their reported 
experimental biological activity data. These are the ID50 values in vitro of the 
model anthracyclines against L1210 leukemia and two human colon tumour 
cell lines (Colon 4 and HT 29). Extensive statistical correlations between the 
physiochemical parameters (total energy, heat of formation, dipole moment 
and molecular refractivity) and ID50 values were executed to yield about four 
hundred tables of paired data. The tables which give the highest r-values were 
chosen for further treatment. Thus two tables for each cell line were obtained, 
one represents one hour in vitro incubation and the other represents continuous 
incubation versus one of the calculated physiochemical parameters. Total 
energy parameters as calculated by AM1 and PM3 (used as such or 
transformed into their reciprocals) were found to give the highest linear 
correlation coefficients. Upon establishing a correlation between the 
physiochemical parameters and biological response (ID50), mathematical 
formulas were derived and used to calculate the anticipated biological 
responses of a designed set of hypothetical aza-analogue of the training set. 
This designed set contains three groups of aza-analogues of daunorubicin (15 
compounds), aclarubicin (5 compounds) and rhodomycin (27 compounds).   
Physiochemical parameters of these aza-analogues were likewise calculated 
and used in aforementioned mathematical model to compute their biological 
activity data.  Upon scrutiny, the calculated ID50 values show very explicit and 
orderly trends which correlate well with calculated log P values of the 
designed set. The present QSAR model was found to be sensitive to the 
expected active cites in the designed set that are similar to those of the training 
set. Our set of designed anthracycline aza-analogues shows two uniform 
activity profile; one for both incubations against Colon 4 and the other for 
both incubation against HT 29 cell lines while L1210 cell line partitioned 
between the two activity profile with one hour incubation mode lining up with 
Colon 4  and continuous incubation mode with HT 29. It also reveals that 
activity is directly proportional to lipophilicity for aza-daunorubicin and aza-
rhodomycin groups while aza-aclarubicins exhibits the reverse behaviour. The 
most important outcome of this in silico model is the indication that the 2-N 
aza-analogues are generally more active than 1-N aza-analogue, a well-known 
behavior for aza-anthracenediones and aza-anthrapyrazoles hitherto unknown 
for anthracyclines. 
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  ﺤﺙﻤﻠﺨﺹ ﺍﻟﺒ
ﻴﻬﺩﻑ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﺇﻟﻰ ﺩﺭﺍﺴﺔ ﺘﺄﺜﻴﺭ ﺇﺩﺨﺎل ﺫﺭﺓ ﺍﻟﻨﺎﻴﺘﺭﻭﺠﻴﻥ ﻓـﻲ ﺍﻟﻬﻴﻜـل ﺍﻟﻜﺭﺒـﻭﻨﻲ ﺍﻟﺤﻠﻘـﻰ 
ﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺴﺭﻁﺎﻥ ﻤﻥ ﻁﺎﺌﻔﺔ ﺍﻻﻨﺜﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻁﺭﻴﻘـﻪ ﺍﻟﻌﻼﺌـﻕ ﺍﻟﻜﻤﻴـﻪ ﻟﻠﺘﺭﻜﻴـﺏ 
ﻋﻠﻴﻪ ﻓﻘﺩ ﺘﻡ ﺍﻨﺘﺨﺎﺏ ﻁﻘﻡ ﺘﺩﺭﻴﺏ ﻤﻜﻭﻥ ﻤﻥ ﺍﺤﺩ ﻋﺸﺭ ﻤﺭﻜﺒﺎﹰ ﻤـﻥ ﻫـﺫﻩ ( RASQ)ﻭﺍﻟﻨﺸﺎﻁﻴﺔ 
  1ﺭﻭﺒﺴﻴﻥ ، ﺩﻜﺴﻭﺭﻭﺒﺴﻴﻥ ، ﺒﻴﺭﺍﺭﻭﺒﺴﻴﻥ ، ﺍﻜﻼﺭﻭﺒﺴﻴﻥ ، ﺭﻭﺩﻭﻤﺎﻴﺴﻴﻥ ﺩﻭﻨﻭ:  ﺍﻟﻁﺎﺌﻔﺔ ﺘﺸﻤل 
 - ﻫﻴﺩﺭﻭﻜـﺴﻰ -1 ، S ، ﺴﺎﻴﺘﻭﺭﺩﻴﻥ D ، ﺴﺎﻴﺘﻭﺭﻭﺩﻴﻥ  A ، ﺴﺎﻴﺘﻭﺭﻭﺩﻴﻥ  II، ﺭﻭﺩﻭﻤﺎﻴﺴﻴﻥ 
 ﻭﺘﻡ ﺍﻗﺘﺒﺎﺱ ﺒﻴﺎﻨﺎﺕ ﺍﻟﻨﺸﺎﻁ ﺍﻟﺤﻴﻭﻯ ﻟﻬﺎ ﻤﻥ ﺍﻻﺩﺒﻴﺎﺕ ﻓﻰ ﺸﻜل Y+X ﻭﺴﺎﻴﺘﻭﺭﺩﻴﻥ Sﺴﺎﻴﺘﻭﺭﺩﻴﻥ 
 ﻟﺜﻼﺙ ﺨﻁﻭﻁ ﻤﻥ ﺍﻟﺨﻼﻴـﺎ ﺍﻟـﺴﺭﻁﺎﻨﻴﺔ ﻭﻫـﻰ  ) 05D1(ﻤﻥ ﺍﻟﻌﻨﺎﺼﺭ % 05ﺠﺭﻋﺔ ﺍﻟﻤﻨﻊ ل 
 ﻭ 4NOLOC ﻨﻭﻋﻴﻥ ﻤﻥ ﺨﻼﻴﺎ ﺴـﺭﻁﺎﻥ ﺍﻟﻘﻭﻟـﻭﻥ ﻫـﻰ  ﻭ 0121Lﺘﺤﺩﻴﺩﺍﹰ ﺨﻼﻴﺎ ﺍﻟﻠﻭﻜﻴﻤﻴﺎ 
 92TH
ﺤﺴﺒﺕ ﺒﻌﺽ ﺍﻟﺜﻭﺍﺒﺕ ﺍﻟﻔﻴﺯﻴﻭﻜﻴﻤﻴﺎﺌﻴﻪ ﻟﻁﻘﻡ ﺍﻟﺘﺩﺭﻴﺏ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻁـﺭﻕ ﻤﻴﻜﺎﻨﻴﻜﻴـﺎ ﺍﻟﻜـﻡ ﺸـﺒﻪ 
 ﻭﺘﻭﺴـﻴﻁ 4 BALSUGRAﺍﻟﺘﺠﺭﻴﺒﻴﺔ ﺒﻌﺩ ﺘﺼﻤﻴﻡ ﺍﻟﺠﺯﺌﻴﺎﺕ ﺍﻟﻤﻜﻭﻨﺔ ﻟﻪ ﺒﺎﺴـﺘﺨﺩﺍﻡ ﺒﺭﻨـﺎﻤﺞ 
ﺍﻟﻰ ﻫﺫﺍ . ﺍﻟﻬﻨﺩﺴﺔ ﺍﻟﻔﺭﺍﻏﻴﺔ ﻟﻬﺎ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻁﺭﻕ ﺍﻟﻤﻴﻜﺎﻨﻴﻜﻴﺎ ﺍﻟﺠﺯﻴﺌﻴﺔ ﺍﻟﻤﻀﻤﻨﻪ ﻓﻲ ﻨﻔﺱ ﺍﻟﺒﺭﻨﺎﻤﺞ 
ﺍﻟﻁﺎﻗﺔ ﺍﻟﻜﻠﻴﺔ ، ﺤﺭﺍﺭﺓ ﺍﻟﺘﻜﻭﻴﻥ ، ﻋـﺯﻡ ﺜﻨـﺎﺌﻲ : ﻓﻘﺩ ﺘﻡ ﺤﺴﺎﺏ ﺍﻟﻤﺤﺩﺩﺍﺕ ﺍﻟﻔﻴﺯﻴﻭﻜﻴﻤﺎﺌﻴﺔ ﺍﻻﺘﻴﻪ 
 ﺍﻟﻤﺭﻜﺒـﺎﺕ ﻜﻤﺎ ﺘﻡ ﺤﺴﺎﺏ ﺍﻻﻨﻜﺴﺎﺭﻴﻪ ﺍﻟﺠﺯﺌﻴﺔ ﻟـﻨﻔﺱ . ﺍﻟﻘﻁﺏ ﻟﻜل ﻤﻥ ﻤﺭﻜﺒﺎﺕ ﻁﻘﻡ ﺍﻟﺘﺩﺭﻴﺏ 
ﺃﺠﺭﻯ ﺍﻟﺭﺒﻁ ﺍﻻﺤﺼﺎﺌﻰ ﻟﻬﺫﻩ ﺍﻟﻤﺤﺩﺩﺍﺕ ﻤﻊ ﺒﻴﺎﻨﺎﺕ ﺍﻟﻨﺸﺎﻁ  . BAL-I/DCAﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺭﻨﺎﻤﺞ 
ﺍﻟﺤﻴﻭﻯ ﻟﻜل ﻤﺭﻜﺒﺎﺕ ﻁﻘﻡ ﺍﻟﺘﺩﺭﻴﺏ ﻟﻨﻭﻋﻴﻥ ﻤﻥ ﺍﻟﺤﻀﻥ ﻓﻰ ﺍﻟﺯﺠﺎﺝ ﻟﻜل ﻤﻥ ﺨﻁـﻭﻁ ﺍﻟﺨﻼﻴـﺎ 
ﻭﺒـﺫﺍ ﺘـﻡ ( ﻟﻤـﺩﺓ ﺍﺴـﺒﻭﻉ ) ﺍﺤﺩﻫﻤﺎ ﺍﻟﺤﻀﻥ ﻟﻤﺩﺓ ﺴﺎﻋﺔ ﻭﺍﻻﺨﺭ ﺍﻟﺤﻀﻥ ﺍﻟﻤﺴﺘﻤﺭ : ﺍﻟﺜﻼﺙ 
ﺘﻡ ﺍﺨﺘﻴﺎﺭ ﺠﺩﻭﻟﻴﻥ ﻟﻜل ﺨﻁ ﻤـﻥ ﺨﻁـﻭﻁ ﺍﻟﺨﻼﻴـﺎ .  ﻤﻥ ﺍﺭﺒﻌﻤﺎﺌﺔ ﺠﺩﻭل ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﺍﻜﺜﺭ 
ﺍﺤﺩﻫﻤﺎ ﻴﻤﺜل ﺍﻟﺤﻀﻥ ﻟﻤﺩﺓ ﺍﻟﺴﺎﻋﺔ ﻭﺍﻵﺨﺭ ﻴﻤﺜل ﺍﻟﺤﻀﻥ ﺍﻟﻤﺴﺘﻤﺭ ، ﻓﻭﺠـﺩ ﺍﻥ ﺍﻟﻁﺎﻗـﺔ ﺍﻟﻜﻠﻴـﺔ 
ﺘﻌﻁـﻰ (ﺍﻤﺎ ﺒﺼﻭﺭﺘﻬﺎ ﺍﻻﺼﻠﻴﺔ ﺍﻭ ﻤﺤﻭﻟﺔ ﺍﻟﻰ ﻤﻘﻠﻭﺒﻬـﺎ  )1MA ﻭ  3MPﺍﻟﻤﺤﺴﻭﺒﺔ ﺒﻁﺭﻴﻘﺔ 
ﻭل ﺍﻟﺴﺕ ﻓﻰ ﺍﻴﺠﺎﺩ ﻤﻌﺎﺩﻻﺕ ﺭﻴﺎﻀﻴﺔ ﺘﺭﺒﻁ ﻤﺎﺒﻴﻥ ﺘﻡ ﺍﺴﺘﺨﺩﺍﻡ ﻫﺫﻩ ﺍﻟﺠﺩﺍ . ﺍﻋﻠﻰ ﻤﻌﺎﻤﻼﺕ ﺍﺭﺘﺒﺎﻁ 
ﻭﺍﺴﺘﺨﺩﻤﺕ ﻫـﺫﻩ  . 7 BALTAMﺍﻟﻨﺸﺎﻁ ﺍﻟﺤﻴﻭﻱ ﻭﺍﻟﻤﺤﺩﺩ ﺍﻟﻔﻴﺯﻴﻭﻜﻴﻤﻴﺎﺌﻰ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺭﻨﺎﻤﺞ 
ﺍﻟﻤﻌﺎﺩﻻﺕ ﻓﻰ ﺍﻴﺠﺎﺩ ﺍﻟﻨﺸﺎﻁ ﺍﻟﺤﻴﻭﻯ ﻟﻁﻘﻡ ﺘﻡ ﺘﺼﻤﻴﻤﻪ ﻟﻘﺭﺍﺌﻥ ﺍﻻﻨﺜﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﺍﻟﺤﺎﻭﻴﺔ ﻋﻠـﻰ ﺫﺭﺓ 
) ﻤﺭﻜﺒﺎﹰ ﻤﻥ ﻗﺭﺍﺌﻥ ﺍﻟﺩﻭﻨﻭﺭﻭﺒـﺴﻴﻥ  51:  ﻤﺭﻜﺒﺎﹰ ﻋﻠﻰ ﺍﻟﺘﻔﺼﻴل ﺍﻻﺘﻰ 74ﻨﺎﻴﺘﺭﺠﻴﻥ ﻤﻜﻭﻥ ﻤﻥ 
 ﻤﻥ ﻗﺭﺍﺌﻥ ﺍﻟﺭﻭﺩﻭﻤﺎﻴﺴﻴﻥ 12 ﻤﻥ ﻗﺭﺍﺌﻥ ﺍﻻﻜﻼﺭﻭﺒﺴﻴﻥ ، ﻭ 5،( ﺍﻟﺩﻭﻜﺴﻭﺭﻭﺒﺴﻴﻥ ﻭﺍﻟﺒﺭﺍﺭﻭﺒﺴﻴﻥ 
 ﻤﺭﻜﺒﺎﹰ ﺒﻨﻔﺱ ﺍﻟﻁﺭﻴﻘﺔ ﺍﻟﺘﻰ ﺍﺴﺘﺨﺩﻤﻨﺎﻫﺎ ﻓﻰ ﻁﻘـﻡ ﺍﻟﺘـﺩﺭﻴﺏ 74ﺼﻤﻡ ﻫﺫﺍ ﺍﻟﻁﻘﻡ ﺍﻟﻤﻜﻭﻥ ﻤﻥ . 
iiv 
ﺎﻴﻜﻠﻴﻥ ﻤـﻊ ﺍﻻﺤﺘﻔـﺎﻅ ﻭﺫﻟﻙ ﺒﻨﻘل ﺫﺭﺓ ﺍﻟﻨﺎﺘﺭﻭﺠﻴﻥ ﻋﻠﻰ ﻁﻭل ﺍﻟﻬﻴﻜل ﺍﻟﺤﻠﻘﻰ ﺍﻟﺭﺒﺎﻋﻰ ﻟﻼﻨﺘﺭﺍﺴ 
 ﺍﻟﺫﻯ ﺍﺸﺘﻕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻁﻘﻡ ﺍﻟﺘـﺩﺭﻴﺏ -ﻭﺒﺫﺍ ﺴﻴﺸﻌﺭ ﺍﻟﻨﻤﻭﺫﺝ ﺍﻟﺭﻴﺎﻀﻰ . ﺒﺎﻟﺯﻤﺭﺍﻟﻭﻅﻴﻔﺔ ﻜﻤﺎ ﻫﻰ 
 ﺒﻬﺫﺍ ﺍﻟﺘﻌﺩﻴل ﻓﻰ ﺍﻯ ﻤﺭﻜﺏ ﻋﻠﻰ ﺍﻨﻪ ﺘﺩﺭﺝ ﻋﺎﺩﻯ ﻗﺩ ﻴﺤﺩﺙ ﺒﺎﻻﻨﺘﻘﺎل ﻤﻥ ﻤﺭﻜﺏ ﺍﻟـﻰ ﺁﺨـﺭ –
 ﺍﻟﺴﺕ ﺘﻡ ﻓﻰ ﺍﻟﻤﻌﺎﺩﻻﺕ ﺍﻟﺭﻴﺎﻀﻴﺔ ( ﻤﻘﻠﻭﺒﻬﺎ )ﻭﺒﻭﻀﻊ ﻗﻴﻡ ﺍﻟﻁﺎﻗﺔ ﺍﻟﻜﻠﻴﻪ ﺍﻭ . ﻀﻤﻥ ﻁﻘﻡ ﺍﻟﺘﺩﺭﻴﺏ 
 ﻟﻜل ﻤﻥ ﺍﻟﻤﺭﻜﺒﺎﺕ ﺍﻟﻤﺼﻤﻤﺔ ﻟﻨﻭﻋﻰ ﺍﻟﺤﻀﻥ )05DI(ﺤﺴﺎﺏ ﻗﻴﻡ ﺠﺭﻋﺔ ﺍﻟﻤﻨﻊ ﻟﻨﺼﻑ ﺍﻟﻌﻨﺎﺼﺭ 
ﻓﻰ ﺍﻟﺯﺠﺎﺝ ﻟﻠﺨﻁﻭﻁ ﺍﻟﺨﻠﻭﻴﻪ ﺍﻟﺜﻼﺙ ﻭ ﺒﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ ﺍﻟﺘﻰ ﺘﻡ ﺍﻟﺤﺼﻭل ﻋﻠﻴﻬﺎ ﻭﺘﻤﺜﻴﻠﻬـﺎ ﺒﻴﺎﻨـﺎﹰ 
ﻤـﺎﺀ ﺍﻟﻤﺤـﺴﻭﺏ ﺒﺎﺴـﺘﺨﺩﺍﻡ / ﻤﻌﺎﻤل ﺍﻟﺘﺠـﺯﺅ ﻟﻨﻅـﺎﻡ ﺍﻭﻜﺘـﺎﻨﻭل  )Pﻭﻨﺴﺒﻬﺎ ﺍﻟﻰ ﻟﻭﻏﺭﻴﺜﻡ 
 ﻋـﻥ ﺍﺩﺨـﺎل ﺫﺭﺓ – ﻓﻰ ﺘﻘـﺩﻴﺭﻨﺎ – ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﻨﺘﺎﺌﺞ ﻓﻰ ﻏﺎﻴﺔ ﺍﻻﻫﻤﻴﺔ ﺘﻡ ( BALDCA
  : ﺍﻟﻨﺎﺘﺭﻭﺠﻴﻥ ﻓﻰ ﻫﻴﻜل ﺍﻻﻨﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﺘﺘﻤﺜل ﻓﻰ ﺍﻷﺘﻰ 
ﻨﻘل ﻤﺎ ﺃﻜﺘﺸﻑ ﻓﻰ ﻤﺭﻜﺒﺎﺕ ﺃﺯﻭﺍﻨﺜﺭﺍﺴﻴﻥ ﺩﺍﻴﻭﻥ ﻭﺃﺯﻭﺍﻨﺜﺭﺒـﺎﻴﺭﺍﺯﻭل ﻤـﻥ ﺍﻥ ﺍﺒـﺩﺍل  -1
ﺫﺍ  ﻨﻘل ﻫ  ـ- 1 ﻴﻌﻁﻰ ﻤﺭﻜﺒﺎﺕ ﺍﻜﺜﺭ ﻨﺸﺎﻁﺎﹰ ﻤﻥ ﺍﺒﺩﺍﻟﻪ ﻓﻰ ﻤﻭﻗﻊ 2ﺍﻟﻨﺎﺘﺭﻭﺠﻴﻥ ﻓﻰ ﻤﻭﻗﻊ 
  ﺍﺫﺍ ﺍﻥ ﺃﻨﻤﻭﺫﺠﻨﺎ ﻫﺫﺍ ﻴﺅﻴـﺩ ﻫـﺫﻩ ﺍﻟﻨﻅﺭﻴـﺔ -ﺍﻻﻜﺘﺸﺎﻑ ﺍﻟﻰ ﻤﺭﻜﺒﺎﺕ ﺍﻻﻨﺜﺭﺍﺴﺎﻴﻜﻠﻴﻥ 
  .ﺒﺼﻭﺭﺓ ﻤﻁﺭﺩﺓ
ﻓﻰ ﺍﻟﺘﺎﺜﻴﺭ ﻋﻠﻰ ﻨﺸﺎﻁ ﻤﺭﻜﺒﺎﺕ (  ﻟﻴﺒﻭﻓﻴﻠﻴﺎ –ﻤﺤﺒﺔ ﺍﻟﺩﻫﻭﻥ ) ﺍﻫﻤﻴﺔ ﺍﻟﺫﻭﺒﺎﻨﻴﺔ ﻓﻰ ﺍﻟﺩﻫﻭﻥ  -2
ﺍﻻﺯﻭﺍﻨﺜﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﺍﺫﺍ ﺍﻥ ﺍﺭﺘﺒﺎﻁﺎﹰ ﺍﺤﺼﺎﺌﻴﺎﹰ ﻋﺎﻟﻴﺎﹰ ﻗﺩ ﺘﻡ ﺍﻴﺠﺎﺩﻩ ﻤﺎﺒﻴﻥ ﺍﻟﻨـﺸﺎﻁ ﺍﻟﺤﻴـﻭﻯ 
 (ﺘﻨﺎﺴﺏ ﻁﺭﺩﻯ  ) Pﻟﻭﻏﺭﻴﺜﻡ ﻭ
 ﻭﺍﻻﺨﺭﻯ ﺘﻌﻤل ﻋﺒﺭ 4 NOLOC ﻭﺠﻭﺩ ﻤﻜﺎﻨﻴﻜﻴﺘﺎﻥ ﻟﻠﻨﺸﺎﻁ ﺍﺤﺩﻫﻤﺎ ﺘﻌﻤل ﻋﺒﺭ ﺨﻼﻴﺎ  -3
ﻓﻴﻨـﺘﻅﻡ :  ﻋﻠـﻰ ﺍﻟﻤﻴﻜـﺎﻨﻴﻜﻴﺘﻥ 0121L ﻟﻨﻭﻋﻲ ﺍﻟﺤﻀﻥ  ﺒﻴﻨﻤﺎ ﺘﺘﻭﺯﻉ ﺨﻼﻴﺎ 92 TH
 ﺒﻴﻨﻤﺎ ﻴﻨﺘﻅﻡ ﺍﻟﺤﻀﻥ ﺍﻟﻤﺴﺘﻤﺭ ﻟﻬﺎ ﻤﻊ 4 NOLOCﺍﻟﺤﻀﻥ ﻟﻤﺩﺓ ﺴﺎﻋﺔ ﻟﻬﺫﻩ ﺍﻟﺨﻼﻴﺎ ﻤﻊ 
     92 TH
ﻟﻤﺠﺎل ﻴﻌﺘﺒﺭ ﺍﺭﺽ ﺒﻜﺭ ﻭﻴﺤﺘﺎﺝ ﺍﻟﻰ ﺍﻟﻤﺯﻴﺩ ﻤﻥ ﺍﻟﺒﺤﺙ ﻭﻋﻤل ﻓﺭﻴﻕ ﻤﻥ ﺍﻟﺒـﺎﺤﺜﻴﻥ     ﻫﺫﺍ ﺍ 
  ﻤﻥ ﻤﺠﺎﻻﺕ ﺍﻟﺘﺨﻠﻴﻕ ﺍﻟﻌﻀﻭﻱ ، ﺍﻟﻜﻴﻤﻴﺎﺀ ﺍﻟﺼﻴﺩﻟﻴﺔ ، ﻋﻠﻡ ﺍﻷﺩﻭﻴﺔ ﻭﻋﻠﻭﻡ ﺍﻹﺤﻴﺎﺀ  
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1- Introduction 
Attempt to rationalized the development of new anticancer drugs is a very 
difficult task. There is no sharp demarcation between a malignant cell and a 
rapidly dividing normal cell. Thus it is very difficult to design a drug, which 
is selectively toxic to tumour cells and non-toxic toward normal cells. 
Further complications arise from the heterogeneity of tumours, which could 
be composed from several subpopulations differing in morphology, growth 
rate, metastasis and response to drug. Moreover, the therapeutic limitation of 
many anticancer drugs is manifested in the appearance of resistant tumours 
against these drugs. This resistance involves different mechanisms e.g., 
multidrug resistance (MDR)1, impaired drug uptake2 or and increased DNA 
repair3. The lack of tumorigenic targets is reflected in many of the first 
generation of clinically useful drugs many of which have very ancient roots4 
It seems that there is no substitute to continuation of screening programs of 
natural or synthetic drugs to discover lead compounds endowed with 
anticancer activity. Analogue synthesis of these lead compounds can not 
only help to define structure activity relationships but lead to the discovery 
of more potent drugs which may overcome problems of host toxicity and 
drug resistance. Mechanistic studies must be continue to uncover the nature 
of the killing events of existing drugs to more precisely define potential 
tumorigenic targets.  
The availability of modern methods of computer-aided molecular design 
makes screening of potential anticancer agents a much more easier task than 
what it used to be.  Technological advances have placed powerful computers 
on the desk top of bench chemists; bringing inexpensive computer aided 
molecular modeling of physical and chemical properties into the chemistry 
laboratory. Examination of the pertinent chemical and biological literature 
shows that molecular modeling has been used frequently in the 
pharmaceutical industry, to find promising new drug candidates, with a great 
deal of success4.Often, the approach is to match the molecular ‘shape’ of a 
compound with a sensitive region of an enzyme such that the compound will 
interfere with the function of the enzyme.  
1-1 Objectives of this research in outlines 
1 To investigate the effect of introducing N-atom in the anthracycline                         
tetracyclic backbone. 
2 To establish a new methodology of presynthetic in silico screening of                
promising anthracycline aza-analogues 
3  to extend the discoveries about the importance of position of N –
substitution( 2N to 1N)  found in aza-anthrapyrazoles to anthracycline 
family.of.drugs.                                                                                                                             
 - 3 -
We will discuss the scope and objective of present work later on in chapter 
four to examine whether these objectives have been realized.  
In this work we design a number of aza-anthracycline analogues (carrying 
anthracene-9,10-dione chromophore) and derived some of their 
physicochemical parameters computationally.  These were fed into a 
mathematical model connecting the same type of physicochemical 
parameters to the reported biological activity data of a training set of 11 
known anthracyclines taken from literature114. The biological activity data 
predicated therewith were used to assess the impact of introducing nitrogen 
atom into the carbocyclic anthracycline backbone  
 Before we delve into our main research conquest, we consider it convenient 
to briefly review some of the most important members of  anthracene-9, 10-
dione- based anticancer agents 
1-2..Carbocyclic.Anthracene-9,10-diones                                                      
Many natural products contain the quinone moiety. These quinone- 
containing compounds are involved in many biological processes based on 
redox mechanisms5(see section 1-8). Anthacene-9,10-diones have been 
isolated from many higher plants, for instance plants in the rubiaceae family 
biosynthesize compounds with anthracene-9,10-dione chromophore 6.Many 
of these plants still find use in tradition medicine and some of  these natural 
products have been investigated in hope of obtaining new drugs and learning 
more about the mechanism of action. In this section a few representative of 
naturally occurring anthracen-9,10-diones will be given followed by their 
synthetic bioisosteres as representatives of this class of compounds.                         
1-2-1..Anthracen-9,10-dione.natural.products                                               
A few illustrative examples of cytotoxic phytochemicals holding  
anthracene-9,10-dione.chromophore.are.discussed.below.                                 
Compound (1) is cytotoxic antileukemics which have been isolated from 
Morinda parvifolia 7 
 
 the cytotoxic 1,8-dihydroxy substituted anthracene-9,10-diones (2) ( R= β-
D-glucose)  have been isolated from the roots of an Indonesian medicinal 
 - 4 -
plant kelembak.8 The cytotoxic 1,5-dihydroxy analogue (3) have been 
isolated from Cassia italica found in Pakistan 9 
 
1-2-2 Synthetically modified plant products                                         
Some of the lead compounds from natural resources have been structurally 
modified with the goal of obtaining more potent antitumour agents. For 
instance, a series of chysophanol and emodin chemotypes have been 
investigated 10. Compound (4)is an example of these 
 
The chemotypes (5) and (6) have been reported to be cytotoxic 11a- 
 
1-2-3..Synthetic anthracene-9,10-diones                                                                  
1-2-3-a (Aminoalkyl) amino substituted 9,10-anthraquinone: Mitoxantrone 
In 1973, the anthracene-9,10-diones analogue (7a), which was developed as a 
potential blue ballpoint ink in USA, was shown to have a good antineoplastic 
activity 12 . This led to the synthesis of many compounds among which cogener 
 - 5 -
(7b) exhibited outstanding antineoplastic activity13. This compound was named 
mitoxantrone and was released to market in 1988. Compounds (7a) and (7b) have 
a narrower spectra of anticancer activity in comparison to anthracyclines 14. 
Myelotoxicity and cardiotoxicity remain problems for these compounds 
 
 
1-2-3-b. Mitoxantrone. analogues                                                              
The potent antitumour activity of mitoxantrone actuated investigations 
dealing with synthesis and antitumour activity of related chemotypes in 
order to combat cardiotoxicity, myelotoxicity and MDR of mitoxantrone. 
Synthesis and antitumour evaluation of a number of unsymmetrically 
substituted 1, 4-bis[(aminoalkyl)amino analogue of mitoxantrone have been 
reported 15.  For instance, compound (8) exhibit activity both in vitro and in 
vivo 
 
Mono (1- and 2- ) substituted as well as di (1,5- and 1,8- substituted ) 
regioisomeric compounds have also been synthesized16. For example the 
1,8-regioisomer of mitoxantrone (9) has been synthesized and was found  to 
be devoid of any activity in some experimental tumours17. 
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Variation of the side arm with grouping different from those of  
mitoxantrone was also tried 18. Thus a series of 1,4-bis(amidoalkyl)amino 
analogues have been prepared and evaluated. It seems that these compounds 
offer no particular advantage over mitoxantrone. Compound (10), for 
instance was found to be inactive against murine leukemia screens. 
Regioisomeric compounds carrying the amidoalkyl amino group at position 
1-; 2-; 2,4-; 2,5-19; 1,5-; 1,8- and 2,6- 20have also been studied 
 
Unlike compound (10) and its analogues, compound  (11) which carries an 
aminohydroxyl alkylamino side arm exhibits potent cytotoxicity in human 
tumour cloning assays 21. 
 
The N-oxide (12) is reported to be of low cytotoxicity but it was found to be 
highly active under in vitro hypoxic conditions 22 
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The sulphonium salt derivative of anthracene-9,10-dione (13) was prepared 
and biologically tested 23. It showed a 72% increase in life span of mice 
transplanted with p338 leukemia cell. 
 
Six enamine analogues of 1,4-bis[(2-aminoethyl)amino]anthracene-9,10-
diones were synthesized based on antileukemic activity shown by an 
enamine analogue of daunorubicin 24. For instance, compound  (14)  showed 
activity comparable to that of amentantrone 
 
In attempt to enhance synergy between cis platinum and anthracene-9,10-
diones, two series of compounds were synthesized. In the first series the 
anthracene-9,10-dione intercalator is linked to Pt(II) cation at position 1 [e.g. 
compounds  (15); n = 3, 4, 6, 12.]  and in the other, the link is at position 2 
25. 
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The platinum complexes of 2-substituted antracene-9,10-diones are 
significantly less potent than their 1-substituted analogues in the series, 
compounds with shorter linker chain were as active as cisplatin while 
activity drops significantly in complexes with longer chains.  
 
Another instance of the endeavors to enhance synergism is represented by 
linking of polypeptide to anthracene-9,10-dione chromophore. Theoretical 
studies of 1,4-polypeptide analogues have been reported  and these 
molecules have been synthesized in anticipation of synergism between metal 
chelation potential of  the peptide side arm and ability of the chromophore to 
produce destructive free radicals. The analogue (16) has been prepared and 
tested. It was found to be active against p388 leukemia in mice 26.   
 
the mitoxantrone regioisomeric hydroxy-analogue (17) has been synthesized 
and found to be less active in comparison with mitoxantrone in an L1210 
mouse leukemia screen27. 
 
The tetrahydrobenz[a]anthraquinone derivative  (18) exhibits anticancer 
activity against both murine and human tumour cell line 
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The replacement of the polar hydroxy group with a nonpolar hydrocarbon 
residue does not appear to impair the antitumour activity 28 
1-3..Carboyclic.tetracene-5,12-dione                                                                               
1-3-1..Anthracyclines                                                                 
Anthracyclines are well-established anti-cancer drugs. The name 
anthracyclines refer to a group of     antibiotic of which there are more than 
2000 representatives are already known. The hydrocarbon residue of 
anthracycline composed of a linearly fused alicyclic six-member ring to an 
anthracene-9,10-dione ring system. They could be regarded as derivatives of 
9-hydroxy-9-ethyl- 7,8,9,10-tetracene-5,12-dione (19).The β-position to the 
anthraquinone nucleus in the alicyclic ring carries two side chains, an ethyl 
(or carboethyl) and hydroxy groups 29. 
 
 Anthracyclines are sparingly soluble in water but they are found in the 
cluture medium of streptomyces species as soluble glycoside of aglycones 
that correspond to that glycoside.. Anthracyclines are a diverse group of 
aromatic polyketide antibiotics. Most natural anthracyclines are secondary 
metabolites of gram-positive soil bacteria Streptomyces. These bioactive 
compounds are known to have a wide spectrum of antifungal, antibacterial 
and antitumoral activities. Biosynthetically, the anthracyclinones (and hence 
anthracyclines) are derived initially from acetate and proprionate units which 
undergo an aldol condensation to afford a polyketide intermediate which is 
further transformed by the enzymes in Steptomyces to various 
anthracyclines. Typical anthracyclines are red pigments such as those 
derived from ε-rhodomycinone (e.g. rhodomycin A )  or yellow such as 
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those derived from aklavinone(e.g. aclacinomycin A ). The originally 
discovered members of anthracyclines includes isorhodomycin (20), 
rhodomycin (21), pyrromycin (22)and aklavin (aclarubicin)30 (23). 
 
 
These pigments showed pronounced antibiotic activity but they were found 
to be too toxic to be useful. In early 1960s, Cinerubine (a ε-rhodomycinone-
based glycoside ) was discovered to have antitumour activity. This represent 
the first step in the development of the antitumour anthracyclines. In 1964 
daunorubicin (24a), the first member in the clinically useful anthracyclines 
was discovered by Italian workers lead by Arcamone. Pharmacological 
testing of the compound indicated a promising activities especially in acute 
leukemias. This class of S. peucetius metabolites also includes, among 
others, doxorubicin (24b), dihydrodaunorubicine (25) and the disaccharide 
4`-O-α-L-daunosaminyldaunorubicine (26)30. 
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1-3-2 A review of clinically important members of anthracycline            
In recent years, intensive research effors were directed toward finding new 
anthracycline analogues with better efficacy and less toxicity than 
daunorubicin and doxorubicin. Biosynthesis yielded over 300 new 
compounds whereas more than 2000 analogues were obtained via semi-
synthesis or total synthesis31.  Carminomycin (27) is a  4-hydroxy analogue 
of daunorubicin produced by Actinomadura carminata  . It was originally 
developed in the Soviet Union in 1980s and once marketed in Europe32. 
Aclacinomycin A (Aclarubicin 23) is the only representative of class II 
anthracyclines which has been once marketed in Europe and Japan for 
treatment of leukemia. It is believed to interfere with the RNA synthesis 
more than DNA synthesis. It also lacks the cardiotoxicity shown by 
daunorubicin and doxorubicin. 33 
 - 12 -
 
 Among the important derivatives of daunorubicin are 4-demethoxy- 
daunorubicin (idarubicin 28)34  which is orally active and the benzoyl-
hydrazone of daunorubicin (rubidazone29) 35. Transformation of the sugar 
moiety include 4`-epi-doxorubicin or  epirubicin (Farmorubicin 30a)36 
,4`deoxy analogue (30b)  and esorubicin iodoxorubicin ( 4`-iodo-4`-deoxo-
doxorubicin (31) also give compounds with interesting activity37.                
The N-triflouroacetyl derivative of the 14-valerate ester,  valrubicin   (32)  is 
indicated for intravesical therapy of refractory carcinoma of the urinary 
bladder38. A synthetic 4`-tetrahydropyranyl-doxorubicin, pirarubicin (33), 
was originated and developed in Japan39 .                                               .    
Another anthracycline of significant anti tumour activity is nogalamycin (34) 
which was isolated and characterized by Wiley et al. from S. nogalater 40. It 
differ from other anthracyclines in that the amino-sugar is joined to the 
nucleus by carbon-carbon bond and a cyclic acetal linkage in ring D. The 
usual place of attachment of the sugar residue at C-7 is, however occupied 
by a non-amino sugar nogalose. Nogalamycin, with its ring-D bicyclic sugar 
substituent actually intercalates with nucleic acids, and the DNA bases 
buckle even more than other anthracyclines. This has been proved by X-ray 
analysis of drug-DNAhexamers41.                                                .     
Although nogalamycin is not an established anti-neoplastic drug, it was 
subsequently modified to furnish menogaril (7-con-O-methylnogarol or 
TUT-7 35) 42. 
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Menogaril has the nogalose moiety replaced by a methoxy group and a 
reversed chirality at C-7. It also differs from nogalamycin by the absence of 
carbomethoxy group at C-10. These structural changes result in a change in 
the mode of action from intercalation into DNA, to some other site and type of 
cytotoxic process. Thus menogaril localized in the cytoplasm rather than the 
nucleus, and it has negligible effect on DNA and RNA synthesis at cytotoxic 
dose. menogaril has lower efficacy than doxorubicin, but its much lower 
cardiotoxicity and potential oral activity might offer clinical advantage. It is 
interesting to note that nogalamycin poisons topoisomerase I but not 
topoisomerase II whereas the situation is opposite  with menogaril.  
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Morpholinyl anthracyclines have received much attention in recent research 
due to their activity, both in vitro and in vivo against MDR tumours and 
altered topoisomerase MDR cells. Two molecules  of this class are currently 
being investigated in phase II clinical trial. These are KRN806 (or MX2 36) 
developed in Japan by Umezawa`s group since the 1980s43, and  FCE 23762, 
(MMRA 37), a 2(s)methoxy-4-morphlinyl doxorubicin developed by 
Phamacia in Italy 44. This compound is about 80 times more potent than 
doxorubicin and presents equivalent anti tumour activity when administered 
i.p. i.v. or by oral route.  
 
 
 
Morpholino doxorubicin (MRA,  38) and cyanomorpholino doxorubicin 
(CMRA, 39) which are closely related to MMRA, were also prepared45. All 
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these morpholino derivatives were ca. 100-fold more polar than classical 
anthracyclines and they are claimed to be non-cardiotoxic at the therapeutic 
levels. They have a distinct mechanisms of action since CMRA causes DNA 
cross-linking, whereas MRA and MMRA act through topoisomerase I 
inhibition and DNA cross-linking. 
Few years ago a number of alkylcyclines that represent a new class of 
molecules were reported, with both DNA alkylating and intercalation 
properties. PNU 159548 or FCE 28729 , a 4-demethoxy-3`-deamino-3`-
aziridinyl-4`-methylsulphonyl-daunorubicin (40), is the lead compound in this 
novel series46. This is molecule endowed with double mechanism of action: 
DNA intercalation via anthracycline backbone, and DNA covalent binding  to 
the reactive alkylating group on the sugar moiety. It is also free from 
cardiotoxicity. Selected among other derivatives such as PNU-159550 (41),  
compound (40) displays high antitumour activity in a number of preclinical 
tests and a favourable toxicity profile47. It is able to overcome the resistant to 
all other major classes of cytotoxic including MDR-related drugs, alkylating 
agents and topoisomerase inhibitors. Due to its high lipophilicity PNU-159548 
may cross the blood-brain barrier, and is effective against intracranial 
tumours, and the dose-limiting toxicity is myelosuppression  
 
Based upon the same concept hybrid, 2-chloroethylnitrosoureido-
anthracyclines derived from doxorubicin [AD-312 ( 42)], DAU (AD-347) and 
epirubicin have been synthesized 48. AD-312 overcome resistance conferred 
by either reduced DNA-topoispmerase II or by p-glycoprotein over-
expression. Thus cellular resistance to this hybrid should be due to some other 
resistance mechanism. 
Priebe and Perez-Soler explored the double advantage approach for designing 
more effective anticancer anthracycline able to overcome MDR substitution49. 
Anthracycline antibiotic with reduced basicity and increased stability of the 
glycosidic bond were thus synthesized. So far among the numerous 
compounds which have been prepared,2`-iodo-3`-deamino-4-demethoxy-
 - 16 -
doxorubicin or anamycin (43)  proved to non-cross-resistant, or partially 
cross-resistant with doxorubicin, while displaying high antitumour activity. 
Therefore, anamycin has been incorporated in a liposomal formulation for 
phase I clinical trials. 
 
 
Amrubicin hydrochloride (44), a glycoside of synthetic 4-demethoxy-9-
deoxy-9-amino-daunomycinone has undergone phase II clinical trial for 
effective treatment of non-small cell lung carcinoma50, whereas DA-125 (45)  
has been developed and tested against both human gastric and pulmonary 
adenocarcinoma cells resistant to doxorubicin51. 
Taking into account the fact that anthracycline act primarily by  
topoisomerase II through a block of the DNA religation , 8-and 10-flouro 
derivatives were synthesized by Minarini`s group both in the the daunorubicin 
series 4-demethoxydaunorubicin series . 8(R)-flouro-idarubicin 93(46) was 
effective in stimulating topoisomerase II-mediated DNA cleavage, and was 
almost as effective as doxorubicin in the inhibition of human ovarian 
carcinoma xenografted in nude mice. The 10-flouro derivative were less 
potent than the parent drug although 10(S)-flouro-idarubicin (47) inhibited by 
50% the growth of all 58 cell lines tested by NCI30 
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The same group also reported the synthesis of new derivatives of 
anthracycline disaccharide, the design of which was based on several 
consideration, among which the displacement of the amino group to the 
second sugar moiety should have consequence on both sequence specificity 
and in the recognition of the protein domains in the minor groove52. Among 
different analogues, 2-deoxyfucosyl-daunosaminyl-glycoside of 4-demethoxy-
daunorubicin (48) showed high efficacy in the inhibition of a spectrum of 
human tumour xenografted in nude mice, and has already entered phase I 
clinical trial53 
 
in the last decade, drug carrier technology has been intensively developed 
with the aim of overcoming MDR and to achieve better internalization of the 
drugs. Thus doxorubicin was conjugated to different amino acids and one of 
these conjugates, N-l-leucyl-doxorubicin (49) emerged as  the most 
promising candidate. This prodrug was found to be less toxic than 
doxorubicin and of superior efficacy in human melanoma xenografts54. 
Several conjugates of doxorubicin to various biological molecules were 
prepared and shown to have interesting activities as elegantly reviewed by  
Monneret31 
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 1-4 Heterocyclic anthracene-9,10-dione aza-analogue 
1-4-1  Anthracene-9,10-dione aza-analogue: natural products 
Many anthraccene-9,10-diones, as we have already discussed, have been 
isolated from natural resources but aza bioisosteres have been rarely found 
in nature. Some derivatives of 2-aza-anthracene-5,10-diones have been 
isolated from fungal sources. This includes bostrycoidin (2-aza-3-methyl-
5,8-dihydroxy-6-methoxyanthracene-5,10-dione 50) and its derivatives55. 
 
Some of the naturally occurring 1-azaanthracene-5,10-diones include 
phomarazarine (51a)56, isophomarazarine (51b)57, and cleistopoline 
(52)58.The latter is reported to have some antitumour activity.  
 
The above class also includes the phenanthridine derivatives (53) isolated 
from bacterial sources59. They are found to be active against experimental 
lung carcinoma. 
 
1-4-2 Synthetic Anthracene-9,10-dione 1- and 2-aza-analogues  
Due to the scarcity of naturally occurring aza-anthracene-9,10-diones 
synthesis of these compounds were resorted to in order to make them 
available for screening and evaluation. The replacement of a carbocyclic 
moiety in a bioactive molecule by pyridine, pyridazine, pyrazine or 
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pyrimidine ring should significantly alters the physicochemical properties 
and therefore, chemotherapeutic efficacy of the molecule  . The synthesis of 
molecules which bear essentially the same backbone as anthracene-9,10-
diones or anthracyclines with the inclusion of nitrogen atoms should yields 
compounds that possess the same spatial characteristics (including  
planarity) for DNA recognition  but endowed with increased basicity or  
sites for hydrogen bond making. This feature could possibly increase the 
affinity of these analogues for DNA binding and /or other interactions   with 
cellular components such as topoisomerases. These bioisosteres would 
undergo enzymatic reduction more readily to form anion-radicles which 
might be less prone to undergo electron-transfer to molecular oxygen to 
create superoxides. The latter is believed to be involved in the production of 
hydroxyl radical held responsible for carditoxicity of anthracyclines (see 
section 1-9)  
A group of  6,9-bis[(aminoalkyl)amino] benzo(g)quinoline-5,10-diones have 
been synthesized and biologically tested. Compound (54); n = 2. R1 = R2 = 
CH3, exhibits antitumor activity in some experimental tumours similar to the 
carbocyclic model with the same side arms. 
 
It is interesting to note that a congener of compound (54); n = 2  R1 = H     
R2 = (CH2)2OH   with the same side chain as ametantrone and mitoxantrone 
exhibit poorer activity as compared to them 60. 
In the 2-aza series, three derivatives of 1-(aminoalkyl)amino-6,9-
dihydroxybenzo[g]isoquinoline-5,10-dione (55) were synthesized ( R = three 
different substituted amino groups) 
 
all the three derivatives were found to be devoid of any significant 
antitumour activity61. 
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In order to establish the effect of the position of the nitrogen atom on 
antitumour activity, a number of regioisomeric 2-aza bioisostere have been 
synthesized. The bis(alkylamino)amine analogues (56) were prepared with 
different (akylamino)amine side chains and two of these were converted to 
amine oxides (57) 
 
the introduction of the nitrogen atom at position 2 of the anthracene-9,10-
diones to give the above compounds exerts a substantial effect on the 
antitumour activity of these chemotypes. Compounds (56) is extremely 
active in vivo and exhibits a wide range of tolerated dosage. It is also non-
cardiotoxic, which make it a promising candidate for clinical trial. 
As was the case with compound (54) of  1-aza series(where n =  R1 = H, R2 
= (CH2)2OH), the congener of compound (56) which carries the same side 
chains as ametantrone and mitoxantrone is less active than the latter two 
compounds. This demonstrates that SAR relationships found in carbocyclic 
compounds cannot be assumed to be predictive for the heterocyclic 
congeners 62.  
The enhanced antitumour activity shown by mitoxantrone in comparison 
with amentantrone suggested that it would be of interest to study the effect 
of hydroxy substitution on the 2-aza bioisosteres. Thus analogues (58) were 
developed. 
 
Congener (58c) exhibits higher potency than ametantrone, but not 
mitoxantrone against certain tumour cell lines. It also has a favourable 
resistance index values compared to both the latter compounds. Compound 
(58b) was found to be also active and has the ability to overcome MDR. 
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Compound (58a) was found to be remarkably active both in vitro and in vivo 
against some cancer cell lines.  
In the limited number of compounds tested, the 4-hydroxy substitution 
seems to lead to compounds of higher potency in comparison to the non-
hydroxylated compounds 63. 
A number of triones [(59), R1 & R2 various groups] were prepared along 
with their N- and O-methyl analogues (altogether 12 compounds).  
 
 All the 12 compounds failed, upon testing, to show any appreciable 
 activity 64.  
1-4-3  Anthracene-9,10-dione Diaza-analogues  
with exception of diazaquinomycin A  [(60) R = CH3] which has been 
isolated from the fermentation broth a streptomyces strain65 and 
characterized by a Japanese group66, all the other members of this class of 
compounds are synthetic. 
 
diazaquinomycin A itself has demonstrated in vitro cytotoxicity against 
tumour cells but was not effective in vivo on tumour in mice. This was 
attributed to its poor solubility. In attempt to improve the solubility ten 
analogues were synthesized and three of them ( R = CH2CO2CH2CH3 or  
CH2OAc or CH2OCH2CH3 ) were found to be active67. 
A similar nucleus to that of diazaquinomycin A were also synthesized . This 
is represented by a number of 1,8-diaza-2,9,10-anthracenetriones (61). 
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Some of these compound were found to be active against Hela cells68.  
A number of analogues containing quinoxaline ring [(62), X= amino groups] 
were prepared and tested. All of them, howeve, were found to be inactive69. 
 
Krapcho et. al. prepared a number analogues containing quinazoline nucleus, 
e.g. (63) 
 
These analogues showed a limited activity70.  
Two  series of of substituted benzo[9]phthalazines-5,10-diones were 
prepared one contains two 6,9-bis(aminoalkyl)amino groups C5 and C8 
(64)70 and the others contains the similar grouping at C1 and C4 (64) 
 
while compounds (64) were devoid of activity, compounds (65) were found 
to be substantially active in vitro against various cancer cell lines with 
favourable resistance indexes and some of them [e.g. when R=(CH2) 3N-
(CH3) 2 ] were able to overcome MDR mechanism operating in LoVo/Dx 
cell line induced by doxorubicin71. 
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1-5 Heterocyclic aza-tetracenequinone 
Considerable efforts have been expended to synthesize heterocyclic 
anthracycline analogues. Non of these, however, showed the outstanding 
activity exhibited by the carbocyclic compounds. Various heteroatom were 
incorporated into the tetracyclic nucleus of anthracycline and at various 
position72.  Here some examples of aza-tetracenediones which had been 
prepared and tested.  
Four substituted anthracene-6,11-diones (66) were prepared and biologically 
tested. Non of these compounds showed any activity against L1210 or  P388 
cells73. 
 
a naphtho[2,3-g]isoquionoline-5,12-dione (67) and five 4-methyl congeners 
(68) were prepared and biologically evaluated.The former were inactive 
against erthroblastic cells 74561and the latters (altogether five analogues R = 
alkylamino groups) were found to be inactive in the P388 in vivo screen74 
 
 
 
The synthesis of ring-D pyridine (69) and pyrazine (70)analogues of 11-
deoxydaunomycin have been reported72, 75 
 
Both were obtained as 1:1 inseparable mixtures of diastereomers at C9 and 
showed inhibitory activity against L 1210 in vitro comparable to that of 
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doxorubicin. The synthesis of the aglycone part of D-ring pyridine (71) and 
pyrazine (72) analogues of the (69) and (70) with 11-hydroxy substitution 
were also reported. These compound were also obtained as inseparable 
mixture ( R1=COCH3, R2=H; R1=H, R2=COCH3). No biological activity data 
was supplied76. 
 
9-Aza-analogues of N-triflouroacetyl-4-demethoxydaunomycin (73) and 
(74) were prepared. Unexpectedly, both compounds were inactive in mice 
carrying the p-388 leukemia 77. 
 
Reports about ring B aza-analogues of anthracyclines are extremely rare. 
Acton et. al. synthesized  an analogue with a phenazine chromophore (75) 
and (76)and attempted to convert it  to the dioxide analogue similar to 
phenazine-5,10-dioxide (77) which is known to have antitumour properties. 
Their attempt, however, were not met with success78. 
 
1-6 Anthrpyazoles and their aza-bioisostere    
Chromophore modification of the anthracenediones related to mitoxantrone 
(7b)  in attempt to provide agents with diminished or no cardiotoxicity has 
resulted in a novel class of DNA binders, the anthrapyrazoles (anthra [1,9-
cd]pyrazol-6(2H)-one 78). In these compounds, not only is the central quinone 
moiety being mdified to quasi-iminoquinone but also, in contrast to 
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chromophore modified anthracenediones, another ring was incorporated into 
the chromophore.  
 
several members of the above class of compounds were synthesized and 
biologically evaluated. Losoxantrone  [(78a) R1 =  -C2H4-NH-C2H4OH,  R2 = 
H,  R3 = -C2H4-NH-C2H4OH] emerged as the most promising candidate. 
This compound has demonstrated good clinical efficacy in treatment of 
breast cancer but cardiac toxicity was still observed during the clinical 
trials79. 
Because in the anthracenediones series the nitrogen for carbon bioisosteric 
substitution retains antitumour activity and abolishes cardiac toxicity 
(section 1-4b), novel aza-analogues of anthrapyrazoles were synthesized and 
tested. The main modification on the anthrapyrazole ring structure being the 
incorporation of N-atoms either in position 5or position 9. in particular the 
9-aza-anthrapyrazoles, as they are termed by their inventors, seem to be very 
promising. In vitro evaluation of these compounds demonstrated high 
cytotoxic potency and the ability to overcome multidrug resistance induced 
in a doxorubicin-resistant cell line. Of these, two derivatives BBR 3434 and 
BBR 3576 (79a & b) have surfaced as potential clinical candidates80   
 
both the above compounds could be considered as bioisosteric analogues of 
losoxantrone. 
1-7  Main synthetic pathways 
A great deal of efforts have been expended in the field of anthracenediones 
Synthesis. Various reactions and synthetic routes were tried chief among 
which  are the following 
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1-7-1  Friedle-Craft acylation 
this reaction has been used extensively to construct the chromophore part of 
various anthracenedione derivatives. For instance, 1,4-diflourophthalic 
anhydride (80) was reacted with p-xylene to synthesize the substituted 
anthracenedione (81) which was used in the synthesis of the mitoxantrone 
analogue (82)81 
 
This reaction was also successfully applied to diaza-anthracenediones to 
synthesize the precursor (83) used to obtain  some aza-bioisosteres of  
amentantrone70. 
  
In the anthracycline series this reaction was used to obtain various 
precursors useful in constructing tetracyclic backbone. 7-O-methyl-4-
demethoxydaunomycinone (86)  was first synthesized by Wong et al. 
through the reaction of phthalic acid half ester [(84). DC-building block] and 
[(85) AB- building block] to give (86) in a stepwise Friedel-Craft reaction82 
(scheme 1-3A) 
 
Scheme 1-3A 
The Friedel-Craft reaction with symmetrically substituted phthalic 
anhydrides (87) can also occur in one-pot procedure. 4-
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Demethoxydaunomycinone [(88), R =R` = H] is now manufactured in large 
scale this way, in addition to other derivatives83  (scheme 1-3B) 
 
Scheme 1-3B 
Basically, the acylation using phthalic anhydride derivatives  proceed in two 
steps whereby the first deactivate the arene for a second electrophilic attack; 
this hold even if  in practice one pot procedures (e.g. AlCl3/ NaCl melt) are 
used83. Consequently, vigorous reaction condition can not be avoided. The 
drastic condition of the Friedel-Craft reaction limit this methods to the 
daunomycinone- type anthracyclinones and do not allow the use of 
dihydroxylated AB building blocks. Another limitation of Friedel-Craft 
reactions is the lack of regioselectivity when using non-symmetrically 
substituted phthalic acid derivatives 
1-7-2  Diels-Alder reaction 
The very mild conditions of this reaction made it a very attractive option to 
choose in the anthracenediones synthesis. This (2+4) cycloaddition offers 
ideal possibilities for the construction of linearly annelated ring systems 
containing six-membered rings. Indeed, this reaction is increasingly used 
when regioselectivity or stereospecifity is the question.. The regioselectivity 
of Diels-Alder reaction with juglone derivatives has been thoroughly 
investigated experimentally84 and is in good agreement of frontier orbital 
considerations85.  
The strong hydrogen bridge in juglone (89) is responsible for the extremely 
different orbital coefficient in the LUMO of the quinone, which 
consequently leads to the formation of (91) in the reaction of (89) with the 
diene (90). By contrast, the methyl ether (92) yields the adduct (93) with 
inverse orientation of the methoxy group86 (scheme 1-4). 
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The reaction of the quinone of bromojuglone methyl ether (94) with the 
keten acetal (95)86 or  (96)87 to give the tetracycle (98) also proceed with 
formation of ring B. 
 In this case the bromine atom direct the regioselectivity. The presence of the 
bromine atom facilitates the aromatization of ring B with elimination of HBr 
and alcohol. An aromatization with CO2 elimination follows the addition of 
juglone (89)  to the bicyclic 6-alkoxypyranone (97) to afford (99) 88 (scheme 
1-5). 
 
Abdallah et al. used the intermediate (95) to synthesized ring-D modified 
11-deoxydaunomycinone by reacting it with various AB building blocks as 
depicted in scheme 1-6. the tetracyclic ketones (98), (101), (104), (108) and 
(111 were then subjected to elaborate ring A functionalization. The desired 
stereochemistry of C-7 and C-9 hydroxy groups (cis- configuration)  was 
thus achieved 89.  
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Scheme 1-6 
In aza-anthracenedione series , the intermediate (94) was used to construct 
ring D-modified tetracycles76  
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Scheme 1-7 
Kita et.al. use the precursor  (115) to synthesize D-ring aza-analogue of 11-
deoxyanthracyclinone (116) utilized in the synthesis of the two heterocyclic 
daunorubicin analogues (69) and (70)75 
 
 
1-aza-anthracene-5,10-diones nucleus  (119) was synthesized smoothly and in 
good yields by reacting the azadiene  (118) with 1,4-naphthaquinone (117) in 
the synthesis of cleistopholine  and its analogues90 
 
These analogues were employed in the synthesis of the anti fungal sampagine 
and also in the synthesis of  the experimental antitumour agent 3-alkenyl-1-
azaanthracen-5,10-dione (120) and its analogue (121)91 
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1-7-3 Anionic Reactions 
The specific generation of anionic centers in one building block and acceptor 
center in another enables selective bond formation and, therefore, an 
excellent control of regiochemistry. There are many possible method for the 
first bond formation; however, Michael additions and the specific metalation 
of arene certainly have the priority. Although the coupling of the two 
building blocks is usually a two-step process (the second step is often a 
Friedel-Craft reaction) many condensations can be conducted in a single 
reaction vessel. A good example for this is the elegant work of Parker et al.92 
and Kende et al.93 who make use of the Michael addition of benzyl cyanide 
(122) to the cyclic α,β-unsaturatedesters (123) for the regioselective 
synthesis of the precursor (124).  Further transformation to tetracycles is 
accomplished via oxidative elimination of the cyano group and a Friedle-
Craft cyclization 
 
A novel anionic mechanism was employed by Krapcho et al.94 to synthesize 
cleistopholine (52) and its analogues. The key step envolved nickel-
catalysed regiospecific coupling of benzylic zink bromides (125) with 
methyl-2-bromo-4-methyl nicotonate (126) to afford benzylated pyridines 
(127)-(129) followed by their subsequent transformations to the 
benzo[g]quinoline-5,10-diones (130). 
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    1-8 Mode of action of quinone-containing anticancer agents      
Anthracene-9,10-diones are DNA intercalators and combine with DNA into 
defined stoichiometric complexes. As evidenced by x-ray diffraction and 
NMR analysis95, the anthracycline molecules are oriented in the DNA 
structure with the planar quinone ring system intercalated between base 
pairs, and with the sugar moiety in the minor groove of the DNA double 
helix as depicted in figure 1-1 below99. This amino sugar group is believed 
to interact with the negatively charged phosophate group in the major groove 
of the DNA  It was early recognized that DNA-related functions such as 
replication and transcription are strongly inhibited upon anthracycline 
association with the DNA structure, and that this could provide a possible 
mechanism of cytotoxicity 96.  
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One of the new developments was the finding that the anthracyclines also 
interfere in a more specific manner with the nuclear topoisomerase II 
enzyme (EC 5.99.1.3) 97. The important catalytic function of this enzyme is 
to create the reversible double-stranded DNA breaks needed for replication 
and transcription. Upon anthracycline combination with topoisomerase II, 
the enzyme is locked into an inactive conformation while the DNA is 
covalently associated to the catalytic site. This particular DNA modification 
appears to trigger different cell killing mechanisms depending on drug 
concentration and cell type 98.Topoisomerase II is now generally considered 
as the primary target enzyme in the mechanism leading to tumor cell kill. 
Indeed, structure-activity studies within series of anthracycline derivatives100 
have indicated that cytotoxicity is more strongly correlated to the extent of 
topoisomerase II-induced DNA cleavage than to DNA binding affinity.                          
The anthracenediones class of anticancer agent lack the aminosuger moiety 
and the tetracyclic ring-A of  anthracycline but retain the planar polycyclic 
aromatic ring structure and thus the potential to intercalate between DNA 
base pairs.  
1-9 Redox Cycling of Quinone-Containing Anticancer Agents                              
There is a substantial number of anticancer agents that contain quinone in 
their structure. These include, in addition to compounds that contain 
anthracene-9,10-, dione chromophore, some anticancer alkylating agents 
such as mitomycin (131), aziridinylbenzoquinones (132) and benzoquinone 
mustard (133) 
 
  By virtue of their quinone group, these agents can undergo a biochemical 
reduction by one or two electrons that is catalyzed by flavoenzymes in the 
organism using NADPH as an electron donor. This bioreductive process 
leads to the semiquinone and subsequent reactions with oxygen, all of which 
are believed to be responsible for most of the drugs' activity (1-3). The 
process of reductive activation is the first step in the process of redox 
cycling because bioreduction leads to the semiquinone of the anticancer 
agent which, under aerobic conditions, is oxidized by molecular oxygen to 
the parent compound, a process that results in the concomitant production of 
superoxide radical anion (O2-). The formation of O2- is the beginning of a 
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cascade that generates H2O2 and hydroxyl radicals (.OH), generally referred 
to as reactive oxygen species (ROS) (4, 5). To our knowledge, all quinone-
containing antitumor agents, some of which are depicted above, undergo 
redox.cycling.at.different.rates                                                                                          
The enzymes involved in redox cycling are, in general, flavoenzymes that 
use NAD(P)H as an electron source. The enzymes mediate the transfer of 
electrons to the quinone group of the anticancer agent chemically reducing it 
to the semiquinone. Subsequent electron transfer to oxygen from the 
semiquinone results in the formation of O2-. This redox cycle continues until 
the system becomes anaerobic at which time the oxygen radical production 
decreases and the semiquinone begins to accumulate to detectable levels 
(scheme 1-12, left hand side).  
 
The superoxide anion participates in a sequence facilitated by metal ions that 
results in the formation of H2O2 and hydroxyl radical (.OH). The 
bioreduction of quinone-containing agents and subsequent generation of 
ROS can be summarized by the following reactions:  
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The formation of the superoxide radical and subsequent formation of 
hydrogen peroxide or hydroxyl radical is termed Haper-Wiess reaction.     A 
more complicated cycle for reduction and oxidation of a quinone-containing 
anticancer agent can occur when the quinone is reduced by two electrons to 
the hydroquinone. Some hydroquinones can then be oxidized one electron at 
a time with the formation of the semiquinone and the parental compound 
respectively5. Reduction by two electrons in general leads to detoxification. 
The above discussed  one electron reduction cycle could be applied to 
anthracycline group as depicted in scheme 1-13101 
 
Scheme 1-13 
 Flavenoenzymes catalyze the one-electron reduction of the anthracycline 
quinone chromophore This process generates the chemically reactive 
semiquinone free radical 2` and C7-quinone methide 4`, as well as the 
inactive 7-deoxy-aglycone metabolite 5`.                                                        
1-10..The.free.radicals.theory.of.anthracycline.toxicity                                    
As early as 1977, Myers and colleagues developed the idea that reactive free 
radicals and peroxidation of cell lipids might play a role in the development 
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of the special cardiotoxicity of doxorubicin102. The free radical theory of 
Myers has received support from many investigators, and doxorubicin –
induced free radical formation with the result of oxidative cell damage has 
been demonstrated by a number of techniques. When formed by enzymatic 
reduction in cells, the doxorubicin –semiquinone 2`  (scheme 1-13) free 
radical is either reoxidized by O2 to the parent anthracycline or converted 
into the reactive C7-quinone methide 4` by glycoside elimination.This 
redox-cycling yields the reactive oxidant species O2  , H2O2 and OH ., and is 
catalytic in the sense that many reactive molecules can be generated from a 
single molecule of anthracycline. It follows that the overall process of 
enzymatic reduction of doxorubicin in living cells gives rise to a whole 
range of potentially toxic molecules. Fe3+ plays an important catalytic role in 
the above enzymatic reduction cycle (Haber-Wiess reaction; the Mn in 
scheme 1 could be replaced by ferric ion ). Usually, the superoxide radicle is 
neutralized by superoxide dismutase and the resulting hydrogen peroxide is, 
in turn, decomposed to water  and molecular oxgen by catalases or reduced 
to water by by glutathione peroxidase. In comparison with other tissues, the 
heart is poor in catalases and glutathione peroxidases is destroyed by 
anthracycline (and, of course, other anthracene-9,10-dione based drugs). As 
a result hydrogen peroxide accumulates, thus leading, by reaction with 
oxygen superoxide, to an increased formation of hydroxide radical which 
may produce acute destruction of mitochondria, endoplasmic reticulum, and 
nucleic acids. Efforts to decrease the clinically important chronic 
doxorubicin cardiotoxicity with various antioxidants have been 
disappointing. In fact, other types of compounds with no apparent 
antioxidant properties have proved more effective. These include the 
bisdioxo-piperazine derivative dextrazoxane 184 (ICRF 187).  
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This compound was initially tested as an anticancer drug but it was 
eventually found to have a cardioprotective property.the active form is the 
pure S-enantiomer. Structurally , it is a lipophilic derivative of EDTA 186, a 
well known chelating agent of Ca2+ and heavy metal metabolism. After 
entering the cells, ICRF 187 is metabolized to 185 (ICRF 198), which is able 
to trap Fe3+ and, therefore, inhibit the Haber-Wiess reaction. Dextrazoxane 
exerts its effect without affecting the antitumour efficacy of 
anthracyclines31,102. 
1-11..Multidrug.Resistance.(MDR                                                                
Repeated administration of anticancer agents of  diverse chemical structures 
leads to development of resistance. This resistance operates through 
different mechanisms. The most studied is the one related to overproduction 
of membrane bound P-glycoprotien which occurs as a result of an active 
efflux system operating on a variety of drugs of different structural types. 
This mechanism, therefore, is referred to as multidrug resistance (MDR). P-
Glycoprotein pumps drugs out of cells by a mechanism that requires ATP.  
A different mechanism of resistance is attributed to the multidrug associated 
protein (MRP).This mechanism seems to involve a glutathione conjugate 
transport but no structural requirements for its action has been established1, 
101.                                                                                                                                
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1-12..Quantitative.Structure-Activity.Relationships.(QSAR)                                           
With the development of experimental chemistry, a large number of new 
compounds are synthesized every year. However, a large part of these 
compounds are not tested for fundamental or relevant thermodynamic and 
physicochemical properties or biological activities, which still remain 
unknown due to unavailability or no easily handling (toxic, odorous, etc.). A 
procedure able to predict, within a reasonable error margin, the 
physicochemical properties and biological activities of untested compounds 
is required to evaluate these molecular features in a fast and inexpensive 
way .  this method is embodied in the so-called quantitative structure activity 
relationships (QSAR). This methodology strives to achieve the following 
goals:                                                                                                                         
1-Prediction of the biologic activities in untested compounds                         
2-Definition of the structural requirements for a good fit between the drug 
molecule.and.the.receptors                                                                                                           
3-Designing of  a test set of compounds to maximize the amount of 
information concerning structural requirements for activity from a minimum 
of compounds tested.To achieve these goals, the relationship between a 
chemical structure and  a biological response BR must be quantified in the 
following.manner                                                                                                                          
...........................BR.=.f.(chemical.structure)……..(1-1)                                                            
BR (or biological response) stands for a definable pharmacologic response 
usually expressed in millimoles such as the effective dose in 50% of the 
subjects (ED50), the lethal dose in 50%  of the subjects (LD50) or the 
minimum inhibitory dose for 50% of the subjects (ID50) The problem now 
become one of numerically defining chemical structure  Instead of chemical 
structure in the right side of equation 1-1 above  a physiochemical parameter 
could be used and correlated with biological response. It has been found that 
biologic response could be predicted from physiochemical properties such as 
vapour pressure, water solubility, electronic parameters, steric discriptors 
and partition coefficient. The latter has become the single most important 
physiochemical measurement for QSAR study104. 
 In recent years, numerous QSAR models have been introduced for 
calculating the physicochemical properties with various numerical 
descriptors of chemical structures. These relationships derive correlations 
between the similarities of individual compounds and their biological 
activity/chemical property . 
Ever since scientists began to measure, or quantify, the physical and 
biological properties of the natural world, they also sought patterns or 
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relationships between the measurements they made. However, it was not 
until the 1930's that knowledge of the extent and the rates of chemical 
processes, together with the properties of the reacting molecules (shape, size 
and electronic properties) allowed correlations to be made between the 
nature of molecules and their tendency to react.  
Surprisingly, even though similar types of measurements were possible in 
the biological world, particularly related to drug potency and toxicity, very 
few attempts were made to connect biological activity and physical 
properties.  
1-12-1  Early Conception 
QSAR date back to the 19th century. In 1863, A.F.A. Cros at the University 
of Strasbourg observed that toxicity of alcohols to mammals increased as the 
water solubility of the alcohols decreased 105. In the 1890's, Hans Horst 
Meyer of the University of Marburg and Charles Ernest Overton of the 
University of Zurich, working independently, noted that the toxicity of 
organic compounds depended on their lipophilicity 106.    
1-12-2  The Hammett equation; Linear free energy relationships:                                      
Little additional development of QSAR occurred until the work of Louis 
Hammett (1894-1987), who correlated electronic properties of organic acids 
and bases with their equilibrium constants and reactivity 107. Consider the 
dissociation of benzoic acid:                                                                                            
 
Hammett observed that adding substituents to the aromatic ring of 
benzoic acid had an orderly and quantitative effect on the dissociation 
constant. For example 
 
A nitro group in the meta position increases the dissociation constant, 
because the nitro group is electron-withdrawing, thereby stabilizing the 
negative charge that develops. Consider now the effect of a nitro group 
in the para position: 
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  The equilibrium constant is even larger than for the nitro group in the 
meta position, indicating even greater electron-withdrawal.Now 
consider the case in which an ethyl group is in the para position: 
 
In this case, the dissociation constant is lower than for the 
unsubstituted compound, indicating that the ethyl group is electron-
donating, thereby destabilizing the negative charge that arises upon 
dissociation.Hammett also observed that substituents have a similar 
effect on the dissociation of other organic acids and bases. Consider the 
dissociation of phenylacetic acids, electron-withdrawal by the nitro 
group increases dissociation, with the effect being less for the meta than 
for the para substituent, just as was observed with benzoic acid. The 
electron-donating ethyl group decreases the equilibrium constant, as 
would be expected.Because this relationship is linear, the following 
equation can be written: 
 
where ρ is the slope of the line. we can write the above equation as: 
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Where σ = K/K0.ρ, the slope of the line, is a proportionality 
constant pertaining to a given equilibrium. It relates the effect of 
substituents on that equilibrium to the effect of those substituents on the 
benzoic acid equilibrium. That is, if the effect of substituents is 
proportionally greater than on the benzoic acid equilibrium, then ρ > 1; 
if the effect is less than on the benzoic acid equilibrium, ρ< 1. By 
definition, ρ for benzoic acid is equal to 1.σ is a descriptor of the 
substituents. The magnitude of σ gives the relative strength of the 
electron-withdrawing or -donating properties of the substituents. σ  is 
positive if the substituent is electron-withdrawing and negative if it is 
electron-donating. These relationships as developed by Hammett are 
termed linear free energy relationships. The equation relating free 
energy to an equilibrium constant is:That is, the free energy is 
proportional to the logarithm of the equilibrium constant. These linear 
free energy relationships are termed "extrathermodynamic". Although 
they can be stated in terms of thermodynamic parameters, no 
thermodynamic principle states that the relationships should be true 107. 
1-12-3..Hansch.analysis                                                                      
QSAR based on Hammett's relationship utilize electronic properties as 
the descriptors of structures. Difficulties were encountered when 
investigators attempted to apply Hammett-type relationships to 
biological systems, indicating that other structural descriptors were 
necessary.Robert Muir, a botanist , was studying the biological activity 
of compounds that resembled indoleacetic acid and phenoxyacetic acid, 
which function as plant growth regulators. In attempting to correlate the 
structures of the compounds with their activities, he consulted his 
colleague in chemistry, Corwin Hansch. Using Hammett sigma 
parameters to account for the electronic effect of substituents did not 
lead to meaningful QSAR. However, Hansch recognized the importance 
of the lipophilicity, expressed as the octanol-water partition coefficient, 
on biological activity 108. We now recognize this parameter to provide 
a measure of the bioavailability of compounds, which will determine, in 
part, the amount of the compound that gets to the target 
site.Relationships were developed to correlate a structural parameter 
(i.e., lipophilicity) with activity. In some cases, a univariate relationship 
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correlating structure and activity was adequate. The form of the equation 
is: 
 
where C is the molar concentration of compound that produces a 
standard response (e.g., LD50, ED50). With other data, it was observed 
that correlations were improved by combining Hammett's electronic 
parameters and Hansch's measure of lipophilicity using an equation such 
as 
 
where σ is the Hammett substituent parameter and π is defined 
analogously to σ. That is, 
 
In yet other cases, parabolic relationships between biological 
response and hydrophobicity were observed that could be fit by 
including a (log P)**2 term in the QSAR. One interpretation to account 
for this term is that many membranes must be traversed for compounds 
to get to the target site, and those with greatest hydrophobicity will 
become localized in the membranes they encounter initially. Thus, an 
optimum hydrophobicity may be found in some test systems.          
QSAR are now developed using a variety of parameters as descriptors of 
the structural properties of molecules. Hammett sigma values are often 
used for electronic parameters, but quantum mechanically derived 
electronic parameters such as total energy Et, dipole moment µ and heat 
of formation ∆Hf  may also be used, as is the case in the present work. 
Other descriptors to account for the shape, size, lipophilicity, 
polarizability, and other structural properties also have been devised. 
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1-12-4..Methods.of.identification.of.correlation                                       
The relationship, or function, is usually (but not always) a mathematical 
expression derived by statistical and related techniques, for example, 
multiple linear regression. The parameters describing physicochemical 
properties are used as independent variables and the biological activities are 
dependent variables. In some cases a function cannot be found, and this 
reflects the multi-variate, non-linear nature of biological and physical 
properties. here more sophisticated statistical methods for pattern 
recognition, such as cluster analysis, factor analysis and principal 
components analysis are used in the search for patterns between biological 
and physical data.  Use of such data may be possible using neural networks 
to deduce essential data for activity and then using this.for.prediction.                         
1-12-5..Advantages.of.QSAR:                                                                          
- Quantifying the relationship between structure and activity provides an 
understanding of the effect of structure on activity, which may not be 
straightforward.when.large.amounts.of.data.are.generated.                             
- There is also the potential to make predictions leading to the synthesis of 
novel analogues. Interpolation is readily justified, but great care must be 
taken not to use extrapolation outside the range of the data set.                       
- The results can be used to help understand interactions between functional 
groups in the molecules of greatest activity, with those of their target. To do 
this it is important to interpret any derived QSAR in terms of the 
fundamental chemistry of the set of analogues, including any outliers.  
1-12-6 Disadvantages of QSAR:                                                                   - 
False correlations may arise through too heavy a reliance being placed on 
biological data, which, by its nature, is subject to considerable experimental 
error.                                                                                                                                
- Frequently, experiments upon which QSAR analyses depend, lack design 
in the strict sense of experimental design. Therefore the data collected may 
not reflect the complete property space. Consequently, many QSAR results 
cannot be used to confidently predict the most likely compounds of best 
activity.                                                                                                                        
- Various physicochemical parameters are known to be cross-correlated. 
Therefore only variables or their combinations that have little covariance 
should be used in a QSAR analysis; similar considerations apply when 
correlations are sought for different sets of biological data109.                        
1-13..Quantum.Mechanics:                                                                        
Quantum Mechanical Methods find increasing use in the field of QSAR as a 
tool to derive physiochemical parameters  for drug molecules to be  
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correlated with their biological response data. It is thereof re defendable to 
include.a.short.expose`.about.these.methods.herein                                                
1-13-1..Schrödinger.equation                                                                               
in 1926, Erwin Schrödinger discovered the basic principles of a new kind of 
mechanics which provided mathematical techniques competent to deal with 
the wave-particle duality of matter and energy. In its simplest form the 
Schrödinger equation could be written as follows 
Hˆψ = Eψ 
Where Hˆ is called the Hamiltonian operator which is given in terms of 
location, mass and potential energy of an electron, ψ is called the wave 
function which give the probability of finding an electron at certain region in 
the space around the atomic nucleus and E stands for total energy.             
The simplest application of Schrödinger equation is the case of a free 
particle, i.e., one moving in the absence of any potential field. When this 
equation is extended to multi electron system, no exact solution could be 
given owing to various interactions that happen between electrons with each 
other and with core particles in atomic nuclei. Approximate solutions had 
however being given by neglecting some interactions in what is called 
Hartree-Fock method 
1-13-2..Self.consisten.field.(SCF);..Hartree-Fock.calculations:                                
These are based on a few principles and do not employ any experimental 
data. The important concept is to pick one electron and to approximate the 
interaction between this single and all other electrons by a mean value that is 
determined from their probability densities. Each result from one calculation 
is used in subsequent calculation until no change is detected in electrostatic 
potential this why it is called  the self consistent method110a. This method 
ignores the correlated movement of the electrons as they avoid each other 
because of their equal electric charges. This error is called "electron 
correlation". Despite this deficiency, Hartree-Fock calculations give an 
accurate picture in many cases and are not limited to certain classes of 
chemical compounds. However, they need considerable computer time. The 
methods employing Hartree-Fock approach may be divided into two types; a 
ab initio and  semi-empirical methods110b. 
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1-13-3 Ab initio methods  
This method, which litrally means from the beginning, place a prohibitively 
high demand upon computing power and memory to be generally useful for 
the routine modeling of all but the simplest of molecules. 
 1-13-4  Semi empirical Quantum Mechanical Method                      
Semi-empirical quantum chemistry attempts to address two limitations, 
namely slow speed and low accuracy, of the Hartree-Fock calculation by 
omitting or parameterizing certain integrals based on experimental data, 
such as ionization energies of atoms, or dipole moments of molecules. As a 
result, semi-empirical methods are very fast, applicable to large molecules, 
and may give accurate results when applied to molecules that are similar to 
the molecules used for parameterization. On the downside, accuracy of 
semiempirical.methods.is.erratic.on.many.systems                                
Modern semiempirical models are based on the Neglect of Diatomic 
Differential Overlap (NDDO) method in which the overlap matrix S is 
replaced by the unit matrix. This allows one to replace the Hartree-Fock 
secular equation |H-ES| = 0 with a simpler equation |H-E|=0. Existing 
semiempirical models differ by the further approximations that are made 
when evaluating one-and two-electron integrals and by the parameterization 
philosophy. 
1-13-4-a..Modified.Neglect.of.Diatomic.Overlap.(MNDO)                      
This method was discovered by Michael Dewar and Walter Thiel, 1977. It  
is the oldest NDDO-based model that parameterizes one-center two-electron 
integrals based on spectroscopic data for isolated atoms, and evaluates other 
two-electron integrals using the idea of multipole-multipole interactions 
from classical electrostatics. A classical MNDO model uses only s and p 
orbital basis sets while more recent MNDO/d adds d-orbitals that are 
especially important for the description of hypervalent sulphur species and 
transition metals. MNDO has a number of known deficiencies, such as 
inability to describe the hydrogen bond due to a strong intermolecular 
repulsion. The MNDO method is characterized by a generally poor 
reliability in predicting heats of formation. For example, highly substituted 
stereoisomers are predicted to be too unstable compared to linear isomers 
due to overestimation of repulsion is sterically crowded systems111. 
1-13-4-b..Austin.Model.1.(AM1)                                                                 
AM1 Method takes a similar approach to MNDO in approximating two-
electron integrals but uses a modified expression for nuclear-nuclear core 
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repulsion. The modified expression results in non-physical attractive forces 
that mimic van der Waals interactions. The modification also necessitated 
reparameterization of the model, which was carried out with a particular 
emphasis on dipole moments, ionization potentials, and geometries of 
molecules. While this allows for some description of the hydrogen bond, 
other deficiencies, such as systematic over-estimates of basicities, remained. 
Also, the lowest energy geometry for the water dimer is predicted 
incorrectly by the AM1 model. On the other hand, AM1 improves nicely 
some properties, such as heats of formation, over MNDO112.  
1-13-4-c..Parametric.Method.3.(PM3)                                                        
This method uses a Hamiltonian that is very similar to the AM1 Hamiltonian 
but the parameterization strategy is different. While AM1 was parameterized 
largely based on a small number of atomic data, PM3 is parameterized to 
reproduce a large number of molecular properties. In some sense, chemistry 
gave way to statistics with the PM3 model. Different parameterization, and 
slightly different treatment of nuclear repulsion allow PM3 to treat hydrogen 
bonds rather well but it amplifies non-physical hydrogen-hydrogen 
attractions in other cases. This results in serious problems when analyzing 
intermolecular interactions (methane is predicted to be a strongly-bound 
dimer) or conformations of flexible molecules (OH is strongly attracted to 
CH3 in 1-pentanol). The accuracy of thermochemical predictions with PM3 
is slightly better than that of AM1. The PM3 model has been widely used for 
rapid estimation of molecular properties and has been recently extended to 
include many elements, including some transition metals113. 
1-13-4-d..Semiempirical.Methods:.Applicability.and.accuracy                                            
The semiempirical models MNDO, AM1, and PM3 are available in many 
computational chemistry programs such as Argus Lab used in the present 
work. Despite their limitations, semi-empirical methods are often used in 
computational chemistry because they allow study of systems that are out of 
reach of more accurate methods. For example, modern semi-empirical 
programs allow study of molecules consisting of thousands of atoms while 
ab initio calculations that produce similar thermochemical accuracy are 
feasible on molecules consisting of less than 50-70 atoms. Semi-empirical 
calculations can be useful in many situations, such as 
computational modeling of structure-activity relationships to gain insight 
about reactivity or property trends for a group of similar compounds.  
-  design of chemical synthesis.  
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-  development and testing of new methodologies, for example development 
of hybrid quantum mechanics / molecular mechanics (QM/MM) methods for 
modeling of biochemical processes.  
-  preliminary optimization of geometries of unusual molecules and 
transition states that cannot be optimized with molecular mechanics methods  
-  in many applications where qualitative insight about electronic structure 
and.properties.is.sufficient                                                                                                            
The limitations of semi-empirical methods should be kept in mind when 
deciding if these are suitable tools for the task. For large systems, either 
molecular mechanics or semi-empirical quantum mechanics could be used 
for optimization and calculation of conformational energies. The molecular 
mechanics approach is faster and in most cases produces more accurate 
conformational energies and geometries. Some molecular mechanics 
methods, such as MM3 and MM4, can also predict thermochemistry of 
stable species reasonably well. On the other hand, if there is no suitable 
force field for the system (e.g. in case of reactive intermediates or transition 
states), semi-empirical methods may be the only choice. For small system, 
the compromise must be made between the semi-empirical approach and the 
more reliable but much more time-consuming ab initio calculations. In 
general, semi-empirical results can be trusted only in situations when they 
are known to work well (e.g. systems similar to molecules in the 
parameterization set) and strong caution should be exercised in cases where 
semi-empirical methods are known to fail (e.g. prediction of activation 
barriers). Finally, it is not correct to assume that just because semi-empirical 
methods can be used to model many larger systems, they should be used. No 
computational insight may be better than a wrong computational insight! 
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-1   Hardware and software2      
Design of the molecules and calculations were carried out in a Dell laptop 
[Intel(R) Pentium(R)M processor 1500MHz ,239MHz,512 of ram] . The 
operating system is Microsoft Windows XP professional, Version 2002, 
Service Pack 2. All molecules were designed using Arguslab 4 software, 
Planaria Software LLC, Seattle, USA and ACD\I-lab freeware, Advanced 
Chemistry Development Inc. Toronto, Canada.  
Arguslab software were used to: 
i- design the molecules of a training set of eleven known anthracyclines and 
a set of hypothetical aza-analogue of the training set. 
ii- to optimize the geometry of the molecules of both the training and the 
designed sets and   
iii- to calculate their total energies, heat of formation and dipole moments 
using semi-empirical quantum mechanical methods AM1, PM3 and CNDO. 
ACD\I-lab software were used to calculate:  
i- molar refractivity of both sets 
ii- the logarithm of octanol/water partition coefficients (log P).  
Curves and mathematical formulation were derived using Matlab software 
Version 6.0..0.88 release 12, the Mathwork inc, USA. 
2-2  The training set  
The model anthracyclines are daunorubicin, doxorubicin, pirarubicin, 
aclarubicin (aclacinomycin), β-rhodomycin I, β-rhodomycin II, cytorhodin 
A, cytorhodin D, cytorhodin S, 1-hydroxycytorhodin S and cytorhodin X+Y. 
Scheme 2-1 shows the three anthracyclinones ( the aglycones) and the eight 
sugar moieties the combination of which give the anthracyclines of the 
training set as detailed in table 2-1. some of the model anthracyclines are 
natural, e.g., daunorubicin and other are semi-synthetic, e.g., pirarubicin. 
The choice for these  was based on  the fact that these drugs show 
considerable structural variation within the wider family of anthracycline 
which contain above 2000 of known members. This structural diversity 
make them capable of describing a space which is able to be traversed by 
their physiochemical descriptors (tables 2-3 to 2-6). The latters is believed to 
be connected with another space spanned by their parameters of biological 
activity. Table 2-2 shows the biological activity data for the test set as taken 
from reference 114. It was reported as ID50 values against L1210 leukemia  
and two human colon tumour cell lines ( Colon 4 and HT 29) observed after 
short ( 1 h) and long (7 days ) incubation times. The subsequent section is 
devoted to construct a mathematical model connecting physiochemical 
descriptors and biological data with discreet mathematical equations. 
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Scheme 2-1  
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Table 2-1 The structure of the members of the training set  
Sugar substitute sugar aglycon abbreviation Compound  
  7-D daunomycinone Dau Daunorubicin  
  7-D adriamycinone Dox Doxorubicin 
4`-O-ATP 7-D  adriamycinone Pr Pirarubicin 
  7-RN-df-CA aldavinone clِA Aclarubicin 
  7-D β-rhodomycinone  RMN I β-Rhodomycin I  
  7-RN,10-RN β-rhodomycinone RMN II β-Rhodomycin II 
  7-RN-R-R, 10-RN-
R-R  
β-rhodomycinone CTR A  Cytorhodin A 
  7-RN-Fuci, 10-
RN-R-A 
β-rhodomycinone  CTR D Cytorhodin D  
  7-RN-Fuci, 10-RN  β-rhodomycinone  CTR S Cytorhodin S  
  7-RN-Fuci, 10-RN β-isorhodomycinone  1-OH-CTR S  1-Hydroxycytorhodin S 
  7-RN-R-CA, 10-
RN-R-A  
β-rhodomycinone  CTR X+Y  Cytorhodin X+Y  
 
 
 
 
 
 
 
Table 2-2 Bilogical Data of the training set  
HT 29 
1h(Hh)         cont.(Hc) 
4Colon  
1h(Ch)      cont.(Cc) 
1210L  
1h(Lh)      cont(Lc).
Compound  
0.039 0.33 0.032 0.1 0.028  0.038 Daunorubicin  
0.027  0.35 0.022 0.08 0.03 0.05  Doxorubicin 
0.006 0.07 0.004 0.031 0.004 0.014 Pirarubicin 
0.017 0.4 0.024 0.15  0.018 0.26 Aclarubicin 
0.11 0.85 0.06 0.11 0.028 0.037 β-Rhodomycin I  
0.079 0.78 0.023 0.30 0.04 0.42 β-Rhodomycin II 
0.009 0.13 0.0046 0.022 0.0041 0.032 Cytorhodin A 
0.004 0.09 0.0025 0.023 0.0033 0.017 Cytorhodin D  
0.0022 0.05 0.004 0.024 0.0027 0.012 Cytorhodin S  
0.002 0.1 0.0047 0.037 0.0075 0.031 1-Hydroxycytorhodin S 
0.010 0.2 0.0026 0.031 0.0012 0.005 Cytorhodin X+Y  
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2-3  Computational Methodology 
 The molecular geometries of each of the 11 compounds in Table I were 
built using the Arguslab-4 molecular  modeling package . These structures 
were initially optimized by using the molecular mechanics MMFF option in 
Arguslab-4. This is an extended version of the MMZ force field. No 
electrostatic interactions were considered in these initial optimizations. The 
resulting optimized structures were then processed through the AM1, PM3 
MNDO and ZNDO semi empirical molecular orbital calculations furnished 
by Arguslab-4 package to obtain three set of physiochemical parameters 
representing total energies Et, standard heat of formation ∆Hf and dipole 
moment µ as is shown by tables 2-3 to 2-6. See appendices  7-10 for sample  
of MMFF geometry optimization and semi-empirical AM1 calculations for 
daunorubicin and aza-daunorubicin (pages 122-177) 
 
      Table 2-3  Total energies Et  of the training set   
ZINDO MNDO PM3 AM1 Compound  
51817.9182494.46 83757.6581501.96Daunorubicin  
26009.3992601.18 99789.9391770.58Doxorubicin 
69030.3148694.67 150471.2147448.6Pirarubicin 
336627.6337478.45  46615.44336276.2Aclarubicin 
52287.0797919.40 100187.197004.84β-Rhodomycin I  
88178.195071.82 163498.293860.29β-Rhodomycin II 
455997.7535007.30 553767.8535519.2Cytorhodin A 
331672.6517044.92 519759.3515478.7Cytorhodin D  
284076417185.70 426741.9416020.5Cytorhodin S  
301216.6445495.79 456397.9444584.41-Hydroxycytorhodin S 
447287551137.23 547228.5534235.1Cytorhodin X+Y  
  
 
   Table 2-4 Dipole moment of the training set  
ZINDO MNDO PM3 AM1 Compound  
2086.641610.485 1604.821610.58 Daunorubicin  
1920.551940.722 1985.151941.3 Doxorubicin 
2254.622239.176 2240.052238.94 Pirarubicin 
6243.275299.338  6239.325299.713 Aclarubicin 
2186.621659.358 1664.961659.602 β-Rhodomycin I  
2851.58626.201 2323.68626.364 β-Rhodomycin II 
10211.333366.88 3352.113353.2 Cytorhodin A 
4910.964287.70 4199.574287.146 Cytorhodin D  
6462.536343.764 6421.16344.42 Cytorhodin S  
6584.976498.826 6616.546500.764 1-Hydroxycytorhodin S 
10691.783288.5133221.973595.824Cytorhodin X+Y 
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                Table 2-5 Heat of formation ∆Hf  of the training set     
MNDO PM3 AM1 Compound  
240714.6 228691.4239607.3Daunorubicin  
255361.2 248719.7254267.8Doxorubicin 
333592.5 319812332079.2Pirarubicin 
576991 685796.1575479.3Aclarubicin 
260679.4 249116.8259502.1β-Rhodomycin I  
306891.6 356997.7305404.8β-Rhodomycin II 
861955.8 833318.4862122.5Cytorhodin A 
85877.6 832773.8856779.7Cytorhodin D  
701344 686730.6699792Cytorhodin S  
737048.6 723118.5735704.81-Hydroxycytorhodin S
892864.9 860242.9875536Cytorhodin X+Y  
 
The above data were used to find out correlations between the various ID50  
biological data tabulated in table 2  and total energy, dipole moment or heat 
of formation for the training set of anthracyclines (tables 2-3 to 2-6) . 
Altogether, about 400 paired data tables were constructed and statistically 
tested for significant correlations using the formula: 
 
 
 
 
Where  r is the linear correlation coefficient which take the values +1 when 
there is perfect positive correlation, -1 when there is a perfect negative 
correlation and zero when there is no correlation. n is the number data points 
in the paired data set  x and y  refer to each item in the two column of data to 
be correlated.  Except for few trial runs, the correlation coefficients were 
calculated using correlation function furnished by Microsoft Office Excel 
2003. Examples of the aforementioned trials of statistical correlations are 
included in appendix 1 pages 117-121    
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Tables 2-6 The combinations of Et and ID50s with the highest r values      
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2-4  Graphing and mathematical formulation 
The  above six sets of paired data were graphically analyzed using Matlab 7 
program package. Best fit lines and linear equations were  established 
thereof and are detailed in the subsequent sections. 
2-4-1   L1210 leukemia cell line 
2-4-1-a One hour incubation 
The data tabulated in table 6-1 were used to derive best fit curve and to 
formulate the linear regression equation 2-2  
Figure 2-1 extrapolation of the reciprocal of total energy (mol/Kcal) 
calculated by PM3 (Et pm) semi-emperical quantum mechanical method of 
the training set of anthracyclines versus log ID50 (µg/ml) of L1210 leukemia 
cell line 
  
The linear regression equation which relates the reciprocal  total energy of 
the test set as calculated by PM3 method to the natural logarithm of the 
reported ID50  L1210 Leukemia cell line for one hour incubation period was 
calculated to be; 
y = 5.6*104*x - 1.8 
log ID50Lh = 5.6*104*(1/Et pm) – 1.8 ……….(2-2)                     
n = 11   r = 0.61   s = 0.56  F = 5.33      
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The standard deviation of the data, s, shows how far the activity values 
are spread about their average. This value provides an indication of the 
quality of the guess by showing the amount of variability inherent in the 
data. The standard deviation is calculated as shown below. 
 
The equation above estimates the average value for the IC50 based on the 
value for 1/Et; because assays vary, it is not surprising that individual 
values will differ from the regression estimate. The difference between 
the calculated values and the actual (or measured) values for each 
compound is termed the residual from the model. The calculated values 
for activity and their residuals (or the errors of the estimate for 
individual.values).are.shown.in.Table.2-7                                                                   
Table 2-7 Actual and calculated log ID50s for 1h incub. Of the tr.  Set     
.                vs. L1210 cell line 
 (Residual)Calculated 
LogID50Lh
Actual 
LogID50Lh 
Compound  
-0.28881 -1.1314 -1.42022 Daunorubicin  
-0.06221 -1.23882 -1.30103 Doxorubicin 
-0.42604 -1.42784 -1.85387 Pirarubicin 
0.013655 -0.59868 -0.58503 Aclarubicin 
-0.19075 -1.24105 -1.4318 β-Rhodomycin I  
1.080738 -1.45749 -0.37675 β-Rhodomycin II 
0.204025 -1.69888 -1.49485 Cytorhodin A 
-0.07729 -1.69226 -1.76955 Cytorhodin D  
-0.25205 -1.66877 -1.92082 Cytorhodin S  
0.168662 -1.6773 -1.50864 1-Hydroxycytorhodin S
-0.60336 -1.69767 -2.30103 Cytorhodin X+Y  
  The residuals are one way to quantify the error in the estimate for 
individual values calculated by the regression equation for this data set. 
The standard error for the residuals is calculated by taking the root-
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mean-square of the residuals (in this calculation, the denominator shown 
as decremented by two to reflect the estimation of two parameters.  
 
In order to be an improved model, the standard deviation of the residuals 
calculated from the model should be smaller than the standard deviation of 
the original data. The standard error about the mean was previously 
calculated to be 0.56 whereas the standard error from the QSAR model is 
0.22. Clearly, the use of linear regression has improved the accuracy of our 
analysis.The plot of measured values versus calculated is shown in figure 2-
2 with a 45° line. 
We assume that the variances (or standard deviations) of calculated log 
ID50lh and the experimental one are approximately equal to acount for the 
existance of a correlation as evident from linear correlation coefficient r of -
0.61. this claim is teste by means of F statistics which is given by the 
following formula:  
F(n, 1) = (n-2) r2/1-r2 
= 9(0.3721/0.6279) = 5.33 
The above value can be checked in stastical tables to determine the 
significance of a regression equation. In this case the probability that there is 
no relationship between activity and 1/∆Epm is less than 1% 
  
2-4-1-b Continuous incubation 
Figure 2-3 represents the extrapolation of the reciprocal of the total energy 
 ( Et in mol/Kcal) as calculated by AM1 method versus ID50 ( µg/ml) for 
L1210 leukemia cell line(continuous incubation) 
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The linear regression equation which relates the reciprocal  total energy of 
the test set as calculated by AM1 method to the reported ID50  L1210 
Leukemia cell line for continuous incubation period was calculated to be; 
                                     y = 2.8e+003*x - 0.0011 
which denotes 
                               ID50Lc = 0.028*103(1/Et am) + 0.0011                      (2-4)  
  
 
Using formulas 2-4 above we calculate the following statistics 
  n= 11     s (measured ID50) = 0.0140406    s (regression) = 0.007 
F =28.022.   
These were obtained using data tabulated in table 2-8 below.   
                Table 2-8  Actual and calculated ID50s and their residual for cont. 
                                                   incub. of the tr. set vs. L1210 
(Residual) Calculated 
ID50Lc 
ID50Lc 
ID50Lc 
Compound  
-0.00525 0.033255 0.028 Daunorubicin  
0.000589 0.029411 0.03 Doxorubicin 
-0.01389 0.01789 0.004 Pirarubicin 
0.010774 0.007226 0.018 Aclarubicin 
0.000235 0.027765 0.028 β-Rhodomycin I  
0.011268 0.028732 0.04 β-Rhodomycin II 
-2.9E-05 0.004129 0.0041 Cytorhodin A 
-0.00103 0.004332 0.0033 Cytorhodin D  
-0.00293 0.00563 0.0027 Cytorhodin S  
0.002302 0.005198 0.0075 1-Hydroxycytorhodin S 
-0.00294 0.004141 0.0012 Cytorhodin X+Y  
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Figure 2-4 shows the extrapolation of the experimental ID50 for continuous 
incubation of L1210 leukemia cell line with the calculated values 
  
2-4-2  Colon 4 cell line 
2-4-2a One hour incubation 
 Extrapolation of  the total energy ( Et in Kcal/mol )as calculated by PM3 
method versus the reciprocal ID50 (ml/µg) for Colon 4 cell line(one hour 
incubation, table 2-6-3) is depicted in figure 2-5   
  
The linear regression equation which relates the total energy of the test set as 
calculated by PM3 method to the reciprocal of the reported ID50  Colon 4 
cell line for one hour incubation period was calculated to be; 
y = 6.5e-005*x + 5.4 
or                                      1/ID50Ch = 6.5× 10-5 Etpm + 5.4                (2-5) 
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n = 11    s (measured ID50) = 16.04819   s (regression) = 8.444543 
23.432 =F 
Table 2-9 gives the reciprocal of experimental ID50 with their cacluted 
counterparts in addition to the residuals from which the standard deviation of 
the regression is calaculated  
                    Table 2-9  Actual and calculated ID50s and their residual for 
                                       1h. incub. of the tr. Set vs. Colon 4 cell line 
(Residual) Calc. 
1/ID50 Ch 1/ID50Ch 
Compound  
-0.84425 10.8443 10 Daunorubicin  
0.613654 11.8864 12.5 Doxorubicin 
17.07747 15.1806 32.2581 Pirarubicin 
-1.76333 8.43 6.66667 Aclarubicin 
-2.82125 11.9122 9.09091 β-Rhodomycin I  
-12.6941 16.0274 3.33333 β-Rhodomycin II 
4.059589 41.3949 45.4545 Cytorhodin A 
4.293941 39.1844 43.4783 Cytorhodin D  
8.528473 33.1382 41.6667 Cytorhodin S  
-8.03886 35.0659 27.027 1-Hydroxycytorhodin S 
-8.71175 40.9699 32.2581 Cytorhodin X+Y  
 
Figure 2-6 shows the extrapolation of the experimental ID50 for one hour 
incubation of Colon 4 cell line with the calculated values 
  
 
2-4-2b Continuous incubation 
 The extrapolation of  the total energy ( Et in Kcal/mol )as calculated by 
PM3 method versus the reciprocal ID50 (mol/µg) for Colon 4  cell 
line(continuous incubation, table 2-6-4) is shown in figure 2-7  
-  
The linear equation which relates the total energy of the test set as calculated 
by PM3 method (Etpm in Kcal/mol)to the reciprocal of the reported ID50       
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( ml/µg)  Colon 4 cell line for continuous  incubation period was calculated 
to be; 
y = 0.00058 x + 7.1 
 or                                    1/ID50 = 0.00058 Etpm+ 7.1            (2-6) 
 n =11    s (measured 1/ID50) = 143.7139    s (regression) = 80.83462 
F = 23.432. 
Table 2-10 shows experimental and calculated 1/ID50s in addition to their 
residuals from the standard deviation of the regression is calculated. 
               Table2-10    Actual and calculated ID50s and their residual for cont. 
                                    incub. of the tr. set vs. Colon 4 cell line   
(Residual) Calculated 
1/ID50 Cc 1/ID50Cc 
Compound  
-24.4294 55.67944 31.25 Daunorubicin  
-19.5236 64.97816 45.4545 Doxorubicin 
155.6267 94.3733 250 Pirarubicin 
7.529716 34.13696 41.6667 Aclarubicin 
-48.5419 65.20852 16.6667 β-Rhodomycin I  
-58.4507 101.929 43.4783 β-Rhodomycin II 
-110.894 328.2853 217.391 Cytorhodin A 
91.43961 308.5604 400 Cytorhodin D  
-4.61031 254.6103 250 Cytorhodin S  
-59.0448 271.8108 212.766 1-Hydroxycytorhodin S 
60.12286 324.4925 384.615 Cytorhodin X+Y  
Figure 2-8 shows the extrapolation of the experimental 1/ID50 for one hour 
incubation of Colon 4 cell line with the calculated values 
 
 
2-4-3  HT 29 cell line 
2-4-3-a  One hour incubation 
 Extrapolation of the reciprocal of the total energy as calculated by AM1 
( Etam in mol/Kcal) versus ID50 ( µg/ml) for HT29  cell line (one hour 
incubation, table 2-6-5) is depicted in figure 2-9 
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  The linear equation which relates the reciprocal  total energy of the 
test set as calculated by AM1 method to  the reported ID50  for HT29 cell 
line for one hour incubation period was calculated to be; 
y = 4.3e+004*x + 0.054 
     which implies 
                         ID50 Hh =0.43*104*(1/Etam) +0.054                 (2-7)       
 
           n = 11     s (measured) = 0.28         s (regression) = 0.22 
F = 7.331  
T able 2-11 shows the experimental and the calculated 1/ID50s, as well as 
their residuals from which the standard deviation of regression is estimated 
              Table 2-11 Actual and calculated ID50s and their residual for 
                                   1h. incub. of the tr. set vs.HT 29 cell line  
(Residual) Calc.1/ID50Hh 1/ID50HhCompound  
-0.25159 0.581595 0.33 Daunorubicin  
-0.17256 0.52256 0.35 Doxorubicin 
-0.27563 0.345627 0.07 Pirarubicin 
0.218129 0.181871 0.4 Aclarubicin 
0.352723 0.497277 0.85 β-Rhodomycin I  
0.267872 0.512128 0.78 β-Rhodomycin II 
-0.0043 0.134296 0.13 Cytorhodin A 
-0.04742 0.137418 0.09 Cytorhodin D  
-0.10736 0.15736 0.05 Cytorhodin S  
-0.05072 0.15072 0.1 1-Hydroxycytorhodin S 
0.065511 0.134489 0.2 Cytorhodin X+Y  
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Figure 2-10 shows the extrapolation of the experimental ID50 for one hour 
incubation of HT 29 cell line with the calculated values 
 
2-4-3b Continuous incubation 
Figure 2-11 depicts the extrapolation of the reciprocal of the total energy ( Et 
in mol/Kcal)as calculated by AM1 method versus log ID50  for HT29  cell 
line (continuous incubation, table 2-6-6 )  
The linear equation which relates the reciprocal  total energy of the training 
set as calculated by AM1 method to the  logarithm of the reported ID50  for 
HT29 cell line for continuous incubation period was calculated to be; 
y = 1.1e+005*x - 2.5 
  or           
                         logID50 Hc =1.1*105*(1/Et am) -2.5               (2-8) 
n = 11       s  (measured) =  0.59       s ( regression) = 0.376 
F = 16  
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Table 2-12 shows experimental and calculated 1/ID50s in addition to their 
residuals from the standard deviation of the regression is calculated 
            Table 2-12  Actual and calculated ID50s and their residual for 
                                 cont.. incub. of the tr. set vs.HT 29 cell line 
(Residual) Calculated 
 logID50 Hc
logID50 
Hc 
Compound  
-0.25856 -1.15034 -1.4089 Daunorubicin  
-0.26724 -1.30136 -1.5686 Doxorubicin 
-0.46782 -1.75398 -2.2218 Pirarubicin 
0.40329 -2.17289 -1.7696 Aclarubicin 
0.40744 -1.36604 -0.9586 β-Rhodomycin I  
0.22565 -1.32805 -1.1024 β-Rhodomycin II 
0.24879 -2.29459 -2.0458 Cytorhodin A 
-0.11129 -2.28661 -2.3979 Cytorhodin D  
-0.42201 -2.23559 -2.6576 Cytorhodin S  
-0.44642 -2.25258 -2.699 1-Hydroxycytorhodin S
0.2941 -2.2941 -2 Cytorhodin X+Y  
 
 
Figure 2-12 shows the extrapolation of the experimental log ID50 for 
continuous incubation of HT 29 cell line with the calculated values 
 
 
  2-5  Validation of the models 
In general, the dataset used in building a QSAR model is divided into two 
set, the training set and the test set. The equations produced by the training 
set is validated by the by applying them to the test set. We ,however, could 
apply this approach owing to the smallness of the our dataset. 
Another approach to validate aQSAR model is the so called cross validation 
In which  predictive ability of the models is assessed for the dataset  in the 
training set using the terms o q2: 
q2 = (s - PRESS)/SD 
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where the PRESS (predictive residual sum of squares) and s (standard 
deviation) values are obtained as: 
PRESS = ∑(propertyobserved - propertypredicted)2…… (2-9) 
s = ∑(propertyobserved - propertymean)2… …………..(2-10) 
A model is considered significant when q2 > 0.3. we had not used this 
procedure because it tend to give erroneous results for small datasets 
  In general, a regression equation can be accepted in QSAR studies, 
i-if the correlation coefficient r is around or better than 0.9 for in vitro data 
and 0.8 for whole animal data  
ii-if the standard deviation s is not much larger than the standard deviation of 
the biological data  
iii-if its F value indicates that the overall significance level is better than 
95% 
condition (i) is not fulfilled by our model while the two other conditions (ii 
and iii) are satisfied. This, in our opinion, is quite enough for our purpose as 
we consider this model as grossly qualitative. It is directed toward exposing 
the effect of introducing N atom in the carbocyclic anthracycline backbone. 
See reference(115) for more details about validation aspects of QSAR 
models  
 
  
2-6  The designed azaanthracycline set 
Anthracyclines  could be regarded as derivatives of 9-hydroxy-9-ethyl- 
7,8,9,10-tetracene-5,12-dione (19).The β-position to the anthraquinone 
nucleus in the alicyclic ring carries two side chains, an ethyl (or carboethyl) 
and hydroxy groups. Thus our design strategy depends on keeping as near as 
possible to above structure. This strategy depends on replacing 
unfunctionalized carbon atoms along the tetracyclic backbone of 
anthracycline with nitrogen atom in sequential manner. The unfunctionalized  
carbon atoms are C1, C2, C3, in ring D for all three group of  compounds 
except for 1-hydroxy-cytorhodin S in cytorhodin family, C8 in ring A for all 
groups, C10 in ring A in daunorubicin family and C11 in ring B in 
aclarubicin family. We design  47 aza-analogues of the above precursors 
distributed among three groups; the aza-daurubicins (15 analogues), the aza-
aclarubicin (5 analogues) and the the aza-rhodomycins (27 analogues) 
2-6-1 The aza-daunorubicin group 
This includes five azaanalogues for each of daunorubicin, doxorubicin and 
pirarubicin. Three of these five analogues are ring D-modified with an N 
atom while the other two are ring A-modified. Table 2-13 give the structures 
of the members of this group.  
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                                 Table 2-13   The structures of Aza-daunorubicin group  
R2 R1 G F C B A Compound
D H C C C C N 134  
D H C C C N C 135  
D  H  C  C  N  C  C 136  
D  H  C  N  C  C  C  137  
D  H  N  C  C  C  C  138  
D OH C C C C N 139  
D OH C C C N C 140  
D  OH  C  C  N  C  C 141  
D  OH  C  N  C  C  C  142  
D  OH  N  C  C  C  C  143  
ATPD OH C C C C N 144  
ATPD OH C C C N C 145  
ATPD  OH  C  C  N  C  C 146  
ATPD  OH  C  N  C  C  C  147  
ATPD  OH  N  C  C  C  C  148  
2-6-2 The aza-aclarubicin group 
This group comprise five azaanalogues; three ring D-, one ring A- and one 
ring B-modified with N atom 
 
 
 
      
 
                 
 
                   
 
 
 
Table 2-14  The structure of Aza-aclarubicin group              
R1 G F C B A Compound
RN-df-CA C C C C N 149  
RN-df-CA C C C N C 150  
RN-df-CA  C  C  N  C  C 151  
RN-df-CA  C  N  C  C  C  152  
RN-df-CA  N  C  C  C  C  153  
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2-6-3 The aza-rhodomycin group 
The group contains 27 azaanalogues, four for each of the following aza-
rhodomycin I, aza-rhodomycin II, aza-cytorhodin A, aza-cytorhodin D, aza-
cytorhodin S and aza-cytorhodin X all of which belong to β-aza-
rhodomycinon aglycone. Three of the four aza-analogues of  are modified at 
ring D and one is modified at ring A. An additional subgroup, termed 1-
hydroxyaza-rhodin S, belongs to β-aza-isorhodomycinon aglycone. It 
contains three aza analogues; two ring D- and one ring A-modified.  
 
           Table 2-15  The structures of Aza-rhodomycin group  
R3 R2  R1 F C B A compound
H D nil C C C N 154  
H D H C C N C 155  
H D  H  C N  C  C 156  
H D H N C C C 157 
RN RN  nil  C C  C  N  158  
RN RN  H  C C  N  C  159  
RN RN H C N C C 160  
RN RN H N C C C 161 
RN-R-R RN-R-R nil C C C N 162  
RN-R-R RN-R-R  H  C C  N  C 163  
RN-R-R RN-R-R  H  C N  C  C  164  
RN-R-R RN-R-R  H N C C C 165 
RN-A-R RN-Fuci  nil  C C  C  N  166  
RN-A-R RN-Fuci H C C N C 167  
RN-A-R RN-Fuci H C N C C 168  
RN-A-R RN-Fuci H N C C C 169 
RN RN-Fuci  nil  C C  C  N 170  
RN RN-Fuci  H  C C  N  C  171  
RN RN-Fuci  H  C N  C  C  172  
RN RN-Fuci  H N C C C 173 
RN RN-Fuci OH C C N C 174 
RN RN-Fuci OH C N C C 175  
RN RN-Fuci OH N C C C 176  
RN-R-A RN-R-CA  nil  C C  C  N 177  
RN-R-A RN-R-CA  H  C C  N  C  178  
RN-R-A RN-R-CA  H  C N  C  C  179  
RN-R-A RN-R-CA  H N C C C 180 
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2-7 The physiochemical parameters and the calculated ID50s for the 
designed aza-anthracyclines 
We have obtained the six linear equations 2-2, 2-4, 2-5, 2-6, 2-7 and 2-8  
from extrapolation of total energies use  as calculated by two semi-empirical 
methods AM1 and PM3 versus in vivo ID50s of the three cell line L1210, 
Colon 4 and HT 29 for 1h and continuous incubation modes against the 
eleven compounds of the training set. Figure summarizes the these linear 
equations which constitute the mathematical model for the present QSAR 
study. Thus we have to calculate the total energies for our designed aza-
anthracyclines by the above two methods and use them to obtain the 
expected ID50 for two incubation modes against our three cell lines. Tables 
2-16, 2-17 and 2-18   below give the total energies and their reciprocals for 
the designed set, followed by tables 2-19, 2-20 and 2-21 which give the 
caculated biological data using the equations 2-2, 2-4….2-8 
          Figure 2-13 The mathematical model of six linear equations used to derive 
                                biological data of the designed set of anthracycline aza-analogues           
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  Table 2-16 Parameters for aza-daunorubicin group 
1/Et*10-5  (PM3)Et(PM3) 1/Et *10-5 (AM1) Et(AM1) compound 
0.749082 133496.81 0.765045 130711.21 134  
0.74806 133679.07 0.765231 130679.58 135  
0.748358 133625.93  0.764361 130828.23 136  
0.699287 143002.82  0.708157 141211.73  137  
0.711682 140512.26  0.734483 136150.14  138  
0.759245 131709.72 0.764794 130754.21 139  
0.757795 131961.87 0.763487 130978.03 140  
0.758109 131907.21  0.763741 130934.42 141  
0.722412 138425.23  0.724088 138104.84  142  
0.732722 136477.38  0.754018 132622.89  143  
0.689539 145024.38 0.69866 143131.22 144  
0.690701 144780.39 0.699887 142880.27 145  
0.702176 142414.37  0.676671 147782.24 146  
0.646593 154656.75  0.650068 153830.04  147  
0.65217 153334.21  0.654692 152743.56  148  
  
  
  
  
  
  
  
 
               Table  2-17 parameters for aza-aclarubicin group 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
  
  
 
1/Et 
pm*105 
Et pm 1/Et 
am*105 
Et am compound
0.3009366  332295.870.3021719  330937.43 149  
0.3022867  330811.790.3031306  329890.85 150  
0.3026598  330403.97 0.3058012  327009.85 151  
0.3036669  329308.19 0.3019975  331128.61  152  
0.2962378 337566.61 0.2998711 333476.69  153  
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          Table 2-18 parameters for aza-rhodomycin group 
1/Et pm*105 Et pm 1/Et am*105 Et am compound 
1.072295  93257.94 1.10395  90583.81 154  
1.073973  93112.17 1.105804  90431.93 155  
1.076177  92921.49  1.108094  90245.03  156  
0.980083  102032.17 0.9982517  100175.13 157 
1.087178  91981.28  11.46446  87722.61  158  
1.093951  91411.75  1.147997  87108.23  159  
1.053453  94925.94 1.14921  87016.29 160  
0.9982339  100176.93 1.042295  95942.13 161 
0.1873192  533848.12 15185.3  6.5853173 162  
0.1878403  532367.17 0.188591  530248.15 163  
0.187171  534270.75 0.1883983  530790.23 164  
0.1841674  542984.17 0.1882813  531120.15 165 
0.1843332  542495.99  0.184665  541521.26  166  
0.1840424  543352.95 0.1838827  543825 167  
0.1842585  542715.81 0.1840298  543390.37 168  
0.1845037  541994.62 0.1851497  540103.63 169 
0.2220997  450248.16  0.2231437  448141.78  170  
0.2222044  450036.12  0.2232711  447885.92  171  
0.2242582  445914.67  0.2258433  442784.92  172  
0.2242193  445991.86  0.2255146  443430.32  173 
0.2091359  478157.99 0.2115756  472644.39 174 
0.2096935  476886.55 0.2123822  470849.27 175  
0.2118548  472021.35 0.2114749  472869.34 176  
0.1845718  541794.42  0.1846991  541421.20  177  
0.1846349  541609.53  0.1843174  542542.33  178  
0.1852155  539911.57  0.1853796  539433.59  179  
0.1859722 537714.89  0.1859644 537737.39  180 
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Table 2-19  calculated biological data for aza-daunorubicin group  
 
 
  
                        Table 2-19  cont.  
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
ID50Cc 1/ID50Cc ID50Ch 1/ID50ChID50Lc ID50Lh  LogID50Lhcompound 
0.01183 84.52815  0.071036 14.07729  0.020321 0.041638 -1.38051 134  
0.011816 84.63386  0.070977 14.08914  0.020326 0.041583 -1.38109 135  
0.01182 84.60304  0.070994 14.08568  0.020302 0.041599 -1.38092 136  
0.011106 90.04163  0.06805 14.69518  0.018728 0.039048 -1.4084 137  
0.011287 88.59711  0.068808 14.5333  0.019466 0.039677 -1.40146 138  
0.011977 83.49164  0.071627 13.96113  0.020314 0.042187 -1.37482 139  
0.011956 83.63789  0.071543 13.97752  0.020278 0.042108 -1.37564 140  
0.011961 83.60618  0.071562 13.97397  0.020285 0.042125 -1.37546 141  
0.011443 87.38663  0.069456 14.39764  0.019174 0.04023 -1.39545 142  
0.011593 86.25687  0.070072 14.27103  0.020012 0.040768 -1.38968 143  
0.010963 91.21413  0.067446 14.82659  0.018462 0.03856 -1.41386 144  
0.01098 91.07262  0.067519 14.81073  0.018497 0.038618 -1.41321 145  
0.011148 89.70034  0.068227 14.65694  0.017847 0.039194 -1.40678 146  
0.01033 96.80092  0.064714 15.45269  0.017102 0.036483 -1.43791 147  
0.010413 96.03384 0.065076 15.36672 0.017231 0.036746 -1.43479 148  
ID50 logID50  ID50Hh compound 
0.021956 -1.65845 0.3829695  134  
0.021966 -1.65825 0.3830491  135  
0.021918 -1.6592 0.3826753  136  
0.01901 -1.72103 0.3585073  137  
0.02032 -1.69207 0.3698278  138  
0.021942 -1.65873 0.3828613  139  
0.021869 -1.66016 0.3822993  140  
0.021883 -1.65989 0.3824087  141  
0.019792 -1.7035 0.3653577  142  
0.021351 -1.67058 0.3782276  143  
0.018558 -1.73147 0.3544236  144  
0.018616 -1.73013 0.3549513  145  
0.017552 -1.75566 0.3449687  146  
0.016409 -1.78493 0.3335293  147  
0.016602 -1.77984 0.3355176 148  
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Table 2-20 calculated biological data of aza-aclarubicin group 
                  Table 2-20 cont.                                                                                              
ID50Hc logID50Hc  ID50Hh compound 
0.006798 -2.167610.1839339  149  
0.006815 -2.166560.1843462  150  
0.006861 -2.163620.1854945  151  
0.006795 -2.16780.1838589  152  
0.006759 -2.170140.1829445 153  
 
Table 2-21 Biological data of aza-rhodomycin group 
ID50Cc 1/ID50Cc ID50Ch 1/ID50Ch ID50Lc .ID50Lh  LogID50L hcompound 
0.016343 61.1896 0.087247 11.46177 0.029811 0.063166 -1.1995 154  
0.016365 61.10506 0.087319 11.45229 0.029863 0.063303 -1.1986 155  
0.016395 60.99446 0.087413 11.4399 0.029927 0.063483 -1.1973 156  
0.015088 66.27868 0.083111 12.03209 0.026851 0.056085 -1.2512 157 
0.016543 60.44914 0.087883 11.37878 0.030819 0.06439 -1.1912 158  
0.016634 60.11882 0.08817 11.34176 0.031044 0.064955 -1.1874 159  
0.016088 62.15704 0.086429 11.57019 0.031078 0.06165 -1.2101 160  
0.015337 65.2026 0.083952 11.9115 0.028084 0.057413 -1.241 161 
0.003157 316.7319 0.024938 40.10013 0.004166 0.020179 -1.6951 162  
0.003166 315.873 0.024998 40.00387 0.004181 0.020193 -1.6948 163  
0.003155 316.9771 0.024921 40.1276 0.004175 0.020175 -1.6952 164  
0.003105 322.0308 0.024574 40.69397 0.004172 0.020097 -1.6969 165 
0.003108 321.7477 0.024593 40.66224 0.004071 0.020101 -1.6968 166  
0.003103 322.2447 0.024559 40.71794 0.004049 0.020094 -1.6969 167  
0.003107 321.8752 0.024584 40.67653 0.004053 0.020099 -1.6968 168  
0.003111 321.4569 0.024613 40.62965 0.004084 0.020106 -1.6967 169 
0.003728 268.244 0.028847 34.66613 0.005148 0.021105 -1.6756 170  
0.00373 268.1209 0.028858 34.65235 0.005152 0.021107 -1.6756 171  
0.003763 265.7305 0.029083 34.38445 0.005224 0.021163 -1.6744 172  
0.003763 265.7753 0.029079 34.38947 0.005214 0.021162 -1.6744 173 
0.003516 284.4316 0.027412 36.48027 0.004824 0.020755 -1.6829 174 
0.003525 283.6942 0.027474 36.39762 0.004847 0.02077 -1.6826 175  
0.00356 280.8724 0.027715 36.08139 0.004821 0.020828 -1.6814 176  
0.003112 321.3407 0.02462 40.61664 0.004072 0.020108 -1.6966 177  
0.003113 321.2335 0.024628 40.60462 0.004061 0.020109 -1.6966 178  
0.003123 320.2487 0.024695 40.49425 0.004091 0.020124 -1.6963 179  
0.003135 318.9746 0.024782 40.35147 0.004107 0.020144 -1.6959 180 
ID50Cc 1/ID50CcID50Ch 1/ID50ChID50Lc .ID50Lh  LogID50Lh compound 
0.005004 199.8316 0.03703826.99923 0.0073610.023363 -1.63148 149  
0.005026 198.9709 0.03717126.90277 0.0073880.023404 -1.63072 150  
0.005032 198.7343 0.03720826.87626 0.0074620.023415 -1.63051 151  
0.005048 198.0988 0.03730626.80503 0.0073560.023445 -1.62995 152  
0.004929 202.88860.03657427.341830.0072960.023222 -1.63411 153  
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                              Table 2-21 cont.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
2-8 Log P for the designed set 
 Log Ps were calculated using the log P estimation facilities provided in 
ACD/ I-Lab freeware and is tabulated with refined biological activity data 
for each group next section.                
 
 
 
  
ID50Hc logID50Hc  ID50Hh Compound 
0.051802 -1.28566 0.5286985  154  
0.052046 -1.28362 0.5294957  155  
0.052348 -1.2811 0.5304804  156  
0.039635 -1.40192 0.4832483  157 
0.056748 -1.24605 0.5441815  158  
0.057916 -1.2372 0.5476387  159  
0.058094 -1.23587 0.5481603  160  
0.044312 -1.35348 0.5021868  161 
0.005092 -2.29313 0.1348671  162  
0.005099 -2.29255 0.1350941  163  
0.005096 -2.29276 0.1350113  164  
0.005095 -2.29289 0.134961  165 
0.005048 -2.29687 0.133406  166  
0.005038 -2.29773 0.1330696  167  
0.00504 -2.29757 0.1331328  168  
0.005054 -2.29634 0.1336144  169 
0.005565 -2.25454 0.1499518  170  
0.005567 -2.2544 0.1500066  171  
0.005603 -2.25157 0.1511126  172  
0.005598 -2.25193 0.1509713  173 
0.005404 -2.26727 0.1449775  174 
0.005415 -2.26638 0.1453243  175  
0.005403 -2.26738 0.1449342  176  
0.005049 -2.29683 0.1334206  177  
0.005044 -2.29725 0.1332565  178  
0.005057 -2.29608 0.1337132  179  
0.005065 -2.29544 0.1339647 180 
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3-1 The aza-anthraquinones and aza-anthrapyrazoles clue 
 It has been shown that introduction of nitrogen atom into the carbocyclic 
nucleus of anthracene-9, 10-dione have a profound effect on their activity. 
This effect depends on the position; for instance mitoxantrone 7b and its two 
aza-analogues 101a and 103a exhibit the following activity profile against 
L1210 leukemia cell line: (7b) > (56)>(54). 
The same phenomenon has also been observed for anthrapyrazoles and their 
aza-analogues. For instant, BBR 3438 (79) is more active than losoxantrone 
(78) which is more active than compound (181)  
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(78) (79)     (181)  
This work is an attempt follow up the effect of introduction of a nitrogen 
atom at various unfunctionalized positions around the anthracycline nucleus 
in silico as a prior step toward their synthesis. As it is well-known, 
mitoxantrone and its analogues resemble anthracyclines in that both contain 
rigid planar aromatic anthraquinone chromophore. Losoxantrone and its 
analogue also possess a rigid aromatic quasi quinone chromophore and are 
considered as derivatives of mitoxantrone. The above described norm of 
behaviour shown by the aza-analogues of mitoxantrone and losoxantrone is 
anticipated to be shown by anthracycline aza-analogues owing to 
physicochemical similarities between these classes of anticancer agents. The 
proceeding discussion will examine whether this supposition holds for aza-
anthracyclines. 
The designed anthracycline aza-analogues were divided into three groups. 
Two of these groups, namely aza-daunorubicin and aza-rhodomycins, were 
further divided into two subgroups; ring A- and ring D-modified subgroups. 
Aza-rhodomycins group were also considered from two perspective based 
on methods of grouping. These classifications were made to facilitate the 
manipulation of the voluminous data extracted from our QSAR model as is 
treated in following section 
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 3-2 The aza-daunorubicin group 
This group comprises three subgroups of aza analogues for daunorubicin, 
doxorubicin and pirarubicin each contains five members, three ring D-     
and two ring A-modified analogues, making altogether fifteen analogues. 
3-2-1  Daunorubicin aza-analogues modified at ring D 
   The calculated biological data for this group from our QSAR model, in 
addition to the calculated log P values, are tabulated in table 3-1 below. This 
group could be further subdivided into three subgroups; aza-daunorubicins, 
aza-doxorubicins and aza-pirarubicins 
 
Table 3-1 Calculated log P and Biological data of ring D-modified 
daunorubicin aza-analogues 
 
  3-2-1-a Aza-daunorubicin 
This.includes.1-aza-daunorubicin [ [(134). 9-acetyl-7-daunosaminyl-6,9,11-
trihydroxy-,7,8,9,10-tetrahydronaphtho[g]quinolin-5,12-dione].and its 
analogues, 2 and 3 respectively.  
 
Scheme 3-1 
One hour incubation against L1210 leukemia cell line: as it could be 
discerned from table 3-1 the order of activity in this series 
(135)>(136)>(134). The smaller ID50 value the more active the compound. 
This is quite reminiscent of the order of relative activity observed in aza-
anthrapyrazoles. 
ID50Hc ID50Hh ID50Cc ID50Ch ID50Lc ID50Lh  Log p compound 
0.021956 0.3829695  0.01183 0.071036 0.020321 0.041638 2.17 134  
0.021966 0.3830491  0.011816 0.070977 0.020326 0.041583 2.25 135  
0.021918 0.3826753  0.01182 0.070994 0.020302 0.041599 2.5 136  
0.021942 0.3828613  0.011977 0.071627 0.020314 0.042187 2.07 139  
0.021869 0.3822993  0.011956 0.071543 0.020278 0.042108 2.15 140  
0.021883 0.3824087  0.011961 0.071562 0.020285 0.042125 2.4 141  
0.018558 0.3544236  0.010963 0.067446 0.018462 0.03856 3.1 144  
0.018616 0.3549513  0.01098 0.067519 0.018497 0.038618 3.18 145  
0.017552 0.3449687  0.011148 0.068227 0.017847 0.039194 3.43 146  
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 Continuous incubation against L1210 leukemia cell line: the order of 
activity is (136)>(134)>(135). Although both (135) and (136) are 2-aza 
analogues, they are different in the present connection in their activity with 
the 1-aza analogue (134) occupying an intermediate position.   
One hour incubation against Colon 4 cell line: the order of activity is 
(135)>(136)>(134) which is the same as that for one hour incubation for 
L1210 cell line    
Continuous incubation against Colon 4 cell line: the order of activity 
(135)>(136)>(134) which is same as one hour incubation for both L1210 
and Colon 4 but different from continuous incubation for L1210     
One hour incubation against HT 29 cell line: the order of activity 
(136)>(134)>(135) same as that for continuous incubation for L1210 
Continuous incubation against HT 29 cell line: the order of activity 
(136)>(134)>(135) same as that for continuous incubation for L1210 and 
one hour incubation for HT 29 
  Thus for compounds (134), (135) and (136), two order of activity can be 
observed: 
i-  (135)>(136)>(134) for 1h incubation against L1210 and for both 
incubation modes for Colon 4. This order of activity is the comparable to 
that reported for aza-anthrapyrazoles and aza-anthracenediones. 
ii- (136)>(134)>(135)  for continuous incubation against L1210 and for both 
modes of incubation against HT 29. Here, at least one of the two compounds 
with the anticipated higher activity [compound (136), a 2-aza analogue],  
shows enhanced activity over the compound with anticipated  lower activity 
( 1-aza analogue)  
3-2-1-b Aza-doxorubicins  
This includes 1-azadoxorubicin [(139) 9-(2'-hydroxyacetyl)-7-
daunosaminyl-6,9,11-trihydroxy-,7,8,9,10-tetrahydronaphtho[g]quinolin-
5,12-dione], in addition to 2- aza analogues, (140) and (141) respectively 
 
 
Scheme 3-2 
This series shows complete compliance with the order of activity observed 
in aza-anthrapyrazoles and aza-anthracenediones for both incubation modes 
and for all three cell lines. That is: (140)>(141)>(139). The general trend in 
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activity is comparable to that calculated for aza-daunorubicin and 
corresponds closely to that of the training set (see table 2-2, part two) 
3-2-1-c Aza-pirarubicin 
These tetrahydropyranyl derivatives of aza-doxorubicin exhibit higher 
activity than the parent molecule, as calculated from our QSAR model. This 
corresponds to what is exhibited by its carbocyclic cogener pirarubicin 
which shows similar activity profile compared to doxorubicin. Scheme 3-3 
shows the structures of these compounds.   
 
Scheme 3-3 
Surprisingly, the patterns of activity shown by these compounds are 
markedly different from both aza-daunorubicin and aza-doxorubicin groups 
in connection with 1h incubation against L1210and both incubation modes 
against Colon 4. The order of activity for these compounds is 
(144)>(145)>(146) which is at variance with the order observed in aza-
anthrapyrazoles.  For continuous incubation against L1210 and both 
incubation modes against HT 29, the order of activity is (146)>(144)>(145) 
which corresponds to that observed in aza-daunorubicin for the same cell 
lines with the same incubation modes.  
 
3-2-1d   log P of  aza-daunorubicins modified at ring D 
The calculated lipohilicity parameter log P has a direct and strong 
correlation with the various ID50 calculated from our QSAR model. The 
correlation coefficient r was derived for both incubation modes against the 
three cell line using formula 2-1 and are shown in table 3-1-1 below 
As it is apparent from table 3-1-1(last column), there is a general negative 
correlation between log P and ID50 for both incubation modes and against all 
the three cell lines, i.e., the higher is the value of log P the smaller is the 
value of ID50. This signifies that there is a parallel positive correlation 
between Log P and activity, i.e., the higher is log P the higher is the activity. 
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          Table 3-1-1 Correlation coefficients of P &K vs. –log ID50s for 
             the training set and log P vs. cal. ID50s of the designed set. 
r for aza-
analogues 
 r for 
training set  
Incubation 
mode  
Cell line  
-0.93  0.85  1h.  L1210 
-0.97  0.90  Cont.  L121o 
-0.93  0.87  1h.  Colon 4 
-0.93  0.86  Cont.  Colon 4 
0.97-  0.71  1h.  HT 29 
0.97-  0.79  Cont.  HT 29 
 
Using data tabulated above together with activity profiles of this group we 
could discern three definite categories for this group: 
i- Compound with medium log P values shows the highest activity:  this is 
observed in aza-daunorubicin for one hour incubation against L1210 and 
both incubation modes against Colon 4 and also in aza-doxorubicins for both 
incubation modes against all the three cell lines. The order of activity for this 
category is (135)>(136)>(134) for aza-daunorubicins and (140)>(141)>(139) 
for aza-doxorubicins which means that the 2-aza analogues (135), (136), 
(140) and (141) are more active than the 1-aza analogues (134) and (139). 
This order of activity indicates that the compound of the lowest log P, i.e., 1 
and 6 are the least active while those with the highest log P, i.e., 3 and 8 are 
of intermediated activities. This finding is quite in harmony with what has 
been reported114 in some carbocyclic anthracyclines used to build the present 
QSAR model. The linear correlation coefficient r for this group (-0.93) is 
lower than that (-0.97) of next category discussed below. The reflects that 
activity, in going from one compound to the next, undergoes an increase 
then a decrease with increasing lipohilicity within each subgroup  even if the 
general trend for the whole group is that activity increases with increasing  
lipophilicity.  
ii- Compound with the highest log P shows the highest activity. This is 
shown by aza-daunorubicin and aza-pirarubicin subgroups for continuous 
incubation against L1210 and both incubation modes against HT 29 cell line. 
The order of activity is (136)>(134)>(135) for aza-daunorubicin and 
(145)>(144)>(145) for aza-pirarubicin which implies that the 2-aza 
analogues (136) and (146) are more active than the 1-aza analogues (134) 
and (144) which, in their turn, more active than the 2-aza analogues (135) 
and (145) for these particular incubation mode and cell lines. The trend 
exhibited by the two aforementioned subgroups is in accord with the general 
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trend of the whole group with a nearly perfect correlation (r = -o.97 for log 
P/ID50 which means +0.97 for log P/activity) 
ii- Compounds with the lowest log P shows highest activity this is observed 
in the aza-pirarubicin for 1h incubation against L1210  and for both 
incubation modes against Colon 4 cell line. This order of activity is 
restricted to this subgroup although the general trends for the whole aza-
daunorubicin group is the reversed this why linear correlation coefficient r 
for this category (-0.93) is lower than the category discussed in (ii) above. 
The above discussion leads to the conclusion that there could be three 
different operative cytotoxic mechanisms, for the ring D-modified 
daunorubicin aza analogues, working concomitantly. The most prominent of 
which is dependent on lipophilicity of the drug as it is indicated by high 
linear dependence of activity on log P. The  two other mechanisms, which 
could not possibly be identified by our limited QSAR model, are of  lesser  
importance but both are preferentially operative for 1h  incubation mode 
against L1210 leukemia and both incubation modes against Colon 4. The 
above finding closely corresponds to what has been reported in the literature 
for the same carbocyclic anthracyclines used to construct our QSAR 
model114, which is that extrapolation of octanol/water partition coefficient P 
and DNA binding affinity K with cytotoxicity ( as -log ID50) for the same 
compounds of our training set give the  correlation coefficients r for 
different cell line tabulated in table 3-1-1 above. As it could be discerned 
from table, there is close correspondence between the r-values for both the 
training and the designed sets. There is  a parallel increase in going from the 
two r values for one hour incubation to r values for continuous incubation 
against L1210 (0.05 units for 1h to cont. for the training set,  0.04 units for 
1h to cont. for the aza-analogues). Approximately equal r value for training 
set for both incubations against Colon 4 parallel the same situation for the 
aza-analogues. The r value for HT 29 shows discrepancy in that the two r 
values for training set span 0.08 units from each other while those for the 
aza-analogue are equal. The higher r values for the aza-analogues reflects 
that lipophilicity play a more important role for this group compared to the 
case of the training set for which the above tabulated r values are the 
outcome ,not only of lipophilicity, but also of DNA binding affinity.  
It also noteworthy that our hypothetical daunorubicins aza-analogues have a 
general trend to be partitioned in activity profiles into two group; one 
contains Colon 4 cell line for both incubation modes, the other contains HT 
29 cell line also for both modes while leukemia L1210 shows two traits; 1h 
incubation mode partitions along with Colon 4, while continuous incubation 
mode partitions along with HT 29 cell line. This is equivocally echoed in the 
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training set, at least for the group which contains Colon 4 for both 
incubation modes and L1210 one hour incubation mode ( r = 0.87, 0.86 for 
1h  and cont. incubations against Colon 4; 0.85 for 1h incubation against 
L1210 respectively) while the other  group shows discrepancy again, 
perhaps because of intrusion of unknown factor  specific for this group  that 
could not possibly be sensed by our model.  The above mentioned 
phenomenon of partitioning of activity profile into two categories provoked 
us to scrutinize the reported ID50s of the training set in search for similar 
trends. To the that end we correlated ID50s  for 1h (Lh) and continuous(Lc) 
incubations of L1210 cell line against those of both incubations against each 
of Colon 4 and HT 29 cell lines. Table 3-1-2 shows the resulted r values 
As could be observed from the above table, 1h incubation of L1210 has 
higher correlation with both incubations of Colon 4 than with those of HT 29 
cell line while the reverse is true for continuous incubation of L1210. 
   Table 3-1-2 r values for correlating ID50s 
       of  the training set against each other        
 
 
 
 
 
 
 
* the reciprocal of both ID50 is taken 
This is in agreement of what we have observed for the designed set. The 
segregation into categories in activity profiles is, however, less pronounced 
in the training set as compared to the designed set 
 In attempt to gain a better insight into the relation between log P and IC50  
we plot log P versus ID50s  for each of 1h  and cont. incubation against 
L1210. We try both linear and parabolic fittings for each of the two sets of 
data points calculating the norm of residuals for each .Thus figures 3-1 and 
3-2 below were obtained. The norm of residual is a measure of the goodness 
of the fit between two data sets, i.e., a lower norm signifies a better fit. 
Norm of residuals is given by equation 3-1 below 
Norm = [∑(property observed - property predicted)2 ]  1/2………(3-1) 
Figure 3-1 represents, in addition to 1h incubation against L1210, both 
incubations against Colon 4 cell line (r = 0.93). While figure 3-2 represents, 
in addition to  cont incubation against L1210, both incubations against HT 
29 cell line (r = 0.97) 
 
Lc  Lh    
0.84  0.94  Ch  
0.75  0.74*  Cc  
0.85  0.61  Hh  
0.79  0.41  Hc  
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On scrutinizing the four values of the norm of residuals we could arrive at 
the following facts 
i- For data depicted by figure 3-1, linear fitting is nearly as good as parabolic 
(quadratic ) fitting as evident from the nearly equal norm of residual: 
 linear norm = 0.0016022 
quadratic norm =  0.0015977 
ii- For data depicted by figure 3-2, parabolic fitting is much better than 
linear fitting as  the quadratic norm of residual is higher than linear one: 
linear norm = 0.00073937 
quadratic norm =  0.00046753 
This could visually be discerned from the graph in fig.3-2 in which the curve 
( a parabola) fits the data points better than the straight line. We could also 
calculate quadratic correlation coefficient for the parabolic fitting of the data 
set from the following formula: 
r2 =1 – norm2/(n-1)s2…….(3-2) 
Where n = number data point  = 9,  s = standard deviation of the data 
represented in the y-axis.  
r =[ (0.00046753)2 / (9-1)(0.001034)2 ]1/2 = 0.99  
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The improved value of r on going from linear ( r = 0.97)  to quadratic (r = 
0.99)  fitting indicate that there is a parabolic relation between log P and 
ID50 which is the same as in the carbocyclic anthracyclines of the training 
set114. 
For the sake of comparison, quadratic r value for data of figure 3-1 is 
calculated below using formula 3-2 
r = [(0.0015977)2 / (9-1)(0.001569)2]1/ 2 = 0.87 
Clearly there is no improvement in going from linear (r = 0.93) to quadratic 
( r = 0.87) fitting for these data points. 
To summarize the above argument we can say that in case of 1h incubation 
against L1210 and both incubations against Colon 4 for ring D-modified 
aza-daunorubicins the relation of log P to ID50 is linear while continuous. 
incubation against L1210 and both incubations against HT29 the relation 
between these two parameter is parabolic. 
 
3-2-2  Daunorubicin aza-analogue modified at ring A 
Table 3-2 shows the biological activity data for this group calculated from 
our QSAR model 
      Table 3-2   Calculated log P and biological activity data for ring A- 
                          modified aza-daunorubicins  
 
The structures of compounds (137),(138),(142),(143),(147) and (148) are 
depicted in scheme   3-4 below. Comparing the data tabulated in table 3-2 
with that of table 3-1, one will immediately note that ring A-modified aza 
analogue are  generally more active than ring D-modified ones. This is to be 
expected since the activity of the parent anthracyclines are largely due to the 
cyclohexane residue attached to planar anthracene-9,10-dione chromophore. 
This, of course, is replaced here with the heterocyclic piperidine ring which 
resembles, in many aspects, the cyclohexane ring, especially in their 
stereochemistry. The order of activity for this group follows the aza-
anthrapyrazole norm, i.e., 2-N analogues are more active than 1-N analogues 
for both incubation modes and against all three cell lines. As it is the case in 
the carbocyclic training set, aza analogues (147) and (148) of pirarubicin 
ID50Hc ID50Hh ID50Cc ID50Ch ID50Lc ID50Lh  Log P compound 
0.01901 0.3585073 0.011106 0.06805 0.018728 0.039048 2.88 137  
0.02032 0.3698278 0.011287 0.068808 0.019466 0.039677 3.2 138  
0.019792 0.3653577 0.011443 0.069456 0.019174 0.04023 3.79 142  
0.021351 0.3782276 0.011593 0.070072 0.020012 0.040768 3.24 143  
0.016409 0.3335293 0.01033 0.064714 0.017102 0.036483 6.24 147  
0.016602 0.33551760.010413 0.065076 0.017231 0.036746 5.69 148  
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shows enhanced activity as compared to aza-daunorubicin (137)and (138) 
and aza-doxorubicin  (142) and (143). 
 
Scheme 3-4 
3-2-2a Log P of aza-daunorubicins modified at ring A 
  Extrapolation of log Ps for this group against ID50 for both incubation 
modes and for all cell lines give r (linear) value of approximately -0.89. This 
indicates that dependence of activity on lipophilicity is somewhat less 
marked here than in the ring D-modified aza-analogues. Upon inspecting log 
P and ID50 tabulated in table 3-4 above, we immediately notice that 
compound (137) has higher activity and lower log P compared to compound 
(138) in the ring A modified aza-daunorubicin subgroup. This situation is 
reversed for the respective analogues, (142) versus (143) in aza-doxorubicin 
and (147) versus (148) in aza-pirarubicin subgroups in which the increase in 
log P is attended with an increase in activity. 
Upon plotting log P versus ID50 for cont incubation against L1210 as an 
example for this group figure 3-3 below is obtained 
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Quadratic norm of residual (0.0010336) is lower than the linear (0.0011706) 
which is indicative of a parabolic rather than a linear dependence of activity 
on log P. this is also evident from values of correlation coefficient which are 
0.92 for parabolic and 0.89 for linear 
3-3 The aza-aclarubicin group 
  This group contains three ring D-, one ring A- and one ring B-modified 
aza-analogues. Table 3-3 shows the calculated biological activity data for 
them. 
  Table 3-3   Calculated log P and biological activity data for aza-
aclarubicins   
 
Scheme 3-5 depicts the structure of compounds 16-20  
  ID50Hc ID50Hh ID50Cc ID50Ch ID50Lc ID50Lh  Log p compound 
0.0067980.1839339  0.0050040.0370380.0073610.023363 3.95 149  
0.0068150.1843462  0.0050260.0371710.0073880.023404 4.04 150  
0.0068610.1854945  0.0050320.0372080.0074620.023415 4.28 151  
0.0067950.1838589  0.0050480.0373060.0073560.023445 4.5 152  
0.0067590.1829445 0.0049290.0365740.0072960.023222 2.3 153  
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Scheme 3-5 
Two order of activity can be observed for compounds 16-20: 
i-  (153)>(149)>(150)>(151)>(152) for 1h incubation against L1210 and for 
both incubation modes for Colon 4. This order of activity is contrary to that 
reported for aza-anthrapyrazoles and aza-anthracenediones in that compound 
(149) (1-N analogue) is more active than compounds (150)-(152) (2-N 
analogues). Note that compound (152), a ring A-modified analogue, is the 
least active one. 
ii- (153)>(152)>(149)>(150)>(151) for continuous incubation against L1210 
and for both modes of incubation against HT 29. The situation changed for 
compound (152) (ring A) which is here more active than (149)-(151) (ring 
D). 
Ring B-modified aza analogue (153) give the highest activity for both 
incubation modes and against all the three cell lines. 
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3-3-1 Log P of aza-aclarubicin group 
This group is anomalous in that there a general positive correlation between 
log P and ID50 which implies that there is   a negative correlation between 
Log P or lipophilicity and cytotoxic activity. Table 3-3-1 below shows linear 
correlation coefficient resulted from extrapolation of log Ps against ID50s for 
both incubation modes against the three cell lines. 
 
                   Table 3-3-1 Correlation coefficients of log P vs. ID50s  
                                        for aza-aclarubicin   
r  Incubation mode  Cell line  
0.99  1h.  L1210  
0.70  Cont.  L1210  
0.99  1h.  Colon 4  
0.99  Cont.  Colon 4  
0.70  1h.  HT 29  
0.70  Cont.  HT 29  
r values closely parallels the observed order of activity for this group. As 
there are two order of activities, there are also two corresponding sets of r 
values; r = 0.99 for 1h incubation against L1210 and for both incubation 
modes against Colon 4 cell line, r = 0.70 for continuous incubation against 
L1210 and for both incubation against HT 29 cell line. 
For the first of the above two categories, the correlation between decreasing 
lipophilicity (lower log P) and increasing activity is almost perfect. For 
second category, the large drop in r value is caused by shifting, relative to 
the former category, of compound [(152) ring A aza-analogue] next to the 
most active analogue (153). This made a series in which the least lipophilic 
most active analogue (153) is followed by the most lipophilic next most 
active analogue (152). The rest of analogues followed the same pattern, 
relative to each other, as that observed in the first category. This shifting of 
compound (152) is indicative of an underlying mechanism independent of 
lipophilicity, operative solely in this aza-analogue. Partition of activity 
profile into two groups, already observed for aza-daunorubicins, is also 
observed here in this group. This must be interpreted cautiously because on 
removing compound (152)  the  two activity profiles become one and the 
same for both incubation modes and for all the three cell lines. Thus we can 
say that the activity of series is inversely dependent on lipophilicity except 
for compound (152)  which shows anomalousness only for cont. incubation 
against L1210 and both incubations against HT 29. 
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Figure 3-4 shows the plotting of log P versus ID50 for cont. incubation 
against Colon 4 cell line as a representative of this group. The relation of the 
two parameters is decidedly Linear as it is clear from the grap                     
 
  
It remains to state that the activity of aza-aclarubicin is generally higher than 
their carbocyclic analogues as our QSAR model indicates, a thing which can 
only unequivocally be proved by total synthesis. 
 
3-4 The aza-rhodomycin group 
3-4-1 Aza-rhodomycins modified at ring D 
This group possesses very orderly patterns of activity profile as will be 
detailed shortly. Table 3-6 shows the biological activity data for compounds 
-)167(-)166( [,])164(-)163(-)162[(, ])160(-)159(-)158[(, ])156(-)155(-)154([
 ,])179(-)178(-)177( [and] )175(-)174[(, ])172(-)171(-)170[(, ])168(
each three compound represents a subgroup 
3-4-1-a Aza-rhodomycin I  
This includes compounds [(154),(155) and (156) which is depicted in 
scheme 3-6 
The order of activity is[(154)>(155)>(156)  for all incubation modes and 
against all the three cell lines. This order of activity is opposite to that 
observed in aza-anthrapyrazoles 
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Scheme 3-6  
Table 3-4 Calculated log P & biological activity data for ring D-modified 
                  aza-rhodomycins       
 
3-4-1-b Aza-rhodomycin II 
Scheme 3-7 depicts this subgroup 
There are two activity profiles in this subgroup:  
i- (160)>(158)>(159) for one hour incubation modes against L1210 and for 
both incubation modes against Colon 4 
ID50Hc ID50Hh ID50Cc ID50Ch ID50Lc .ID50Lh  Log p Compound 
0.051802 0.5286985 0.016343 0.087247 0.0298110.0631662.23 154  
0.052046 0.5294957 0.016365 0.087319 0.0298630.0633034.27 155  
0.052348 0.5304804 0.016395 0.087413 0.0299270.0634832.99 156  
0.056748 0.5441815 0.016543 0.087883 0.0308190.06439 3.07 158  
0.057916 0.5476387 0.016634 0.08817 0.0310440.0649555.02 159  
0.058094 0.5481603 0.016088 0.086429 0.0310780.06165 3.73 160  
0.005092 0.1348671 0.003157 0.024938 0.0041660.0201796.05 162  
0.005099 0.1350941 0.003166 0.024998 0.0041810.0201938 163  
0.005096 0.1350113 0.003155 0.024921 0.0041750.0201756.72 164  
0.005048 0.133406  0.003108 0.024593 0.0040710.0201015.37 166  
0.005038 0.1330696 0.003103 0.024559 0.0040490.0200947.32 167  
0.00504 0.1331328 0.003107 0.024584 0.0040530.0200996.04 168  
0.005565 0.1499518 0.003728 0.028847 0.0051480.0211054.57 170  
0.005567 0.1500066 0.00373 0.028858 0.0051520.0211076.52 171  
0.005603 0.1511126 0.003763 0.029083 0.0052240.0211635.24 172  
0.005404 0.1449775 0.003516 0.027412 0.0048240.0207556.38 174 
0.005415 0.1453243 0.003525 0.027474 0.0048470.02077 6.38 175  
0.005049 0.1334206 0.003112 0.02462 0.0040720.0201084.27 177  
0.005044 0.1332565 0.003113 0.024628 0.0040610.0201096.22 178  
0.005057 0.1337132 0.003123 0.024695 0.0040910.0201244.93 179  
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ii- (158)>(159)>160) for continuous incubation mode against L1210 and for 
both incubation modes against HT 29 
 
Scheme 3-7 
3-4-1-c Aza-cytorhodin A 
This group comprises compounds (162),(163) and (164) depicted in scheme 
3-8 
 
Scheme 3-8 
We could also discern here two activity profiles: 
i- (164)>(162)>(163) for one hour incubation against L1210 and both 
incubation modes against Colon 4. 
ii- (162)>(164)>(163) for continuous incubation against L1210 and for both 
incubation modes against HT 29                                                                        
3-4-1-d Aza-cytorhodin D 
This includes compounds (166), (167) and (168) depicted in scheme 3-9  
The order of activity is:  (167)>(168)>(166) for all incubation modes and 
against all  the three cell lines. This is in accord with aza-anthrapyrazole 
norm. 
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Scheme 3-9 
3-4-1-e Aza-cytorhodin S 
Scheme 3-10 shows the members of this subgroup. 
 
 
Scheme 3-10 
 
The order of activity is:  (170)>(171)>(172) for all incubation modes and 
against all  the three cell lines. This is quite contrary to the anthrapyrazole 
norm. 
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3-4-1-f  1-Hydroxy-az-acytorhodin S 
Owing to blocking of C1 by a hydroxyl residue, we have got only two 
members in this subgroup. These are depicted in scheme 3-11 below 
Compound (174) is more active than compound (175) for all incubation 
modes and against all  the three cell lines 
 
Scheme 3-11.  
3-4-1-g  Aza-cytorhodin X 
  The members of this subgroup are shown in scheme 3-12 below 
The order of activity is:  44>45>46 for all incubation modes and against all 
the three cell lines. Again, this order of activity is opposite to that observed 
in aza-anthrapyrazoles. 
3-4-2 Log P aza-rhodomycin modified at ring D 
the relation between log P and cytotoxic activity for this group may be 
considered  from two perspectives or approaches:                                          
i- Taking the parent aza-rhodomycin as basis and dividing the whole group 
into seven subgroups, each contains three molecules. Thus we will have the   
subgroup discussed above, I.e., aza-rhodomycin I, aza-rhodomycin II, aza-
cytorhodin A….etc 
ii- Taking the position of nitrogen atom around ring D as the basis. Three 
groups are obtained this way; 1-N-9-acetyl, 2-N-9-acetyl and 2-N-8-acetyl 
aza-analogues. 
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Scheme 3-12 
 
3-4-1a First Approach 
The following remarks could be mentioned regarding the first approach 
- Subgroups in which the compounds with the lowest log P are most active, 
followed by compounds with highest log followed by compounds with 
medium log P. This includes aza-rhodomycin I and aza-cytorhodin s for both 
incubation modes and against all the three cell lines; aza-rhodomycin II for 
continuous incubations against L1210 and both incubation modes against 
HT 29 cell line; aza-cytorhodin X for 1h incubation against L1210 and both 
incubation modes against Colon 4 cell line. 
- Subgroups in which the compounds with the medium log P are most active, 
followed by compounds with lowest log P followed by compounds with 
highest log P. this include aza-rhodomycin II and aza-cytorhodin A  for 1h 
incubation against L1210 and both incubation modes against Colon 4 cell 
line. 
- Subgroups in which the compounds with the highest log P are most active, 
followed by compounds with lowest log P followed by compounds with 
medium log P. this includes   aza-cytorhodin D for both incubation modes 
against all the three cell lines; aza-cytorhodin X for continuous incubation 
against L1210 and both incubation modes against HT 29 cell line.   
- A subgroup in which the compound with the lowest log P is most active, 
followed by the compound with medium log P followed by the compound 
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with highest log P. this includes   aza-cytorhodin A for  continuous 
incubation against L1210 and both incubation modes against HT 29 cell line. 
- 1-Hydroxy-aza-cytorhodins S which comprise two compounds (174) and 
(175) with identical log P but (174) is more active than (175). 
The linear correlation coefficient r for extrapolation of log P versus activity 
within each of the seven ring D-modified is around 0.30 while the whole 
group gives r ≈ 0.75. This is indicative of the presence of some factors, other 
than lipophilicity, which affect cytotoxic activities. These factors are more 
important within each subgroup than within the whole group. The last 
remark about 1-hydroxy-aza-cytorhodin S bears evidence for this; both 
compounds (174) and (175) have same log P but (174) is more active than 
(175). For a better understanding of the relationship between log P and 
activity for aza-rhodomycin group in general, we plot the two parameters as 
depicted in figure 3-5 below 
 
 
the most striking feature of the above graph is the distinction of the data 
points into two bands which indicative of two activity profiles. By 
inspection we find that the upper data point band corresponds to aza-
rhodomycin I and aza-rhodomycin II (ID50 lies between 0.015-0.02 µg/ml) 
while the lower band corresponds to aza-cytorhodins A, D, S, 1-OH S and X 
(ID50 0.001-0.005). quadratic norm of residual is higher (0.020177) than the 
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linear one (0.021373) indicting that the relationship between log P and 
activity is parabolic (r = 0.75) rather than linear (0.71). 
Similar situation is found to hold for the carbocyclic analogues of the 
training set for which the plot of calculated log P versus IC50 is depicted by 
figure 3-6 below. The segregation of the two activity band is also distinctly 
echoed here with the carbocyclic rhodomycin I and rhodomycin II  lying in 
the upper band the cytorhodin A, D, S, 1-OH S and X lying in  the lower 
band. The parabolic relationship between log P and activity is strongly 
pronounced here as the quadratic norm of residual is considerably higher 
(0.0040169) than the linear norm (0.018559). the value quadratic correlation 
coefficient r is 0.997≈ 1.00 which is indictive of a nearly perfect parabolic 
relationship. 
   
 
 
This is apparent from the graph where the parabola joint six of the seven 
data points in contrast to the straight line which just runs between the points. 
3-4-2b  Second approach 
The second approach mention in ii above give improved r value  ≈ 0.88 for 
the three ring D-modified aza-rhodomycin group. The average parameters 
for these groups are tabulated below.  
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    Table 3-4-1 Average values of log P, ID50s and r values for aza- 
                       rhodomycin using the second approach (see text) 
Av. r Average ID50 
Lh                Lc          Ch           Cc       Hh           Hc 
Av. 
Log p 
Subgroup 
0.88  0.0216 0.271 0.0077 0.0464 0.013 0.035 4.26 1-N-9-
acetyl 
0.86  0.0194 0.253 0.0071 0.0437 0.01188 0.033 6.25 2-N-9-
acetyl 
0.88  0.0195 0.254 0.0070 0.0435 0.01191 0.0325 5.15 2-N-8-
acetyl 
0.92 0.0157 0.241 0.0067 0.0425 0.01105 0.31 7.13 2-N-3-
acetyl 
         
Referring to the table above, the repeated connection between 1h incubation 
mode against L1210 and both incubation modes against colon 4 on one 
hand, and continuous incubation against L1210 and both incubation modes 
against HT 29 on the other hand  is also observed here. This is an indication 
for the existence of two distinct cytotoxic mechanisms. Table 3-4-1 also 
shows that the 2-aza-analogues are generally more active than 1-
azaanalogues which closely correspond to what is observed for aza-
anthrapyrazoles. 2-N-9-acetyl aza-anthracyclines have an averagely higher 
lipophilicity than 2-N-8-acetyl aza-analogues. They are also more active in 
cont. incubation against L1210 and both incubation against HT 29. The 2-N-
8-acetyl aza-analogues are more active in 1h incubation against L1210 and 
both incubations against Colon 4 cell line 
To gain extra insight into the relationship between log P and activity using 
the second approach discussed above, we plotted the two parameter, i.e. log 
P and ID50 for cont. incubation of 1-N  aza-anthracycline against Colon 4 
and did the same with 2-N-9-acetyl and 2-N-8-acetyl and to obtain the three 
figures 3-7, 3-8 and 3-9 below  
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The quadratic norms of residuals for the three groups are higher than their 
linear norms indicating parabolic relationships between log P and activity. 
The quadratic correlation coefficients reflect the same remarks we have 
already made about activity; the respective r values for 1-N-9-acetyl, 2-N-9-
acetyl and 2-N-8-acetyl aza-analogues are 0.92, 0.94 and 0.96 which 
corresponds to their activity: 2-N-8-acetyl > 2-N-9-acetyl >  
1-N-9-acetyl. It is astonishing to discover in this connection that although 
the 2-N-8-acetyl aza-analogues are of medium average lipophilicity, they 
have higher r value compared to their 2-N-9-acetyl counterparts which has 
higher average lipophilicity and lower r value. an interpretation for  could be 
deduced upon scrutinizing figures 3-7, 3-8 and 3-9 more closely we could 
immediately noticed  that  compounds of medium lipophilicity occupy the 
lower central part of all the three parabolas  which correspond to lower ID50s 
and so to higher activity but the parabola of figure 3-7 is shifted to lower log 
Ps(data points between 2.25 to 6.2) and that of figure 3-8 to higher log Ps 
(4.25 to 8) while the parabola in figure 3-9 is located in intermediate 
position (3 to 6.75). The above argument about cont. incubation against 
Colon 4 holds also for 1h incubation against both L1210 and Colon 4 
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3-4-3 Aza-rhodomycins modified at ring A 
 This group contains compounds (157), (161), (165), (169), (173), (176) and 
(180). the biological data for this compounds are tabulated in table 3-5 
Table 3-5 Calculated log P & biological activity data for ring A- 
             modified aza-rhodomycins 
Scheme 3-13 depicts this subgroup.   
In spite of the fact that the aglycone in this subgroup is β-aza-
rhodomycinone (except for compound (176) in which the aglycone is β-
isorhodomycinone), they differ markedly in their activity trends. 
Compounds (157), (161) and (165) can be looked upon as one subgroup as 
they enjoy higher activities for both incubation modes and against all the 
three cell lines as compared to their ring D-modified aza-analogues. 
Compound (169), (173), (176) and (180) constitute one subgroup with 
generally lower activities than their ring D-modified counterparts.  
 
 
Scheme 3-13  
ID50Hc ID50Hh ID50Cc ID50Ch ID50Lc .ID50Lh  Log p compound 
0.039635 0.4832483 0.015088 0.083111 0.0268510.056085 4.73 157 
0.044312 0.5021868 0.015337 0.083952 0.0280840.057413 5.48 161 
0.005095 0.134961  0.003105 0.024574 0.0041720.020097 8.93 165 
0.005054 0.1336144 0.003111 0.024613 0.0040840.020106 8.25 169 
0.005598 0.1509713 0.003763 0.029079 0.0052140.021162 7.45 173 
0.005403 0.1449342 0.00356 0.027715 0.0048210.020828 7.94 176  
0.005065 0.13396470.003135 0.024782 0.0041070.020144 7.15 180 
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3-3-4a Log P 0f aza-rhodomycin modified at ring A 
The general trend in ring A aza-rhodomycin is that compound with higher 
log P enjoy higher activity, i.e., activity is directly proportional to 
lipophilicity. This is strictly true for both incubations of these compounds 
against L1210 and Colon 4 cell. HT 29 cell line shows some discrepancy in 
that compound (180) which medium in lipophilicity exhibit the highest 
activity. Leaving this compound out, the others follow the same pattern as 
that mentioned above 
Figure 3-11 depicts the plotting of log P versus ID50 for 1h incubation of 
ring A-modified aza-rhodomycins. The relationship is parabolic as usual, 
with lower quadratic norm of residual and higher r ( 0.020088 and 0.96 
respectively) compared to the linear fitting ( norm = 0.026611, r = 0.92) 
The two bands of data point observe for the carbocyclic rhodomycins and 
heterocyclic Ring D aza-rhodomycin is also observed here. The lower band 
of data point is strikingly similar to the corresponding band in the graph of 
the carbocyclic analogues depicted in figure 3-6 
  
  
  
  
 
 
 - 100 -
Chapter four 
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
Summary and Prospectives  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 - 101 -
4-1 Summary  
Eleven known anthracyclines together with their biological data were picked 
from literature and used to construct a training set for the purpose of 
building a  mathematical model able to give insight on the effect of 
introducing nitrogen atom into the tetracyclic anthracycline backbone. Semi-
empirical quantum mechanical methods were employed to derive some 
physicochemical parameters for the compounds of the training set to be 
correlated with their biological data. These are inhibitory dose for 50% of 
the subjects (ID50) for in vivo incubations against murine Leukemia L1210 
and two colon cancer cell; Colon 4 and HT 29 cell lines as reported in 
reference 114. Total energy parameters calculated by AM1 and PM3 
methods were found to give the highest statistical correlation with the 
reported ID50s. Six Linear equations were then derived, two for each of the 
three cancer cell lines representing in vivo incubation; one for one hour and 
other for continuous (7days) periods. The six linear equation were used to 
calculate ID50s for a set of  hypothetical anthracycline aza-analogues. These 
unknown anthracycline analogues were designed and their geometries were 
optimized using molecular mechanics force field (MMFF) calculations. 
Their total energy were then likewise calculated.The calculated biological 
response data were then scrutinized to arrive at the following  general 
remarks: 
1- Activity profiles of the designed anthracycline aza-analogues tend to 
cluster with respect to their calculated biological response into two definite 
categories: 
     i- one comprises the two incubation modes against Colon 4 cell line               
and one hour incubation against L1210 Leukemia cell line. For                 
subsequent easy reference let us call this category  Catg. 1     
     ii- the other includes the two incubation modes against HT29 in                     
addition to continuous incubation against L1210. let us call this                  
category catg.2           
2-  cytotoxic activity is generally directly proportional to lipophilicity for all 
groups except for aza-aclarubicin. The relationship is parabolic rather than 
linear. 
3- the 2-N-aza-analogue are generally more active than 1-N-aza-analogues 
as was observed for aza-anthrapyrazole and aza-anthracenediones. Let us 
call this phenomenon aza-anthrapyrazol norm 
 The following groups obey the aza-anthrapyrazole norm; 
- in the ring D-modified aza-daunorubicin group: aza-daunorubicin for 
catg.1, aza-doxorubicin for both catg,1 & 2 
- All ring A-modified aza-daunrubicins 
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- All ring D-modified aza-rhodomycins, 2-N-9-acetyl group is more active 
than 2-N-8-acetyl group for catg.1 while the reverse is true for catg. 2. 
4- Aza-aclarubicin shows anomalous behaviour in that activity is inversely 
proportional to lipophilicity. Our QSAR model indicates that ring B N-
substitution would markedly increase activity for aclarubicin basic nucleus. 
 The most active subgroup is the aza-cytorhodine D subgroup [compounds 
(166), (167), (168)& (169)] ,  2-aza-cytorhodin D(167) being the most  
active of all. The following order of activity is observed for the whole 
designed aza-anthracycline set 
 aza-cytorhodins(compounds (162)-(180) > aza-acalrubicin ((149)-(153) > 
aza-pirarubicins (144)-(148) > aza-doxorubicin (139)-(143) > aza                
daunorubicins (134)-(138)) > aza-rhodomycin I (21-24) >aza-rhodomycin II 
(158)-(161). 
The activity, however, does not give sharp demarcation in going from one 
subgroup into other. It gives two spectrums for catg. 1 and catg 2 with 
overlapping between subgroups as depicted by figure 3-1 below. This 
spectrum is generally similar to that of the parent molecules of the training 
set except for the fact that pirarubicin overlaps with cytorhodins as most 
active in the case of the latter while aza-pirarubicin come after aza-
cytorhodins and aza-aclarubicins in the former.   
 
  
4-2  Research Objectives; have they been realized ? 
This work is intended to provide a presynthetic screening methodology for 
new aza analogues of anthracycline with anticipated anticancer activity. The 
method of “trial-success- or- failure" in organic synthesis proved to be very 
costly and time consuming. The present method belongs to in silico sciences 
which are now assuming an increasing importance in chemical and 
pharmaceutical research. It could be used as a pointer which indicates the 
most promising candidates and highlights them for synthesis. It is well 
known that anthracyclines suffer from many drawbacks as antineoplastic 
therapeutic agents as detailed in part 1. The inclusion of a nitrogen atom in 
the tetracyclic nucleus of anthracyclines may improve the therapeutic 
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properties of these drugs (see section 1-4-2). We choose to include the 
nitrogen atom because it was shown that the inclusion of this atom in 
anthracene-9,10-dione nucleus of aza-anthracene-5,10-dione and 
anthrapyrazoles enhances anticancer activities of these compounds. It is also 
well known that the position of the N atom in these nuclei is crucial in 
determining the intensity of antineoplastic activity. For instance, 2-aza-
anthraprazoles are by far more active than 1-aza-analogues. Surveying  the 
literature of the anthracyclines area of research reveals that very little 
attention was paid to explore the effect of inclusion of N atom in the 
anthracycline nucleus, let alone exploration of relative activity of different 
position around the nucleus. Attempts at synthesis of structural isomers of 
anthracycline aza analogue would entail different synthetic procedure for 
each analogue. This would probably be very troublesome and costly. The  in 
silico design and biological screening represent a very attractive alternative 
which make possible the study and evaluation of hypothetical   drug-like 
molecules and uncover trends in different series of such molecule. We have 
been  encouraged by the work of Kita et.al.72, who synthesized and tested 
ring-D modified daunorubicin and doxorubicin with 1-N and 1,4-di N 
replacement of the carbon atoms. These analogues exhibits in vivo activity 
comparable to that of the parent carbocyclic compounds. 
The most prominent discovery of the present QSAR study is the outspoken 
support of the finding associated of aza-pyrazoles and aza-anthracene-5,10-
diones uncovered by Krapcho et.al.80 Namely, that  2-az-analogues are more 
active than 1-aza-analogues. To the best of our knowledge, no report cited in 
the pertaining literature appears to extend the aforementioned discovery to 
the anthracycline group. This work serve to direct attention toward synthesis 
and evaluation of the promising 2-aza analogues of anthracyclines.  
The conservation of the original functional groups of the parent 
anthracyclines intact in our designed molecules is believed to keep 
convergence in properties at minimum allowing our in silico  model to take 
the variation produced by the introduction of one nitrogen atom at  a time as 
it would do for any other variations produced by different structural features 
in going from one anthracycline to another. 
In our opinion, the objectives of the present research have been fairly 
realized as we have: 
- theortically proved that introduction of nitrogen atom into anthracycline 
backbone exert  substantial effects on different classes of anthracycline 
- proposed a simple and inexpensive method for presynthetic design and 
screening in search of lead anticancer agents 
- supported the the aza-anthrapyrazole norm  
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4-3 Prospective   
This QSAR model is only iterative as it is build upon iterative parameters 
and upon experimental biological data that would carry, unavoidably, 
inherent experimental errors generally associated with this kind of data. The 
value of this work lies in that it gives indicative trends useful in pinpointing 
most promising candidates to be forwarded for synthesis and evaluation. The 
following hints could be made from the present QSAR model 
- There is a voluminous biological data buried in old literature which will 
yield valuable information about the anticancer drugs if treated with the  
now available computational methods. So we strongly recommend that  
these data be exposed to treatment similar to the forgoing one executed by 
this work to single out promising candidates 
- The customary practice of removing outliers to get best fit between 
biological data and physiochemical parameters in regression analysis should 
be revised as these outliers could describe some inherent trends not 
considered by a researcher. These trends may represent hidden factors which 
work concomitantly with the ones under the researcher's scrutiny. They 
serve as unseen clues which direct predications about non-existent drug-like 
molecules. This is clearly born out by the outcomes of the present QSAR 
model which implies a phenomenon not previously observed for 
anthracyclines, that is what we call the anthrapyrayzole norm (see section 3-
4 above). The clues for this trend, i.e., the enhanced activity upon 2-N cf. 1-
N substitution, is, no doubt, hidden in the "space" which is described by the 
biological data of the training set. Our designed set serves to expose the 
effect of these hidden factors.  
- The above argument about outliers advocates the use of other methods of 
pattern recognition to find non-linear relationships between biological data 
and physicochemical parameters. In this connection artificial neural 
networks ANN represent attractive methodology which is gathering 
momentum nowadays as the number of research papers using ANN is 
constantly and dramatically increasing. 
- Any future synthetic endeavors should include computational part to arrive 
at promising active structures and rule out unpromising ones. This will 
dramatically decrease the cost of chemicals and time of  experimentations. 
- The clustering of activity profiles of the designed set into two categories as 
discussed above (see section 3-4 and figure 3-1 ) is very interesting  and 
need scrutiny from the viewpoints of other pertaining disciplines, e.g.,  
oncology and cell biology. We have seen that this phenomenon is also 
echoed in the case of the original biological data of the training set (see 
section 3-2-1d page 82   ).  
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- The search for a "better anthracycline" has so far led to the birth of some 
very important classes of anticancer agents such as amentatrone and 
mitoxantrone of anthracenedione family, anthrapyrazoles and their aza-
isobiostere …etc. Although certain members these classes enter into clinical 
use as established anti-neoplastic agent, none of them supersedes  
daunorubicin and doxorubicin. Moreover, the undesired side effect known 
for anthracyclines and anthracenediones as general, i.e., cardiotoxicity and 
induction of MDR, could not be successfully eradicated.  Aza-
anthrapyrazoles gave improved activity profile compared to anthrapyrazole; 
thus, as it is clearly outspoken by the present QSAR studies, aza-
anthracyclines would probably give interesting activity profiles and might 
reduce the undesired effects associated with the carbocyclic anthracyclines. 
This work help to inaugurate an interesting and fertile area of research which 
call for the collaboration of various disciplines from synthetic organic 
medicinal chemistry to pharmacology and oncology. We firmly recommend 
that a multidisciplinary research group be formed to follow up synthesis and 
biological evaluation of this promising novel class of compounds.  
We could only hope from our Lord, Glory be to him, that our humble effort 
be  step toward curing this formidable malady taking our good omen from a 
tradition of our holy prophet Mohammed, peace be upon him, in which he is 
reported to declare:  
“Whatever an ailment sent by Allah, exalted He, He surely sent its antidote 
be it known or unknown”   
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5-2 Appendices  
Appendix 1 Tables of correlation between ID50 Lh and physiochemical 
parameters Et, ∆Hf and µ 
These tables were extracted from 400 tables for both incubation modes 
against the three cell lines used in this study. The tables shown hereunder for 
1h incubation against L1210 are just given as examples. Every  set three of 
tables grouped together represents correlation trials between  a 
physiochemical paranmeter and ID50  in their original values or after 
transformation to their reciprocal or their logarthms. The correlation 
coefficient r is given for each correlation trial in the last row of each table. 
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Appendix 6 Quantum mechanical calculations       
     1-Geometry optimization using Molecular Mechanics Force Field 
          (MMFF) 
In the framework of molecular mechanics, molecules consist of atoms with a 
certain geometry and bending forces, which act between bonded atoms and 
van der Waals forces, which act between non-bonded atoms. These bonds 
have "natural" distances and angles, which are exposed to strain forces under 
deformation. The Force Field of a molecule is divided into a sum of model 
forces, which are described in terms of classical mechanics.    
One of the first was the Force Field MM2 ; mostly the more advanced 
version MM3 is used. MM3 describes a valence force field, which is defined 
in internal coordinates. These are bond distances, bond angles, and torsion 
angles.  
The steric energy Esteric of a molecule in the force field is caused by the 
deviation from an ideal structure and can be formulated as the sum of 
different energetical contributions.  
Esteric = ES + EB + ET + EvdW + Eµ  (important terms of the 
FF) 
           + EOOP + ESB + EBB + ETS  (cross terms) 
             + EQ + EQµ             
(terms for ions only) 
 
The summations include all bond distances, bond angles, torsion angles, and 
all non-bonding interactions (1,4-interactions and higher).  
• ES :   stretching energy;  
• EB :   bending energy;  
• ET :   torsion energy;  
• EvdW :   van der Waals non-bonding energy (including Hydrogen-
bonding);  
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• Eµ :   energy of dipol-dipol interactions (MM3; charge interaction in 
other FF);  
• EOOP :   out of plane energy;  
• ESB :   stretch-bend cross term;  
• EBB :   bend-bend cross term (limited for angles at the same central 
atom;  
• ETS :   torsion-stretch cross term (limited for torsions around the 
stretched bond);  
• EQ :   electrostatic interaction between ions;  
• EQµ :   interaction between ions and dipoles.  
The above calculation is done automatically by Arguslab 4 two example are 
included as an instance and are detailed in appendices 7 and 9   
 2-Semi-empirical MINDO and its refined version AM1 
Approximations of the MNDO method are: 
• Neglect of 3- and 4-centre integrals drastically simplifies elements of 
the Fock matrix, if the associated basis functions have different origin.  
• The 1- and 2-centre integrals <ss|ss>, <pp|pp>, <sp|pp>, <sp|sp>, and 
<pp|p'p'> are determined from spectroscopic data or treated as optimizable 
parameters.  
• One-electron integrals Hµ  are computed from the overlap S'µ . This is 
inconsistent with the ZDO approximation, but accepted (the M in MNDO 
means Modified).  
Hµµ = UµµA + B  A VµµB  
Hµ  = S'µ  (βµA + βµB )/2 
βµ and Uµµ are "atomaric" quantities and are treated as optimizable 
parameters.  
Disadvantages of the MNDO approximation: 
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• Basis set of s- and p-Slater type orbitals, hence no coverage of 
transition metals;  
• d-Slater type orbitals in a newer version [Thiel, Voityuk, 1994];  
• Intermolecular hydrogen bonds are incorrectly modelled, since the            
repulsion energy is overestimated for atomic distances close to the sum of   
the van der Waals radii. 
• Energies of sterically hindered molecules too high.  
• Energies of four-membered rings too low.  
• Not very good for conjugated -systems.  
AM1 is a semiempirical theory that has emerged from MNDO with the 
purpose of correcting the repulsion energy overestimation. To do so, the 
core-core terms were described by Gauss functions with a width parameter 
L and distance parameters M and K:  
 
The original AM1 procedure contained four such terms for carbon, three for 
hydrogen and nitrogen, and two for oxygen. This increased the number of 
parameters per atom from 7 (MNDO) to 16 (AM1) and managed to correct 
most errors in the repulsion energy. AM1 is especially useful for larger 
organic systems, although the performance still has some limitations.  
• Heats of formation: deviations of approximately 5-5.8 kcal/mol;  
• Dipole moment: deviations of approximately 0.3 D;  
• Ionisation energies: deviations of approximately 0.3 eV;  
• Rotational barriers: larger deviations.   
AM1 calcuations are performed for daunorubicin and its analogue aza-
daunorubicin  using Arguslab 4 software and are shown in appendices 8 and 
10  
 
EAB  =  EABMNDO + (ZA ZB)/RAB { i KAi exp[-LAi (RAB - MAi)²] +      
j KBj exp[-LBj(RAB - MBj)²] }  
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Appendix 7 Geometry optimization for daunorubicin Using MMFF 
******  **Validated Experiment & Chemical System Settings**********    
Calculation started:  Fri Feb 29 10:47:22 2008  
Title:  
C:\Documents and Settings\XPPRESP3\Desktop\args\dau1  
System Type               Molecular Mechanical  
Hamiltonian               UFF (Molecular Mechanics)(  
QEq charges will NOT be used  
Electrostatics Terms      Simple cutoff  
Run Type                  Optimize Geometry  
Search Type               BFGS  
Atoms                     38  
Water Model               SPCE  
Coordinates               angstroms  
Max. geom cycles          100  
Convergence criteria:  
max. grad. component <    0.000084   au.  
MM bond type              quadratic  
  
Scratch Block Size for MM  3000000 bytes  
Update NB list every      20 cycles  
NB list build cutoff      10.0000    angs.  
NB cutoff                 8.0000     angs.  
MM params                 internally stored  
Input Atomic Information  
************************  
1   C   -4.805370   2.475852  -0.262472  
2   C   -3.610349   1.748842  -0.141731  
3   C   -2.390186   2.434556  -0.044185  
4   C   -1.171403   1.722635   0.067754  
5   C    0.070043   2.399364   0.179891  
6   C    1.270649   1.684471   0.278479  
7   C    1.253110   0.279999   0.282405  
8   C    0.035565  -0.406516   0.172306  
9   C   -1.191054   0.299778   0.067581  
10   C   -2.431106  -0.384351  -0.036023  
11   C   -3.646583   0.333026  -0.125072  
12   C   -4.910518  -0.319028  -0.204935  
13   C   -6.081241   0.436413  -0.339862  
14   C   -6.030793   1.825766  -0.365661  
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15   C    2.546087   2.454738   0.457769  
16   C    2.524256  -0.515185   0.344078  
17   O   -2.397662   3.697313  -0.059096  
18   O   -2.452572  -1.645171  -0.054544  
19   O   -5.028296  -1.730229  -0.191236  
20   C   -5.243511  -2.094107   1.187305  
21   O    0.062931  -1.820221   0.172776  
22   O    0.127689   3.812039   0.199456  
23   O    2.903701  -0.918743  -0.982202  
24   C    3.749042   1.595168   0.146680  
25   C    3.631062   0.316888   0.944338  
26   C    5.012213   2.357961   0.541690  
27   C    6.279287   1.637936   0.105626  
28   O    4.988675   3.534547   0.027787  
29   O    3.759026   1.285878  -1.259198  
30   C    2.437240  -4.111967   0.585622  
31   C    1.050961  -3.781951   1.134747  
32   C   -0.050560  -4.348347   0.234299  
33   C    0.218664  -3.895603  -1.204439  
34   O    1.505102  -4.389678  -1.652905  
35   O   -0.069038  -5.788293   0.309173  
36   N    0.915546  -4.294081   2.500136  
37   C   -0.875998  -4.380226  -2.135970  
38   C    2.795839  -2.657583   0.000000  
Cite ArgusLab as:  
*****************  
ArgusLab 4.0  
Mark A. Thompson  
Planaria Software LLC, Seattle, WA  http://www.arguslab.com  
Journal Citations for this Calculation  
**************************************  
Thompson, M. A., Zerner M. C J. Am. Chem. Soc., 113, 8210, (1991(  
Mark A. Thompson, Eric D. Glendening and David Feller, J. Phys. Chem. 
98  
10465-10476 ,)1994(  
Mark A. Thompson, and Gregory K. Schenter, J. Phys. Chem. 99, 6374-
6386, (1995)  
14492-14507 ,)1996( Mark A. Thompson, J. Phys. Chem. 100   
UFF references  
***************  
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Rappe', A. K., et. al. JACS, 114, 10024-10035, 1992  
Casewit, C. J., Colwell, K. S., and Rappe', A. K, JACS, 114, 10035-10046, 
1992  
Casewit, C. J., Colwell, K. S., and Rappe', A. K, JACS, 114, 10046-10053, 
1992  
Rappe', A. K. and Goddard, W. A., JPC, 95, 3358-3363, 1991  
Rappe', A. K., Colwell, K. S., and Casewit, C. J, Inorg. Chem. 32, 3438-
3450, 1993  
*************************************************************  
Constructing Chemical System(s(  
Memory for Main Chemical System  
Memory Requirements (bytes(  
*****************************  
Core         62304  
  Scratch    24004560  
ParamCheck: not checking UFF params. Ignoring oop terms in .top file for 
UFF  
These will be made later, based on UFF atom types  
System charge       0.000000  
Making Bond List  
Making Bond Angle List  
Making Improper Torsion List  
Making Groups Arrays  
Making NonBonded Exclusion List  
NB exclusion list 0 sec  
Assigning NonBonded parameters to atoms  
Making Initial NonBonded Lists  
Initial NB lists 0 sec  
  
 In BuildLists, print bonded lists  
Bonds
  
10  11)   C)-(C)     1.379256  
462.660461  
1  2)   C)-(C)     1.379256  
462.660461  
3  17)   C)-(O)     1.257535  
734.305767  
12  13)   C)-(C)     1.379256  
462.660461  
5  22)   C)-(O)     1.407689  
523.501065  
2  3)   C)-(C)     1.379256  
462.660461  
6  15)   C)-(C)     1.486000  
369.948258  
13  14)   C)-(C)     1.379256  
462.660461  
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7  16)   C)-(C)     1.486000  
369.948258  
3  4)   C)-(C)     1.379256  
462.660461  
8  21)   C)-(O)     1.407689  
523.501065  
1  14)   C)-(C)     1.379256  
462.660461  
10  18)   C)-(O)     1.257535  
734.305767  
4  5)   C)-(C)     1.379256  
462.660461  
19  20)   O)-(C)     1.436155  
492.984516  
5  6)   C)-(C)     1.379256  
462.660461  
12  19)   C)-(O)     1.407689  
523.501065  
6  7)   C)-(C)     1.379256  
462.660461  
7  8)    
 
C)-(C)     1.379256  462.660461  
15  24)   C)-(C)     1.514000  
349.799987  
8  9)   C)-(C)     1.379256  
462.660461  
16  25)   C)-(C)     1.514000  
349.799987  
4  9)   C)-(C)     1.379256  
462.660461  
16  23)   C)-(O)     1.436155  
492.984516  
2  11)   C)-(C)     1.379256  
462.660461  
9  10)   C)-(C)     1.379256  
462.660461  
11  12)   C)-(C)     1.379256  
462.660461  
24  25)   C)-(C)     1.514000  
349.799987  
26  28)   C)-(O)     1.283402  
690.794327  
26  27)   C)-(C)     1.514000  
349.799987  
24  26)   C)-(C)     1.514000  
349.799987  
24  29)   C)-(O)     1.436155  
492.984516  
31  36)   C)-(N)     1.462929  
515.889778  
33  34)   C)-(O)     1.436155  
492.984516  
33  37)   C)-(C)     1.514000  
349.799987  
31  32)   C)-(C)     1.514000  
349.799987  
32  35)   C)-(O)     1.436155  
492.984516  
32  33)   C)-(C)     1.514000  
349.799987  
30  31)   C)-(C)     1.514000  
349.799987  
30  38)   C)-(C)     1.514000  
349.799987  
34  38)   O)-(C)     1.436155  
492.984516  
23  38)   O)-(C)     1.436155  
492.984516  
  
Bond Angles  
**********  
11  10  18)  C)-(C)-(O) 
120.000000 305.738360  
10  11  2)  C)-(C)-(C) 120.000000 
222.595017  
11  10  9)  C)-(C)-(C) 120.000000 
222.595017  
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10  11  12)  C)-(C)-(C) 
120.000000 222.595017  
1  2  3)  C)-(C)-(C) 120.000000 
222.595017  
2  1  14)  C)-(C)-(C) 120.000000 
222.595017  
1  2  11)  C)-(C)-(C) 120.000000 
222.595017  
17  3  2)  O)-(C)-(C) 120.000000 
305.738360  
17  3  4)  O)-(C)-(C) 120.000000 
305.738360  
12  13  14)  C)-(C)-(C) 
120.000000 222.595017  
13  12  19)  C)-(C)-(O) 
120.000000 259.618978  
13  12  11)  C)-(C)-(C) 
120.000000 222.595017  
22  5  4)  O)-(C)-(C) 120.000000 
259.618978  
22  5  6)  O)-(C)-(C) 120.000000 
259.618978  
2  3  4)  C)-(C)-(C) 120.000000 
222.595017  
3  2  11)  C)-(C)-(C) 120.000000 
222.595017  
15  6  5)   
 
 
C)-(C)-(C) 120.000000 
198.274298  
15  6  7)  C)-(C)-(C) 120.000000 
198.274298  
6  15  24)  C)-(C)-(C) 109.470000 
220.229931  
13  14  1)  C)-(C)-(C) 120.000000 
222.595017  
16  7  6)  C)-(C)-(C) 120.000000 
198.274298  
16  7  8)  C)-(C)-(C) 120.000000 
198.274298  
7  16  25)  C)-(C)-(C) 109.470000 
220.229931  
7  16  23)  C)-(C)-(O) 109.470000 
286.552527  
3  4  5)  C)-(C)-(C) 120.000000 
222.595017  
3  4  9)  C)-(C)-(C) 120.000000 
222.595017  
21  8  7)  O)-(C)-(C) 120.000000 
259.618978  
21  8  9)  O)-(C)-(C) 120.000000 
259.618978  
18  10  9)  O)-(C)-(C) 120.000000 
305.738360  
4  5  6)  C)-(C)-(C) 120.000000 
222.595017  
5  4  9)  C)-(C)-(C) 120.000000 
222.595017  
20  19  12)  C)-(O)-(C) 
104.510000 293.439812  
5  6  7)  C)-(C)-(C) 120.000000 
222.595017  
19  12  11)  O)-(C)-(C) 
120.000000 259.618978  
6  7  8)  C)-(C)-(C) 120.000000 
222.595017  
7  8  9)  C)-(C)-(C) 120.000000 
222.595017  
15  24  25)  C)-(C)-(C) 
109.470000 214.211821  
15  24  26)  C)-(C)-(C) 
109.470000 214.211821  
15  24  29)  C)-(C)-(O) 
109.470000 278.259153  
8  9  4)  C)-(C)-(C) 120.000000 
222.595017  
8  9  10)  C)-(C)-(C) 120.000000 
222.595017  
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25  16  23)  C)-(C)-(O) 
109.470000 278.259153  
16  25  24)  C)-(C)-(C) 
109.470000 214.211821  
4  9  10)  C)-(C)-(C) 120.000000 
222.595017  
16  23  38)  C)-(O)-(C) 
104.510000 284.864410  
2  11  12)  C)-(C)-(C) 120.000000 
222.595017  
25  24  26)  C)-(C)-(C) 
109.470000 214.211821  
25  24  29)  C)-(C)-(O) 
109.470000 278.259153  
28  26  27)  O)-(C)-(C) 
109.470000 322.667279  
28  26  24)  O)-(C)-(C) 
109.470000 322.667279  
27  26  24)  C)-(C)-(C) 
109.470000 214.211821  
26  24  29)  C)-(C)-(O) 
109.470000 278.259153  
36  31  32)  N)-(C)-(C) 
109.470000 299.774843  
36  31  30)  N)-(C)-(C) 
109.470000 299.774843  
34  33  37)  O)-(C)-(C) 
109.470000 278.259153  
34  33  32)  O)-(C)-(C) 
109.470000 278.259153  
33  34  38)  C)-(O)-(C) 
104.510000 284.864410  
37  33  32)  C)-(C)-(C) 
109.470000 214.211821  
31  32  35)  C)-(C)-(O) 
109.470000 278.259153  
31  32  33)  C)-(C)-(C) 
109.470000 214.211821  
32  31  30)  C)-(C)-(C) 
109.470000 214.211821  
35  32  33)  O)-(C)-(C) 
109.470000 278.259153  
31  30  38)  C)-(C)-(C) 
109.470000 214.211821  
30  38  34)  C)-(C)-(O) 
109.470000 278.259153  
30  38  23)  C)-(C)-(O) 
109.470000 278.259153  
34  38  23)  O)-(C)-(O) 
109.470000 363.159049  
  
  
  
 
 
 
  
Dihedral Angles
***************  
1 term(s) in expansion  
2  11  10  18  
)C)-(C)-(C)-(O(  
6.737110 2  180.000000  
1 term(s) in expansion  
12  11  10  18  
)C)-(C)-(C)-(O(  
6.737110 2  180.000000  
1 term(s) in expansion  
9  10  11  2  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
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10  11  2  1  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
10  11  2  3  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
12  11  10  9  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
11  10  9  8  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
11  10  9  4  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
10  11  12  13  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
10  11  12  19  
)C)-(C)-(C)-(O(  
6.737110 2  180.000000  
1 term(s) in expansion  
14  1  2  3  
)C)-(C)-(C)-(C(  
13.474221 2  180.000000  
1 term(s) in expansion  
1  2  3  17  
)C)-(C)-(C)-(O(  
6.737110 2  180.000000  
1 term(s) in expansion  
1  2  3  4  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
11  2  1  14  
)C)-(C)-(C)-(C(  
13.474221 2  180.000000  
1 term(s) in expansion  
2  1  14  13  
)C)-(C)-(C)-(C(  
26.948442 2  180.000000  
1 term(s) in expansion  
1  2  11  12  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
17  3  2  11  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
17  3  4  5  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
17  3  4  9  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
19  12  13  14  
)O)-(C)-(C)-(C(  
13.474221 2  180.000000  
1 term(s) in expansion  
11  12  13  14  
)C)-(C)-(C)-(C(  
13.474221 2  180.000000  
1 term(s) in expansion  
12  13  14  1  
)C)-(C)-(C)-(C(  
26.948442 2  180.000000  
1 term(s) in expansion  
13  12  19  20  
)C)-(C)-(O)-(C(  
5.000000 2   90.000000  
1 term(s) in expansion  
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13  12  11  2  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
22  5  4  3  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
22  5  4  9  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
22  5  6  15  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
22  5  6  7  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
11  2  3  4  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
2  3  4  5  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
2  3  4  9  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
3  2  11  12  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
24  15  6  5  
)C)-(C)-(C)-(C(  
1.000000 3  180.000000  
1 term(s) in expansion  
15  6  5  4  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
24  15  6  7  
)C)-(C)-(C)-(C(  
1.000000 3  180.000000  
1 term(s) in expansion  
15  6  7  16  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
15  6  7  8  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
  
1 term(s) in expansion  
6  15  24  25  
)C)-(C)-(C)-(C(  
0.706333 3  180.000000  
1 term(s) in expansion  
6  15  24  26  
)C)-(C)-(C)-(C(  
0.706333 3  180.000000  
1 term(s) in expansion  
6  15  24  29  
)C)-(C)-(C)-(O(  
0.706333 3  180.000000  
1 term(s) in expansion  
25  16  7  6  
)C)-(C)-(C)-(C(  
0.500000 3  180.000000  
1 term(s) in expansion  
23  16  7  6  
)O)-(C)-(C)-(C(  
0.500000 3  180.000000  
1 term(s) in expansion  
16  7  6  5  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
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1 term(s) in expansion  
25  16  7  8  
)C)-(C)-(C)-(C(  
0.500000 3  180.000000  
1 term(s) in expansion  
23  16  7  8  
)O)-(C)-(C)-(C(  
0.500000 3  180.000000  
1 term(s) in expansion  
16  7  8  21  
)C)-(C)-(C)-(O(  
6.737110 2  180.000000  
1 term(s) in expansion  
16  7  8  9  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
7  16  25  24  
)C)-(C)-(C)-(C(  
1.059500 3  180.000000  
1 term(s) in expansion  
7  16  23  38  
)C)-(C)-(O)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
3  4  5  6  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
3  4  9  8  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
3  4  9  10  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
21  8  7  6  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
21  8  9  4  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
21  8  9  10  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
18  10  9  8  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
18  10  9  4  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
9  4  5  6  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
4  5  6  7  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
5  4  9  8  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
5  4  9  10  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
20  19  12  11  
)C)-(O)-(C)-(C(  
5.000000 2   90.000000  
1 term(s) in expansion  
5  6  7  8  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
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1 term(s) in expansion  
19  12  11  2  
)O)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
6  7  8  9  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
7  8  9  4  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
7  8  9  10  
)C)-(C)-(C)-(C(  
6.737110 2  180.000000  
1 term(s) in expansion  
15  24  25  16  
)C)-(C)-(C)-(C(  
0.706333 3  180.000000  
1 term(s) in expansion  
15  24  26  28  
)C)-(C)-(C)-(O(  
0.353167 3  180.000000  
1 term(s) in expansion  
15  24  26  27  
)C)-(C)-(C)-(C(  
0.353167 3  180.000000  
1 term(s) in expansion  
24  25  16  23  
)C)-(C)-(C)-(O(  
1.059500 3  180.000000  
1 term(s) in expansion  
25  16  23  38  
)C)-(C)-(O)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
16  25  24  26  
)C)-(C)-(C)-(C(  
0.706333 3  180.000000  
1 term(s) in expansion  
16  25  24  29  
)C)-(C)-(C)-(O(  
0.706333 3  180.000000  
  
1 term(s) in expansion  
16  23  38  30  
)C)-(O)-(C)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
16  23  38  34  
)C)-(O)-(C)-(O(  
0.097650 3  180.000000  
1 term(s) in expansion  
25  24  26  28  
)C)-(C)-(C)-(O(  
0.353167 3  180.000000  
1 term(s) in expansion  
25  24  26  27  
)C)-(C)-(C)-(C(  
0.353167 3  180.000000  
1 term(s) in expansion  
28  26  24  29  
)O)-(C)-(C)-(O(  
0.353167 3  180.000000  
1 term(s) in expansion  
27  26  24  29  
)C)-(C)-(C)-(O(  
0.353167 3  180.000000  
1 term(s) in expansion  
36  31  32  35  
)N)-(C)-(C)-(O(  
0.529750 3  180.000000  
1 term(s) in expansion  
36  31  32  33  
)N)-(C)-(C)-(C(  
0.529750 3  180.000000  
1 term(s) in expansion  
36  31  30  38  
)N)-(C)-(C)-(C(  
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1.059500 3  180.000000  
1 term(s) in expansion  
38  34  33  37  
)C)-(O)-(C)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
38  34  33  32  
)C)-(O)-(C)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
34  33  32  31  
)O)-(C)-(C)-(C(  
0.529750 3  180.000000  
1 term(s) in expansion  
34  33  32  35  
)O)-(C)-(C)-(O(  
0.529750 3  180.000000  
1 term(s) in expansion  
33  34  38  30  
)C)-(O)-(C)-(C(  
0.097650 3  180.000000  
1 term(s) in expansion  
33  34  38  23  
)C)-(O)-(C)-(O(  
0.097650 3  180.000000  
1 term(s) in expansion  
37  33  32  31  
)C)-(C)-(C)-(C(  
0.529750 3  180.000000  
1 term(s) in expansion  
37  33  32  35  
)C)-(C)-(C)-(O(  
0.529750 3  180.000000  
1 term(s) in expansion  
30  31  32  35  
)C)-(C)-(C)-(O(  
0.529750 3  180.000000  
1 term(s) in expansion  
30  31  32  33  
)C)-(C)-(C)-(C(  
0.529750 3  180.000000  
1 term(s) in expansion  
32  31  30  38  
)C)-(C)-(C)-(C(  
1.059500 3  180.000000  
1 term(s) in expansion  
31  30  38  34  
)C)-(C)-(C)-(O(  
1.059500 3  180.000000  
1 term(s) in expansion  
31  30  38  23  
)C)-(C)-(C)-(O(  
1.059500 3  180.000000  
Improper Torsions  
***************  
18  9  10  11  
)O)-(C)-(C)-(C(  
16.666667 0    0.000000  
2  12  11  10  
)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
3  11  2  1  
)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
2  4  3  17  
)C)-(C)-(C)-(O(  
16.666667 0    0.000000  
19  11  12  13  
)O)-(C)-(C)-(C(  
2.000000 0    0.000000  
4  6  5  22  
)C)-(C)-(C)-(O(  
2.000000 0    0.000000  
5  7  6  15  
)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
6  8  7  16  
)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
5  9  4  3  
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)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
7  9  8  21  
)C)-(C)-(C)-(O(  
2.000000 0    0.000000  
4  10  9  8  
)C)-(C)-(C)-(C(  
2.000000 0    0.000000  
Bonded Topology  
--------------  
Bonds                    42  
Bond Angles              66  
Dihedral Angles          96  
Imp. Torsions            11  
NB Exclusion List        108  
Initial NB List          595  
Groups used in NB list   4  
 *****Initial Energy Evaluation*****   
  
Energy Components (au(  
**********************  
  
MM Bond                               1.56272480  
MM Angle                              0.34057013  
MM Dihedral                           0.00867231  
MM ImpTor                             0.00002573  
MM vdW                                0.13059215  
MM Coulomb                            0.00000000  
------------------------------------------------  
Total                                 2.04258512 au  
Total                               1281.74267232 kcal/mol  
Energy Eval elapsed time 0 sec.  
  
 *****Geometry Optimization*****   
Checkpointing coordinate to C:\Documents and 
Settings\XPPRESP3\Desktop\args\dau1.cor  
Geometry Search using BFGS update  
Cycle   Energy(au)   delE (au)     Grad Norm   |Max Grad(i)|    alpha  
*************************************************************
********  
start     2.042585    0.0000e+000     1.712763     0.964173  
1       1.434979   -6.0761e-001     1.333525     0.741362   2.3354e-001  
2       0.970136   -4.6484e-001     0.986405     0.537538   2.9996e-001  
3       0.646394   -3.2374e-001     0.665635     0.335859   4.0000e-001  
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4       0.494999   -1.5139e-001     0.479845     0.243851   4.0000e-001  
5       0.414045   -8.0954e-002     0.369692     0.201917   4.0000e-001  
6       0.364690   -4.9354e-002     0.301556     0.167883   4.0000e-001  
7       0.331177   -3.3514e-002     0.256225     0.140280   4.0000e-001  
8       0.263226   -6.7951e-002     0.163144     0.073134   4.0000e-001  
9       0.230039   -3.3187e-002     0.106978     0.043961   4.0000e-001  
10       0.214095   -1.5944e-002     0.076049     0.027599   4.0000e-001  
11       0.205516   -8.5788e-003     0.059634     0.018891   4.0000e-001  
12       0.200126   -5.3900e-003     0.051026     0.016584   4.0000e-001  
13       0.196169   -3.9573e-003     0.046415     0.017948   4.0000e-001  
14       0.192861   -3.3076e-003     0.043734     0.019563   4.0000e-001  
15       0.189854   -3.0070e-003     0.041914     0.019029   4.0000e-001  
16       0.187015   -2.8389e-003     0.040424     0.016755   4.0000e-001  
17       0.184319   -2.6962e-003     0.039075     0.013168   4.0000e-001  
18       0.181773   -2.5461e-003     0.037917     0.012630   4.0000e-001  
19       0.179369   -2.4045e-003     0.037100     0.012782   4.0000e-001  
20       0.177069   -2.2997e-003     0.036703     0.012741   4.0000e-001  
21       0.174830   -2.2395e-003     0.036633     0.012486   4.0000e-001  
22       0.172628   -2.2020e-003     0.036588     0.011974   4.0000e-001  
23       0.170484   -2.1437e-003     0.036264     0.011161   4.0000e-001  
24       0.168446   -2.0374e-003     0.035476     0.011988   4.0000e-001  
25       0.166558   -1.8889e-003     0.034355     0.012101   4.0000e-001  
26       0.164818   -1.7399e-003     0.033042     0.011126   4.0000e-001  
27       0.163188   -1.6300e-003     0.031940     0.010056   4.0000e-001  
28       0.161578   -1.6093e-003     0.031415     0.011796   4.0000e-001  
29       0.159918   -1.6608e-003     0.031518     0.013142   4.0000e-001  
30       0.158198   -1.7191e-003     0.032054     0.013082   4.0000e-001  
31       0.156457   -1.7415e-003     0.032602     0.014835   4.0000e-001  
32       0.154745   -1.7118e-003     0.032637     0.015955   4.0000e-001  
33       0.153132   -1.6131e-003     0.031799     0.015263   4.0000e-001  
34       0.151690   -1.4417e-003     0.030090     0.014134   4.0000e-001  
35       0.150454   -1.2360e-003     0.027942     0.013563   4.0000e-001  
36       0.149396   -1.0586e-003     0.025865     0.012059   4.0000e-001  
37       0.148455   -9.4030e-004     0.024226     0.009928   4.0000e-001  
38       0.147585   -8.7076e-004     0.023156     0.007443   4.0000e-001  
39       0.146757   -8.2789e-004     0.022606     0.007119   4.0000e-001  
40       0.145960   -7.9688e-004     0.022419     0.008418   4.0000e-001  
41       0.145187   -7.7318e-004     0.022333     0.008896   4.0000e-001  
42       0.144434   -7.5304e-004     0.022117     0.008351   4.0000e-001  
43       0.143703   -7.3012e-004     0.021536     0.007470   4.0000e-001  
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44       0.143009   -6.9422e-004     0.020471     0.006916   4.0000e-001  
45       0.142372   -6.3741e-004     0.018933     0.007173   4.0000e-001  
46       0.141812   -5.5955e-004     0.017132     0.007206   4.0000e-001  
47       0.141340   -4.7201e-004     0.015414     0.006506   4.0000e-001  
48       0.140947   -3.9296e-004     0.014118     0.005275   4.0000e-001  
49       0.140610   -3.3737e-004     0.013427     0.003908   4.0000e-001  
50       0.140299   -3.1127e-004     0.013339     0.004624   4.0000e-001  
51       0.139985   -3.1322e-004     0.013739     0.004974   4.0000e-001  
52       0.139648   -3.3792e-004     0.014485     0.004970   4.0000e-001  
53       0.139270   -3.7707e-004     0.015350     0.004847   4.0000e-001  
54       0.138850   -4.2036e-004     0.016204     0.005319   4.0000e-001  
55       0.138394   -4.5651e-004     0.016756     0.005775   4.0000e-001  
56       0.137914   -4.7963e-004     0.017115     0.006236   4.0000e-001  
57       0.137427   -4.8700e-004     0.017066     0.005655   4.0000e-001  
58       0.136940   -4.8684e-004     0.017080     0.004920   4.0000e-001  
59       0.136458   -4.8200e-004     0.017043     0.004503   4.0000e-001  
60       0.135971   -4.8667e-004     0.017288     0.005682   4.0000e-001  
61       0.135474   -4.9779e-004     0.018034     0.006593   4.0000e-001  
62       0.134949   -5.2511e-004     0.018442     0.007132   4.0000e-001  
63       0.134392   -5.5683e-004     0.019553     0.007241   4.0000e-001  
64       0.133794   -5.9735e-004     0.019478     0.006839   4.0000e-001  
65       0.133174   -6.2069e-004     0.019654     0.007748   4.0000e-001  
66       0.132559   -6.1433e-004     0.018584     0.007152   4.0000e-001  
67       0.131988   -5.7136e-004     0.017685     0.006464   4.0000e-001  
68       0.131474   -5.1418e-004     0.016340     0.004751   4.0000e-001  
69       0.131017   -4.5732e-004     0.015467     0.004564   4.0000e-001  
70       0.130603   -4.1305e-004     0.014712     0.004098   4.0000e-001  
71       0.130224   -3.7917e-004     0.014306     0.004300   4.0000e-001  
72       0.129871   -3.5375e-004     0.013960     0.004219   4.0000e-001  
73       0.129540   -3.3074e-004     0.013653     0.003965   4.0000e-001  
74       0.129230   -3.0988e-004     0.013285     0.004086   4.0000e-001  
75       0.128940   -2.9038e-004     0.012886     0.003862   4.0000e-001  
76       0.128665   -2.7482e-004     0.012499     0.003472   4.0000e-001  
77       0.128402   -2.6233e-004     0.012139     0.003498   4.0000e-001  
78       0.128151   -2.5166e-004     0.011835     0.003219   4.0000e-001  
79       0.127912   -2.3898e-004     0.011499     0.003391   4.0000e-001  
80       0.127690   -2.2198e-004     0.011114     0.003350   4.0000e-001  
81       0.127490   -1.9999e-004     0.010586     0.003614   4.0000e-001  
82       0.127314   -1.7571e-004     0.009969     0.003529   4.0000e-001  
83       0.127161   -1.5265e-004     0.009291     0.003151   4.0000e-001  
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84       0.127027   -1.3408e-004     0.008681     0.002583   4.0000e-001  
85       0.126906   -1.2116e-004     0.008213     0.001996   4.0000e-001  
86       0.126792   -1.1421e-004     0.007999     0.001825   4.0000e-001  
87       0.126680   -1.1235e-004     0.008040     0.001976   4.0000e-001  
88       0.126565   -1.1499e-004     0.008343     0.002001   4.0000e-001  
89       0.126444   -1.2035e-004     0.008802     0.002041   4.0000e-001  
90       0.126316   -1.2803e-004     0.009277     0.002290   4.0000e-001  
91       0.126181   -1.3567e-004     0.009714     0.002827   4.0000e-001  
92       0.126036   -1.4435e-004     0.009917     0.003235   4.0000e-001  
93       0.125886   -1.4990e-004     0.010002     0.003434   4.0000e-001  
94       0.125733   -1.5357e-004     0.009829     0.003396   4.0000e-001  
95       0.125581   -1.5193e-004     0.009617     0.003093   4.0000e-001  
96       0.125433   -1.4823e-004     0.009270     0.002692   4.0000e-001  
97       0.125292   -1.4052e-004     0.008974     0.002418   4.0000e-001  
98       0.125161   -1.3153e-004     0.008598     0.002684   4.0000e-001  
99       0.125041   -1.2003e-004     0.008259     0.002735   4.0000e-001  
100       0.124932   -1.0844e-004     0.007808     0.002602   4.0000e-001  
<<<Geometry optimization did not converge>>>  
Maximum cycles reached, optimization terminated  
  ****************Final Geometry* ***************  
C   -4.89570068    2.93809057   -0.36620511      6  
C   -3.78864236    2.09826571   -0.16968062      6  
C   -2.50587256    2.65762333   -0.07492241      6  
C   -1.37355850    1.83404553    0.11509625      6  
C   -0.06937162    2.38448514    0.19279819      6  
C    1.04354753    1.55993250    0.39122064      6  
C    0.87116856    0.17487023    0.56720946      6  
C   -0.41698147   -0.37892826    0.52088714      6  
C   -1.54917403    0.43107968    0.25618547      6  
C   -2.84815299   -0.13001238    0.13672163      6  
C   -3.97344328    0.69644853   -0.08554513      6  
C   -5.28979861    0.17023639   -0.22595785      6  
C   -6.36751287    1.03523719   -0.45312167      6  
C   -6.17490923    2.41166513   -0.50984932      6  
C    2.41350401    2.18684356    0.48459959      6  
C    2.05923210   -0.76137460    0.63196470      6  
O   -2.37840324    3.91054376   -0.15717439      8  
O   -3.00365235   -1.37769587    0.23116408      8  
O   -5.54708143   -1.22328768   -0.20215243      8  
C   -5.93259550   -1.53563408    1.15193656      6  
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O   -0.55602851   -1.76897612    0.72902172      8  
O    0.14026568    3.77589393    0.06036885      8  
O    2.10451913   -1.52885599   -0.59653582      8  
C    3.52519963    1.23429805    0.04663691      6  
C    3.39219349   -0.04303581    0.87765351      6  
C    4.90119596    1.87466571    0.29719049      6  
C    6.03976907    0.95208454   -0.11346806      6  
O    5.01196838    2.98113932   -0.34857360      8  
O    3.37322152    0.94177896   -1.35768194      8  
C    2.93871673   -3.41178893    0.91540518      6  
C    1.57669921   -4.04366765    1.20023175      6  
C    1.10236206   -4.91185052    0.03258129      6  
C    1.19946313   -4.08799734   -1.25243945      6  
O    2.57514905   -3.67904213   -1.49580870      8  
O    1.91418026   -6.09848733   -0.07847046      8  
N    1.63580006   -4.82914863    2.43472464      7  
C    0.66251629   -4.86674976   -2.43956249      6  
C    2.94065536   -2.72080468   -0.46608160      6  
  
Final Geom Energy =    0.1249320997 au  
Final Geom Energy =         78.3961 kcal/mol  
Geometry Optimization elapsed time 2 sec.  
 *****Final Energy Evaluation*****   
Energy Components (au(  
**********************  
MM Bond                              0.01551530  
MM Angle                             0.01346615  
MM Dihedral                          0.00601219  
MM ImpTor                            0.00008894  
MM vdW                               0.08984951  
MM Coulomb                           0.00000000  
------------------------------------------------  
Total                                0.12493210 a.u.  
Total                               78.39614691 kcal/mol  
 *****Properties*****   
Ground state properties  
*****************************  
Properties elapsed time 0 sec.  
Total Elapsed Time 2 sec. 
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Appendix 7 AM1 Semi-empirical Quantum Mechanical Calculations 
                        for Daunorubicin  
*************************************************************  
 *********Validated Experiment & Chemical System Settings**********    
  Calculation started:  Tue Jan 22 02:31:40 2008  
: Title  
C:\Documents and Settings\XPPRESP3\mohamed osman\DAU  
  System Type               Quantum Mechanical  
  Hamiltonian               AM1 (NDDO(  
  SCF Type                  UHF  
  Run Type                  SCF  
  Atoms                     38  
  Electrons                 173  
    Alpha                   87  
    Beta                    86  
  
  Multiplicity              2  
  Water Model               SPCE  
  Coordinates               angstroms  
  Basis set                 Minimal Valence Basis as STO 6G  
  Max. SCF cycles           200  
  SCF convergence           1.5936e-013 au. for energy  
  
  AM1 param file            C:\Program Files\ArgusLab\params\am1.prm  
  SCF saved every           1000 cycles  
  
  Two-electron integrals  
    buffer size             1000  
    storage                 random list in core  
  
  Property integrals        one center  
  Dipole integrals          length operator  
 
Input Atomic Information  
************************  
1   C -16.072684  10.281579  -
1.222542  
2   C  -15.078341   9.292680  -
1.237248  
3   C  -13.729370   9.602436  -
0.718005  
4   C  -12.749279   8.507152  -
0.485081  
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5   C  -11.502093   8.754360   
0.129481  
6   C  -10.645248   7.694702   
0.446048  
7   C  -11.030397   6.365537   
0.201603  
8   C  -12.258250   6.116294  -
0.443820  
9   C  -13.095321   7.184253  -
0.841047  
10   C  -14.343760   6.938357  -
1.617161  
11   C  -15.378584   8.000630  -
1.718751  
12   C  -16.673974   7.741333  -
2.233318  
13   C  -17.656886   8.738189  -
2.183823  
14   C  -17.358237  10.002878  -
1.682832  
15   O  -13.434026  10.796752  -
0.440715  
16   O  -14.513406   5.833626  -
2.201106  
17   O  -17.022555   6.473424  -
2.755574  
18   C  -16.855637   6.581873  -
4.183723  
19   O  -11.097093  10.070533   
0.445728  
20   O  -12.667507   4.781453  -
0.658460  
21   C   -9.327274   7.998751   
1.064951  
22   C  -10.199814   5.209411   
0.720162  
23   O  -10.083518   4.146203  -
0.245696  
24   C   -8.361648   6.934075   
0.625445  
25   C   -8.819567   5.620184   
1.228607  
26   C   -6.973274   7.313444   
1.134644  
27   C   -5.864541   6.511017   
0.469595  
28   O   -6.774335   8.567184   
0.941279  
29   O   -8.379866   6.846768  -
0.811424  
30   C  -10.445545   2.974834   
0.505084  
31   O  -11.774282   2.565440   
0.195340  
32   C   -9.457830   1.842828   
0.235294  
33   C   -9.667360   1.232008  -
1.149776  
34   C  -11.130644   0.808268  -
1.333725  
35   C  -12.115722   1.946052  -
1.037307  
36   O  -11.356617   0.239424  -
2.635008  
37   N   -9.234389   2.163859  -
2.198342  
38   C  -12.191894   2.979247  -
2.151744  
  
  Cite ArgusLab as:  
*****************    
  ArgusLab 4.0   
  Mark A. Thompson   
  Planaria Software LLC, Seattle, WA.  
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  http://www.arguslab.com  
 
  Journal Citations for this Calculation  
**************************************    
Thompson, M. A., Zerner M. C.  
J. Am. Chem. Soc., 113, 8210, (1991(  
Mark A. Thompson, Eric D. Glendening,  
and David Feller J. Phys. Chem. 98,  
10465-10476 ,)1994(  
Mark A. Thompson, and Gregory K. Schenter  
J. Phys. Chem. 99, 6374-6386, (1995(  
Mark A. Thompson, J. Phys. Chem. 100,  
14492-14507 ,)1996(  
AM1 references:  
***************  
Michael J. S. Dewar, Eve G. Zoebisch  
Eamonn F. Healy, and James J. P. Stewart  
JACS, 107, 3902-3909, (1985(  
*************************************************************  
   Constructing Chemical System(s(  
   Basis Set  
  ***********  
         basis functions : 152  
         shells          : 76  
         primitives      : 456  
   Memory for Main Chemical System  
   Max. number 2-ele. ints. = 70908  
 Memory Requirements (bytes(  
  *****************************  
   Core       3434672  
   Scratch      376960  
   System charge       0.000000  
 *****Integrals*****   
  AM1 two-center two-electron integrals  
  MNDO-type Two-electron integrals: elapsed 
time 1 sec .  
  elapsed time 1 sec .  
  Coulomb integrals for semi-empirical  
  elapsed time 0 sec .  
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  One-center exchange integrals for semi-
empirical  
  elapsed time 0 sec .  
  Total number of 2-ele integrals 70899  
  Dipole length integrals  
  elapsed time 0 sec .  
  Integrals elapsed time 1 sec .  
 
 *****SCF*****   
  Core repulsion    1664.35 au  
  Calculating one electron matrix  
  Diagonalizing starting one-ele. matrix  
  Performing SCF  
Cycle                 Energy (au)          Difference      
                   1                      0 33.179328  
2          2.392705932                35.572  
3         34.264055311               31.8713  
4        107.303478428               73.0394  
5         86.146250228              -21.1572  
6        129.186824846               43.0406  
7         92.956074110              -36.2308  
8        128.620677057               35.6646  
9         99.193720702               -29.427  
10        129.884302427               30.6906  
11         99.321025278              -30.5633  
12        129.881526794               30.5605  
13         99.320950340              -30.5606  
14        129.881521737               30.5606  
15         99.320949926              -30.5606  
16        129.881521725               30.5606  
17         99.320949924              -30.5606  
18        129.881521725               30.5606  
19         99.320949924              -30.5606  
20        129.881521725               30.5606  
21         99.320949924              -30.5606  
22        129.881521725               30.5606  
23         99.320949924              -30.5606  
24        129.881521725               30.5606  
25         99.320949924              -30.5606  
26        129.881521725               30.5606  
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27         99.320949924              -30.5606  
28        129.881521725               30.5606  
29         99.320949924              -30.5606  
30        129.881521725               30.5606  
31         99.320949924              -30.5606  
32        129.881521725               30.5606  
33         99.320949924              -30.5606  
34        129.881521725               30.5606  
35         99.320949924              -30.5606  
36        129.881521725               30.5606  
37         99.320949924              -30.5606  
38        129.881521725               30.5606  
39         99.320949924              -30.5606  
40        129.881521725               30.5606  
41         99.320949924              -30.5606  
42        129.881521725               30.5606  
43         99.320949924              -30.5606  
44        129.881521725               30.5606  
45         99.320949924              -30.5606  
46        129.881521725               30.5606  
47         99.320949924              -30.5606  
48        129.881521725               30.5606  
49         99.320949924              -30.5606  
50        129.881521725               30.5606  
51         99.320949924              -30.5606  
52        129.881521725               30.5606  
53         99.320949924              -30.5606  
54        129.881521725               30.5606  
55         99.320949924              -30.5606  
56        129.881521725               30.5606  
57         99.320949924              -30.5606  
58        129.881521725               30.5606  
59         99.320949924              -30.5606  
60        129.881521725               30.5606  
61         99.320949924              -30.5606  
62        129.881521725               30.5606  
63         99.320949924              -30.5606  
64        129.881521725               30.5606  
65         99.320949924              -30.5606  
66        129.881521725               30.5606  
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67         99.320949924              -30.5606  
68        129.881521725               30.5606  
69         99.320949924              -30.5606  
70        129.881521725               30.5606  
71         99.320949924              -30.5606  
72        129.881521725               30.5606  
73         99.320949924              -30.5606  
74        129.881521725               30.5606  
75         99.320949924              -30.5606  
76        129.881521725               30.5606  
77         99.320949924              -30.5606  
78        129.881521725               30.5606  
79         99.320949924              -30.5606  
80        129.881521725               30.5606  
81         99.320949924              -30.5606  
82        129.881521725               30.5606  
83         99.320949924              -30.5606  
84        129.881521725               30.5606  
85         99.320949924              -30.5606  
86        129.881521725               30.5606  
87         99.320949924              -30.5606  
88        129.881521725               30.5606  
89         99.320949924              -30.5606  
90        129.881521725               30.5606  
91         99.320949924              -30.5606  
92        129.881521725               30.5606  
93         99.320949924              -30.5606  
94        129.881521725               30.5606  
95         99.320949924              -30.5606  
96        129.881521725               30.5606  
97         99.320949924              -30.5606  
98        129.881521725               30.5606  
99         99.320949924              -30.5606  
100        129.881521725               30.5606  
101         99.320949924              -30.5606  
102        129.881521725               30.5606  
103         99.320949924              -30.5606  
104        129.881521725               30.5606  
105         99.320949924              -30.5606  
106        129.881521725               30.5606  
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107         99.320949924              -30.5606  
108        129.881521725               30.5606  
109         99.320949924              -30.5606  
110        129.881521725               30.5606  
111         99.320949924              -30.5606  
112        129.881521725               30.5606  
113         99.320949924              -30.5606  
114        129.881521725               30.5606  
115         99.320949924              -30.5606  
116        129.881521725               30.5606  
117         99.320949924              -30.5606  
118        129.881521725               30.5606  
119         99.320949924              -30.5606  
120        129.881521725               30.5606  
121         99.320949924              -30.5606  
122        129.881521725               30.5606  
123         99.320949924              -30.5606  
124        129.881521725               30.5606  
125         99.320949924              -30.5606  
126        129.881521725               30.5606  
127         99.320949924              -30.5606  
128        129.881521725               30.5606  
129         99.320949924              -30.5606  
130        129.881521725               30.5606  
131         99.320949924              -30.5606  
132        129.881521725               30.5606  
133         99.320949924              -30.5606  
134        129.881521725               30.5606  
135         99.320949924              -30.5606  
136        129.881521725               30.5606  
137         99.320949924              -30.5606  
138        129.881521725               30.5606  
139         99.320949924              -30.5606  
140        129.881521725               30.5606  
141         99.320949924              -30.5606  
142        129.881521725               30.5606  
143         99.320949924              -30.5606  
144        129.881521725               30.5606  
145         99.320949924              -30.5606  
146        129.881521725               30.5606  
 146
147         99.320949924              -30.5606  
148        129.881521725               30.5606  
149         99.320949924              -30.5606  
150        129.881521725               30.5606  
151         99.320949924              -30.5606  
152        129.881521725               30.5606  
153         99.320949924              -30.5606  
154        129.881521725               30.5606  
155         99.320949924              -30.5606  
156        129.881521725               30.5606  
157         99.320949924              -30.5606  
158        129.881521725               30.5606  
159         99.320949924              -30.5606  
160        129.881521725               30.5606  
161         99.320949924              -30.5606  
162        129.881521725               30.5606  
163         99.320949924              -30.5606  
164        129.881521725               30.5606  
165         99.320949924              -30.5606  
166        129.881521725               30.5606  
167         99.320949924              -30.5606  
168        129.881521725               30.5606  
169         99.320949924              -30.5606  
170        129.881521725               30.5606  
171         99.320949924              -30.5606  
172        129.881521725               30.5606  
173         99.320949924              -30.5606  
174        129.881521725               30.5606  
175         99.320949924              -30.5606  
176        129.881521725               30.5606  
177         99.320949924              -30.5606  
178        129.881521725               30.5606  
179         99.320949924              -30.5606  
180        129.881521725               30.5606  
181         99.320949924              -30.5606  
182        129.881521725               30.5606  
183         99.320949924              -30.5606  
184        129.881521725               30.5606  
185         99.320949924              -30.5606  
186        129.881521725               30.5606  
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187         99.320949924              -30.5606  
188        129.881521725               30.5606  
189         99.320949924              -30.5606  
190        129.881521725               30.5606  
191         99.320949924              -30.5606  
192        129.881521725               30.5606  
193         99.320949924              -30.5606  
194        129.881521725               30.5606  
195         99.320949924              -30.5606  
196        129.881521725               30.5606  
197         99.320949924              -30.5606  
198        129.881521725               30.5606  
199         99.320949924              -30.5606  
200        129.881521725               30.5606  
  
Maximum number of iterations reached: SCF NOT CONVERGED  
  
  Writing final SCF to disk  
  Final SCF Energy =  129.8815217253 au  
  Final SCF Energy =      81501.9589 kcal/mol  
  
  Saving the final SCF to the restart file 
C:\Documents and Settings\XPPRESP3\mohamed osman\DAU.restartscf  
    
  
SCF elapsed time 1 min. 42 sec .  
  
 *****Properties*****   
    Ground state properties  
   ***** Heat of Formation*****   
  239607.3018 kcal/mol  
Atomic spin densities  
**********************  
1    C    0.0000  
2    C    0.0001  
3    C    0.2018  
4    C    0.0246  
5    C    0.0003  
6    C    0.0000  
7    C    0.0000  
8    C    0.0000  
9    C    0.0043  
10    C    0.0000  
11    C    0.0000  
12    C    0.0000  
13    C    0.0000  
14    C    0.0000  
15    O    0.7687  
16    O    0.0000  
17    O    0.0000  
18    C    0.0000  
19    O    0.0000  
20    O    0.0002  
21    C    0.0000  
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22    C   -0.0000  
23    O   -0.0000  
24    C    0.0000  
25    C   -0.0000  
26    C    0.0000  
27    C    0.0000  
28    O    0.0000  
29    O    0.0000  
30    C    0.0000  
31    O   -0.0000  
32    C    0.0000  
33    C   -0.0000  
34    C    0.0000  
35    C    0.0000  
36    O    0.0000  
37    N    0.0000  
38    C    0.0000
  
 S2 operator  
***********   
 exact                 0.750000  
 calculated            0.750000  
                      ) Ground State Dipole (debye  
                    X             Y             Z          length  
            1378.40324609  543.75973404  631.10805598  1610.57987555  
  Properties elapsed time 0 sec .  
 Total Elapsed Time 1 min. 43 sec 
  
  Appendix 9  Geometry Optimization using Molecular Force Field 
(MMFF) for 1-N-Aza-daunorubicin  
  *******************************************************  
  ******Validated Experiment & Chemical System Settings***** ****  
  Calculation started:  Fri Feb 29 11:33:34 2008  
 :  Title  
C:\Documents and Settings\XPPRESP3\Desktop\args\dau1  
  System Type               Molecular Mechanical  
  Hamiltonian               UFF (Molecular Mechanics(  
                            QEq charges will NOT be used  
  Electrostatics Terms      Simple cutoff  
  Run Type                  Optimize Geometry  
  Search Type               BFGS  
  Atoms                     38  
  Water Model               SPCE  
  Coordinates               angstroms  
  Max. geom cycles          100  
  Convergence criteria:  
  max. grad. component <    0.000084   au.  
  MM bond type              quadratic  
  Scratch Block Size for MM  3000000 bytes  
  Update NB list every      20 cycles  
  NB list build cutoff      10.0000    angs.  
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  NB cutoff                 8.0000     angs.  
  MM params                 internally stored  
Input Atomic Information  
************************
1   N   -4.957358   2.899376  -
0.652911  
2   C   -3.886930   2.127473  -
0.270850  
3   C   -2.588075   2.613817  -
0.459082  
4   C   -1.464978   1.833554  -
0.090639  
5   C   -0.141866   2.306347  -
0.282946  
6   C    0.959147   1.517265   
0.072738  
7   C    0.761707   0.251556   
0.655403  
8   C   -0.540436  -0.226566   
0.861988  
9   C   -1.668627   0.546860   
0.483666  
10   C   -2.991790   0.060725   
0.661990  
11   C   -4.104859   0.850184   
0.292648  
12   C   -5.446598   0.408062   
0.453170  
13   C   -6.504900   1.219473   
0.033430  
14   C   -6.247342   2.469796  -
0.513801  
15   C    2.342167   2.106010  -
0.064221  
16   C    1.930140  -0.654792   
0.971128  
17   O   -2.441770   3.759136  -
0.968110  
18   O   -3.180299  -1.088398   
1.146270  
19   O   -5.756433  -0.867103   
0.985794  
20   C   -5.980874  -0.662505   
2.395145  
21   O   -0.700396  -1.496544   
1.461023  
22   O    0.099820   3.583131  -
0.840394  
23   O    2.014840  -1.695015  -
0.024697  
24   C    3.460461   1.062705  -
0.106237  
25   C    3.260537   0.099121   
1.066024  
26   C    4.819180   1.767151   
0.032186  
27   C    5.975679   0.779138   
0.024594  
28   O    4.990684   2.617266  -
0.917599  
29   O    3.410266   0.347586  -
1.358489  
30   C    1.330427  -3.834512   
0.969608  
31   C    0.779904  -4.416662  -
0.328963  
32   C    1.903039  -5.013049  -
1.177250  
33   C    2.982618  -3.946363  -
1.372085  
34   O    3.533970  -3.533778  -
0.092391  
35   O    2.459816  -6.175935  -
0.531536  
36   N   -0.235752  -5.429397  -
0.033614  
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37   C    4.090721  -4.461272  -
2.270203  
38   C    2.484607  -2.871952   
0.669582
  
  Cite ArgusLab as:  
*****************    
  ArgusLab 4.0   
  Mark A. Thompson   
  Planaria Software LLC, Seattle, WA.  
  http://www.arguslab.com  
  
  Journal Citations for this Calculation  
**************************************    
 Thompson, M. A., Zerner M. C.,  
J. Am. Chem. Soc., 113, 8210, (1991  
Mark A. Thompson, Eric D. Glendening  
and David Feller, J. Phys. Chem. 98  
10465-10476 ,)1994(  
Mark A. Thompson, and Gregory K. Schenter  
J. Phys. Chem. 99, 6374-6386, (1995(  
Mark A. Thompson, J. Phys. Chem. 100  
14492-14507 ,)1996(  
: UFF references  
***************    
  Rappe', A. K., et. al. JACS, 114, 10024-10035, 1992  
  Casewit, C. J., Colwell, K. S., and Rappe', A. K  
  JACS, 114, 10035-10046, 1992  
  Casewit, C. J., Colwell, K. S., and Rappe', A. K  
  JACS, 114, 10046-10053, 1992  
  Rappe', A. K. and Goddard, W. A., JPC, 95, 3358-3363, 1991  
  Rappe', A. K., Colwell, K. S., and Casewit, C. J  
  Inorg. Chem. 32, 3438-3450, 1993  
*************************************************************  
   Constructing Chemical System(s(  
   Memory for Main Chemical System  
   Memory Requirements (bytes(  
  *****************************  
   Core         62304  
   Scratch    24004560  
ParamCheck: not checking UFF params  
   Ignoring oop terms in .top file for UFF  
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   These will be made later, based on UFF atom types  
   System charge       0.000000  
   Making Bond List  
   Making Bond Angle List  
   Making Improper Torsion List  
   Making Groups Arrays  
   Making NonBonded Exclusion List  
   NB exclusion list 0 sec  
   Assigning NonBonded parameters to atoms  
   Making Initial NonBonded Lists  
   In BuildLists, print bonded lists  
Bonds  
  *****  
10  11)   C)-(C)     1.379256  
462.660461  
1  2)   N)-(C)     1.356681  
646.835551  
3  17)   C)-(O)     1.257535  
734.305767  
12  13)   C)-(C)     1.379256  
462.660461  
5  22)   C)-(O)     1.407689  
523.501065  
2  3)   C)-(C)     1.379256  
462.660461  
6  15)   C)-(C)     1.486000  
369.948258  
13  14)   C)-(C)     1.379256  
462.660461  
7  16)   C)-(C)     1.486000  
369.948258  
3  4)   C)-(C)     1.379256  
462.660461  
8  21)   C)-(O)     1.407689  
523.501065  
1  14)   N)-(C)     1.356681  
646.835551  
10  18)   C)-(O)     1.257535  
734.305767  
4  5)   C)-(C)     1.379256  
462.660461  
19  20)   O)-(C)     1.436155  
492.984516  
5  6)   C)-(C)     1.379256  
462.660461  
12  19)   C)-(O)     1.407689  
523.501065  
6  7)   C)-(C)     1.379256  
462.660461  
7  8)   C)-(C)     1.379256  
462.660461  
15  24)   C)-(C)     1.514000  
349.799987  
8  9)   C)-(C)     1.379256  
462.660461  
16  25)   C)-(C)     1.514000  
349.799987  
4  9)   C)-(C)     1.379256  
462.660461  
16  23)   C)-(O)     1.436155  
492.984516  
2  11)   C)-(C)     1.379256  
462.660461  
9  10)   C)-(C)     1.379256  
462.660461  
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11  12)   C)-(C)     1.379256  
462.660461  
24  25)   C)-(C)     1.514000  
349.799987  
26  28)   C)-(O)     1.283402  
690.794327  
26  27)   C)-(C)     1.514000  
349.799987  
24  26)   C)-(C)     1.514000  
349.799987  
24  29)   C)-(O)     1.436155  
492.984516  
31  36  ) C)-(N)     1.462929  
515.889778  
33  34)   C)-(O)     1.436155  
492.984516  
33  37)   C)-(C)     1.514000  
349.799987  
31  32)   C)-(C)     1.514000  
349.799987  
32  35)   C)-(O)     1.436155  
492.984516  
32  33)   C)-(C)     1.514000  
349.799987  
30  31)   C)-(C)     1.514000  
349.799987  
30  38)   C)-(C)     1.514000  
349.799987  
34  38)   O)-(C)     1.436155  
492.984516  
23  38)   O)-(C)     1.436155  
492.984516
  
Bond Angles  
***********  
11  10  18)  C)-(C)-(O) 120.000000 305.738360  
10  11  2)  C)-(C)-(C) 120.000000 222.595017  
11  10  9)  C)-(C)-(C) 120.000000 222.595017  
10  11  12)  C)-(C)-(C) 120.000000 222.595017  
1  2  3)  N)-(C)-(C) 120.000000 303.537949  
2  1  14)  C)-(N)-(C) 120.000000 233.893264  
1  2  11)  N)-(C)-(C) 120.000000 303.537949  
17  3  2)  O)-(C)-(C) 120.000000 305.738360  
17  3  4)  O)-(C)-(C) 120.000000 305.738360  
12  13  14)  C)-(C)-(C) 120.000000 222.595017  
13  12  19)  C)-(C)-(O) 120.000000 259.618978  
13  12  11)  C)-(C)-(C) 120.000000 222.595017  
22  5  4)  O)-(C)-(C) 120.000000 259.618978  
22  5  6)  O)-(C)-(C) 120.000000 259.618978  
2  3  4)  C)-(C)-(C) 120.000000 222.595017  
3  2  11)  C)-(C)-(C) 120.000000 222.595017  
15  6  5)  C)-(C)-(C) 120.000000 198.274298  
15  6  7)  C)-(C)-(C) 120.000000 198.274298  
6  15  24)  C)-(C)-(C) 109.470000 220.229931  
13  14  1)  C)-(C)-(N) 120.000000 303.537949  
16  7  6)  C)-(C)-(C) 120.000000 198.274298  
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16  7  8)  C)-(C)-(C) 120.000000 198.274298  
7  16  25)  C)-(C)-(C) 109.470000 220.229931  
7  16  23)  C)-(C)-(O) 109.470000 286.552527  
3  4  5)  C)-(C)-(C) 120.000000 222.595017  
3  4  9)  C)-(C)-(C) 120.000000 222.595017  
21  8  7)  O)-(C)-(C) 120.000000 259.618978  
21  8  9)  O)-(C)-(C) 120.000000 259.618978  
18  10  9)  O)-(C)-(C) 120.000000 305.738360  
4  5  6)  C)-(C)-(C) 120.000000 222.595017  
5  4  9)  C)-(C)-(C) 120.000000 222.595017  
20  19  12)  C)-(O)-(C) 104.510000 293.439812  
5  6  7)  C)-(C)-(C) 120.000000 222.595017  
19  12  11)  O)-(C)-(C) 120.000000 259.618978  
6  7  8)  C)-(C)-(C) 120.000000 222.595017  
7  8  9)  C)-(C)-(C) 120.000000 222.595017  
15  24  25)  C)-(C)-(C) 109.470000 214.211821  
15  24  26)  C)-(C)-(C) 109.470000 214.211821  
15  24  29)  C)-(C)-(O) 109.470000 278.259153  
8  9  4)  C)-(C)-(C) 120.000000 222.595017  
8  9  10)  C)-(C)-(C) 120.000000 222.595017  
25  16  23)  C)-(C)-(O) 109.470000 278.259153  
16  25  24)  C)-(C)-(C) 109.470000 214.211821  
4  9  10)  C)-(C)-(C) 120.000000 222.595017  
16  23  38)  C)-(O)-(C) 104.510000 284.864410  
2  11  12)  C)-(C)-(C) 120.000000 222.595017  
25  24  26)  C)-(C)-(C) 109.470000 214.211821  
25  24  29)  C)-(C)-(O) 109.470000 278.259153  
28  26  27)  O)-(C)-(C) 109.470000 322.667279  
28  26  24)  O)-(C)-(C) 109.470000 322.667279  
27  26  24)  C)-(C)-(C) 109.470000 214.211821  
26  24  29)  C)-(C)-(O) 109.470000 278.259153  
36  31  32)  N)-(C)-(C) 109.470000 299.774843  
36  31  30)  N)-(C)-(C) 109.470000 299.774843  
34  33  37)  O)-(C)-(C) 109.470000 278.259153  
34  33  32)  O)-(C)-(C) 109.470000 278.259153  
33  34  38)  C)-(O)-(C) 104.510000 284.864410  
37  33  32)  C)-(C)-(C) 109.470000 214.211821  
31  32  35)  C)-(C)-(O) 109.470000 278.259153  
31  32  33)  C)-(C)-(C) 109.470000 214.211821  
32  31  30)  C)-(C)-(C) 109.470000 214.211821  
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35  32  33)  O)-(C)-(C) 109.470000 278.259153  
31  30  38)  C)-(C)-(C) 109.470000 214.211821  
30  38  34)  C)-(C)-(O) 109.470000 278.259153  
30  38  23)  C)-(C)-(O) 109.470000 278.259153  
34  38  23)  O)-(C)-(O) 109.470000 363.159049  
  
 Dihedral Angles  
***************   
1 
term(s) in expansion  
2  11  10  18  
)C)-(C)-(C)-(O(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
12  11  10  18  
)C)-(C)-(C)-(O(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
9  10  11  2  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
10  11  2  1  
)C)-(C)-(C)-(N(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
10  11  2  3  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
12  11  10  9  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
11  10  9  8  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
11  10  9  4  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
10  11  12  13  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
10  11  12  19  
)C)-(C)-(C)-(O(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
14  1  2  3  
)C)-(N)-(C)-(C(  
                  13.474221 2  
180.000000  
1 term(s) in expansion  
1  2  3  17  
)N)-(C)-(C)-(O(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
1  2  3  4  
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)N)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
11  2  1  14  
)C)-(C)-(N)-(C(  
                  13.474221 2  
180.000000  
1 term(s) in expansion  
2  1  14  13  
)C)-(N)-(C)-(C(  
                  26.948442 2  
180.000000  
1 term(s) in expansion  
1  2  11  12  
)N)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
17  3  2  11  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
17  3  4  5  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
17  3  4  9  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
19  12  13  14  
)O)-(C)-(C)-(C(  
                  13.474221 2  
180.000000  
1 term(s) in expansion  
11  12  13  14  
)C)-(C)-(C)-(C(  
                  13.474221 2  
180.000000  
1 term(s) in expansion  
12  13  14  1  
)C)-(C)-(C)-(N(  
                  26.948442 2  
180.000000  
1 term(s) in expansion  
13  12  19  20  
)C)-(C)-(O)-(C(  
                   5.000000 2   
90.000000  
1 term(s) in expansion  
13  12  11  2  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
22  5  4  3  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
22  5  4  9  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
22  5  6  15  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
22  5  6  7  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
11  2  3  4  
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)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
2  3  4  5  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
2  3  4  9  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
3  2  11  12  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
24  15  6  5  
)C)-(C)-(C)-(C(  
                   1.000000 3  
180.000000  
1 term(s) in expansion  
15  6  5  4  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
24  15  6  7  
)C)-(C)-(C)-(C(  
                   1.000000 3  
180.000000  
1 term(s) in expansion  
15  6  7  16  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
15  6  7  8  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
6  15  24  25  
)C)-(C)-(C)-(C(  
                   0.706333 3  
180.000000  
1 term(s) in expansion  
6  15  24  26  
)C)-(C)-(C)-(C(  
                   0.706333 3  
180.000000  
1 term(s) in expansion  
6  15  24  29  
)C)-(C)-(C)-(O(  
                   0.706333 3  
180.000000  
1 term(s) in expansion  
25  16  7  6  
)C)-(C)-(C)-(C(  
                   0.500000 3  
180.000000  
1 term(s) in expansion  
23  16  7  6  
)O)-(C)-(C)-(C(  
                   0.500000 3  
180.000000  
1 term(s) in expansion  
16  7  6  5  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
25  16  7  8  
)C)-(C)-(C)-(C(  
                   0.500000 3  
180.000000  
1 term(s) in expansion  
23  16  7  8  
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)O)-(C)-(C)-(C(  
                   0.500000 3  
180.000000  
1 term(s) in expansion  
16  7  8  21  
)C)-(C)-(C)-(O(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
16  7  8  9  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
7  16  25  24  
)C)-(C)-(C)-(C(  
                   1.059500 3  
180.000000  
1 term(s) in expansion  
7  16  23  38  
)C)-(C)-(O)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
3  4  5  6  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
3  4  9  8  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
3  4  9  10  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
21  8  7  6  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
21  8  9  4  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
21  8  9  10  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
18  10  9  8  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
18  10  9  4  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
9  4  5  6  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
4  5  6  7  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
5  4  9  8  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
5  4  9  10  
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)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
  
1 term(s) in expansion  
20  19  12  11  
)C)-(O)-(C)-(C(  
                   5.000000 2   
90.000000  
1 term(s) in expansion  
5  6  7  8  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
19  12  11  2  
)O)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
6  7  8  9  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
7  8  9  4  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
7  8  9  10  
)C)-(C)-(C)-(C(  
                   6.737110 2  
180.000000  
1 term(s) in expansion  
15  24  25  16  
)C)-(C)-(C)-(C(  
                   0.706333 3  
180.000000  
1 term(s) in expansion  
15  24  26  28  
)C)-(C)-(C)-(O(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
15  24  26  27  
)C)-(C)-(C)-(C(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
24  25  16  23  
)C)-(C)-(C)-(O(  
                   1.059500 3  
180.000000  
1 term(s) in expansion  
25  16  23  38  
)C)-(C)-(O)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
16  25  24  26  
)C)-(C)-(C)-(C(  
                   0.706333 3  
180.000000  
  
1 term(s) in expansion  
16  25  24  29  
)C)-(C)-(C)-(O(  
                   0.706333 3  
180.000000  
1 term(s) in expansion  
16  23  38  30  
)C)-(O)-(C)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
16  23  38  34  
)C)-(O)-(C)-(O(  
                   0.097650 3  
180.000000  
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1 term(s) in expansion  
25  24  26  28  
)C)-(C)-(C)-(O(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
25  24  26  27  
)C)-(C)-(C)-(C(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
28  26  24  29  
)O)-(C)-(C)-(O(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
27  26  24  29  
)C)-(C)-(C)-(O(  
                   0.353167 3  
180.000000  
1 term(s) in expansion  
36  31  32  35  
)N)-(C)-(C)-(O(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
36  31  32  33  
)N)-(C)-(C)-(C(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
36  31  30  38  
)N)-(C)-(C)-(C(  
                   1.059500 3  
180.000000  
1 term(s) in expansion  
38  34  33  37  
)C)-(O)-(C)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
38  34  33  32  
)C)-(O)-(C)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
34  33  32  31  
)O)-(C)-(C)-(C(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
34  33  32  35  
)O)-(C)-(C)-(O(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
33  34  38  30  
)C)-(O)-(C)-(C(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
33  34  38  23  
)C)-(O)-(C)-(O(  
                   0.097650 3  
180.000000  
1 term(s) in expansion  
37  33  32  31  
)C)-(C)-(C)-(C(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
37  33  32  35  
)C)-(C)-(C)-(O(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
30  31  32  35  
)C)-(C)-(C)-(O(  
                   0.529750 3  
180.000000  
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1 term(s) in expansion  
30  31  32  33  
)C)-(C)-(C)-(C(  
                   0.529750 3  
180.000000  
1 term(s) in expansion  
32  31  30  38  
)C)-(C)-(C)-(C(  
                   1.059500 3  
180.000000  
1 term(s) in expansion  
31  30  38  34  
)C)-(C)-(C)-(O(  
                   1.059500 3  
180.000000  
1 term(s) in expansion  
31  30  38  23  
)C)-(C)-(C)-(O(  
                   1.059500 3  
180.000000  
 Improper Torsions  
************** *  
18  9  10  11  
)O)-(C)-(C)-(C(  
                  16.666667 0    
0.000000  
2  12  11  10  
)C)-(C)-(C)-(C(  
                   2.000000 0    0.000000  
3  11  2  1  
)C)-(C)-(C)-(N(  
                   2.000000 0    0.000000  
2  4  3  17  
)C)-(C)-(C)-(O(  
                  16.666667 0    
0.000000  
19  11  12  13  
)O)-(C)-(C)-(C(  
                   2.000000 0    0.000000  
4  6  5  22  
)C)-(C)-(C)-(O(  
                   2.000000 0    0.000000  
5  7  6  15  
)C)-(C)-(C)-(C(  
                   2.000000 0    0.000000  
6  8  7  16  
)C)-(C)-(C)-(C(  
                   2.000000 0    0.000000  
5  9  4  3  
)C)-(C)-(C)-(C(  
                   2.000000 0    0.000000  
7  9  8  21  
)C)-(C)-(C)-(O(  
                   2.000000 0    0.000000  
4  10  9  8  
)C)-(C)-(C)-(C(  
                   2.000000 0    0.000000 
   Bonded Topology  
   --------------  
   Bonds                    42  
   Bond Angles              66  
   Dihedral Angles          96  
   Imp. Torsions            11  
   NB Exclusion List        108  
   Initial NB List          595  
   Groups used in NB list   4  
 *****Initial Energy Evaluation*****   
  Energy Components (au(  
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  **********************  
  MM Bond                               0.01437513  
  MM Angle                              0.00789353  
  MM Dihedral                           0.00516130  
  MM ImpTor                             0.00006780  
  MM vdW                                0.08217335  
  MM Coulomb                            0.00000000  
  ------------------------------------------------  
  Total                                 0.10967110 au  
  Total                                68.81971855 kcal/mol  
  
Energy Eval elapsed time 0 sec.  
 *****Geometry Optimization*****   
Checkpointing coordinate to C:\Documents and 
Settings\XPPRESP3\Desktop\args\dau1.cor  
Geometry Search using BFGS update  
Cycle   Energy(au)   delE (au)     Grad Norm   |Max Grad(i)|    alpha  
*************************************************************  
start     0.109671    0.0000e+000     0.001776     0.000459  
1       0.109670   -1.2208e-006     0.001663     0.000424   4.0000e-001  
2       0.109664   -6.0976e-006     0.001140     0.000355   4.0000e-001  
3       0.109661   -2.8333e-006     0.000866     0.000351   4.0000e-001  
4       0.109659   -1.6436e-006     0.000848     0.000345   4.0000e-001  
5       0.109658   -1.2729e-006     0.000893     0.000339   4.0000e-001  
6       0.109657   -1.3101e-006     0.000964     0.000330   4.0000e-001  
7       0.109655   -1.5547e-006     0.001036     0.000317   4.0000e-001  
8       0.109653   -1.8214e-006     0.001078     0.000299   4.0000e-001  
9       0.109651   -1.9688e-006     0.001075     0.000316   4.0000e-001  
10       0.109649   -1.9470e-006     0.001039     0.000344   4.0000e-001  
11       0.109648   -1.8040e-006     0.000981     0.000343   4.0000e-001  
12       0.109646   -1.6401e-006     0.000944     0.000316   4.0000e-001  
13       0.109644   -1.5502e-006     0.000942     0.000268   4.0000e-001  
14       0.109643   -1.5788e-006     0.000981     0.000273   4.0000e-001  
15       0.109641   -1.7232e-006     0.001049     0.000315   4.0000e-001  
16       0.109639   -1.9527e-006     0.001128     0.000340   4.0000e-001  
17       0.109637   -2.2120e-006     0.001193     0.000349   4.0000e-001  
18       0.109635   -2.4232e-006     0.001228     0.000406   4.0000e-001  
19       0.109632   -2.5137e-006     0.001218     0.000431   4.0000e-001  
20       0.109630   -2.4578e-006     0.001174     0.000422   4.0000e-001  
21       0.109627   -2.2946e-006     0.001114     0.000385   4.0000e-001  
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22       0.109625   -2.0993e-006     0.001063     0.000387   4.0000e-001  
23       0.109623   -1.9399e-006     0.001035     0.000361   4.0000e-001  
24       0.109621   -1.8520e-006     0.001034     0.000313   4.0000e-001  
25       0.109620   -1.8388e-006     0.001050     0.000282   4.0000e-001  
26       0.109618   -1.8809e-006     0.001072     0.000315   4.0000e-001  
27       0.109616   -1.9466e-006     0.001087     0.000376   4.0000e-001  
28       0.109614   -2.0047e-006     0.001092     0.000411   4.0000e-001  
29       0.109612   -2.0371e-006     0.001087     0.000419   4.0000e-001  
30       0.109610   -2.0474e-006     0.001081     0.000395   4.0000e-001  
31       0.109608   -2.0564e-006     0.001085     0.000345   4.0000e-001  
32       0.109605   -2.0901e-006     0.001105     0.000345   4.0000e-001  
33       0.109603   -2.1658e-006     0.001140     0.000344   4.0000e-001  
34       0.109601   -2.2846e-006     0.001184     0.000373   4.0000e-001  
35       0.109599   -2.4290e-006     0.001226     0.000426   4.0000e-001  
36       0.109596   -2.5683e-006     0.001256     0.000470   4.0000e-001  
37       0.109593   -2.6707e-006     0.001267     0.000480   4.0000e-001  
38       0.109591   -2.7196e-006     0.001263     0.000455   4.0000e-001  
39       0.109588   -2.7220e-006     0.001251     0.000397   4.0000e-001  
40       0.109585   -2.7023e-006     0.001242     0.000375   4.0000e-001  
41       0.109583   -2.6863e-006     0.001244     0.000360   4.0000e-001  
42       0.109580   -2.6837e-006     0.001254     0.000346   4.0000e-001  
43       0.109577   -2.6805e-006     0.001261     0.000435   4.0000e-001  
44       0.109575   -2.6414e-006     0.001253     0.000485   4.0000e-001  
45       0.109572   -2.5269e-006     0.001215     0.000487   4.0000e-001  
46       0.109570   -2.3176e-006     0.001144     0.000442   4.0000e-001  
47       0.109568   -2.0330e-006     0.001051     0.000359   4.0000e-001  
48       0.109566   -1.7248e-006     0.000952     0.000273   4.0000e-001  
49       0.109564   -1.4505e-006     0.000869     0.000275   4.0000e-001  
50       0.109563   -1.2485e-006     0.000815     0.000265   4.0000e-001  
51       0.109562   -1.1304e-006     0.000792     0.000230   4.0000e-001  
52       0.109561   -1.0883e-006     0.000797     0.000236   4.0000e-001  
53       0.109560   -1.1028e-006     0.000816     0.000246   4.0000e-001  
54       0.109559   -1.1470e-006     0.000837     0.000277   4.0000e-001  
55       0.109558   -1.1898e-006     0.000849     0.000291   4.0000e-001  
56       0.109556   -1.2039e-006     0.000844     0.000274   4.0000e-001  
57       0.109555   -1.1761e-006     0.000821     0.000226   4.0000e-001  
58       0.109554   -1.1126e-006     0.000789     0.000239   4.0000e-001  
59       0.109553   -1.0336e-006     0.000756     0.000258   4.0000e-001  
60       0.109552   -9.6104e-007     0.000731     0.000257   4.0000e-001  
61       0.109551   -9.0967e-007     0.000719     0.000235   4.0000e-001  
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62       0.109550   -8.8448e-007     0.000718     0.000197   4.0000e-001  
63       0.109549   -8.8296e-007     0.000724     0.000231   4.0000e-001  
64       0.109549   -8.9889e-007     0.000734     0.000268   4.0000e-001  
65       0.109548   -9.2609e-007     0.000744     0.000282   4.0000e-001  
66       0.109547   -9.6156e-007     0.000757     0.000272   4.0000e-001  
67       0.109546   -1.0071e-006     0.000775     0.000239   4.0000e-001  
68       0.109545   -1.0686e-006     0.000801     0.000185   4.0000e-001  
69       0.109543   -1.1537e-006     0.000838     0.000203   4.0000e-001  
70       0.109542   -1.2684e-006     0.000887     0.000222   4.0000e-001  
71       0.109541   -1.4142e-006     0.000944     0.000221   4.0000e-001  
72       0.109539   -1.5863e-006     0.001004     0.000236   4.0000e-001  
73       0.109537   -1.7737e-006     0.001061     0.000261   4.0000e-001  
74       0.109535   -1.9632e-006     0.001109     0.000278   4.0000e-001  
75       0.109533   -2.1462e-006     0.001151     0.000304   4.0000e-001  
76       0.109531   -2.3247e-006     0.001190     0.000299   4.0000e-001  
77       0.109528   -2.5117e-006     0.001233     0.000292   4.0000e-001  
78       0.109526   -2.7243e-006     0.001287     0.000336   4.0000e-001  
79       0.109523   -2.9731e-006     0.001352     0.000381   4.0000e-001  
80       0.109519   -3.2508e-006     0.001422     0.000401   4.0000e-001  
81       0.109516   -3.5265e-006     0.001485     0.000390   4.0000e-001  
82       0.109512   -3.7508e-006     0.001527     0.000348   4.0000e-001  
83       0.109508   -3.8758e-006     0.001537     0.000398   4.0000e-001  
84       0.109504   -3.8833e-006     0.001518     0.000431   4.0000e-001  
85       0.109501   -3.8033e-006     0.001481     0.000421   4.0000e-001  
86       0.109497   -3.7050e-006     0.001450     0.000369   4.0000e-001  
87       0.109493   -3.6665e-006     0.001444     0.000350   4.0000e-001  
88       0.109490   -3.7458e-006     0.001476     0.000367   4.0000e-001  
89       0.109486   -3.9600e-006     0.001542     0.000364   4.0000e-001  
90       0.109481   -4.2718e-006     0.001623     0.000360   4.0000e-001  
91       0.109477   -4.5781e-006     0.001689     0.000399   4.0000e-001  
92       0.109472   -4.7254e-006     0.001703     0.000456   4.0000e-001  
93       0.109467   -4.5773e-006     0.001645     0.000518   4.0000e-001  
94       0.109463   -4.1113e-006     0.001517     0.000525   4.0000e-001  
95       0.109460   -3.4546e-006     0.001354     0.000481   4.0000e-001  
96       0.109457   -2.8084e-006     0.001202     0.000398   4.0000e-001  
97       0.109455   -2.3370e-006     0.001104     0.000302   4.0000e-001  
98       0.109453   -2.1241e-006     0.001086     0.000285   4.0000e-001  
99       0.109450   -2.2083e-006     0.001159     0.000301   4.0000e-001  
100       0.109448   -2.6421e-006     0.001325     0.000421   4.0000e-001  
  <<<Geometry optimization did not converge>>>  
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Maximum cycles reached, optimization terminated  
  ****************Final Geometry****************   
N   -4.95975425    2.90082692   -0.69092370      7  
C   -3.89487943    2.13339835   -0.28584145      6  
C   -2.59392466    2.60685500   -0.48449151      6  
C   -1.47695134    1.83021217   -0.09427204      6  
C   -0.15356728    2.30062488   -0.27953041      6  
C    0.94298572    1.50841162    0.07737947      6  
C    0.74294865    0.23710343    0.64694307      6  
C   -0.56127364   -0.23417628    0.85876181      6  
C   -1.68665342    0.55130017    0.49501431      6  
C   -3.01275490    0.08499800    0.69973428      6  
C   -4.12074457    0.87627513    0.31799631      6  
C   -5.46521553    0.45624066    0.50744926      6  
C   -6.51861479    1.26272146    0.06634912      6  
C   -6.25268481    2.48846027   -0.53027961      6  
C    2.32463721    2.09799290   -0.04939793      6  
C    1.91186593   -0.67208208    0.96053929      6  
O   -2.43985288    3.73713418   -1.02381805      8  
O   -3.20853943   -1.04628825    1.22148080      8  
O   -5.78324319   -0.79186664    1.09542847      8  
C   -5.97876486   -0.52735881    2.49909271      6  
O   -0.72583435   -1.51218902    1.43920453      8  
O    0.09322443    3.58248133   -0.82315506      8  
O    1.99316651   -1.72131620   -0.02639709      8  
C    3.43696695    1.05222006   -0.11772747      6  
C    3.24704358    0.07570954    1.04620950      6  
C    4.80044222    1.74919376    0.01076512      6  
C    5.95490524    0.76051192   -0.06559313      6  
O    4.94734457    2.63903647   -0.90680277      8  
O    3.36502261    0.35421026   -1.37803530      8  
C    1.24197504   -3.88179308    0.86709510      6  
C    0.83066007   -4.45489995   -0.48579299      6  
C    2.03771700   -5.04163236   -1.21523399      6  
C    3.12135491   -3.96389378   -1.29665806      6  
O    3.53684361   -3.54523064    0.03211789      8  
O    2.53385519   -6.20018568   -0.51473508      8  
N   -0.20724394   -5.47194370   -0.30585511      7  
C    4.31976639   -4.46506914   -2.07967440      6  
C    2.40821942   -2.90410289    0.69302112      6  
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  Final Geom Energy =    0.1094477039 au  
  Final Geom Energy =         68.6795 kcal/mol  
  Geometry Optimization elapsed time 1 sec.   
 *****Final Energy Evaluation*****   
  Energy Components (au(  
  **********************  
  MM Bond                              0.01416670  
  MM Angle                             0.00801326  
  MM Dihedral                          0.00523232  
  MM ImpTor                            0.00005457  
  MM vdW                               0.08198085  
  MM Coulomb                           0.00000000  
  ------------------------------------------------  
  Total                                0.10944770 a.u.  
  Total                               68.67953307 kcal/mol  
 *****Properties*****   
      Ground state properties  
  *****************************   
   Properties elapsed time 0 sec   
  Total Elapsed Time 1 sec 
 
 
 
 
 
Appendix 10 AM 1 Semi-empirical Quantum Mechanical Calculations 
                          for 1-N-Aza-daunorubicin     
*************************************************************  
*****  ***Validated Experiment & Chemical System Settings**********    
Calculation started:  Fri Jan 25 12:51:17 2008  
Title:  
C:\Documents and Settings\XPPRESP3\mohamed osman\N1DAU  
System Type               Quantum Mechanical  
Hamiltonian               AM1 (NDDO(  
SCF Type                  UHF  
Run Type                  SCF  
Atoms                     38  
Electrons                 174  
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Alpha                   87  
Beta                    87  
  
Multiplicity              1  
Water Model               SPCE  
Coordinates               angstroms  
Basis set                 Minimal Valence Basis as STO 6G  
Max. SCF cycles           200  
SCF convergence           1.5936e-013 au. for energy  
  
AM1 param file            C:\Program Files\ArgusLab\params\am1.prm  
SCF saved every           1000 cycles  
  
Two-electron integrals  
buffer size             1000  
storage                 random list in core  
  
Property integrals        one center  
Dipole integrals          length operator  
  
Input Atomic Information  
************************  
  
1   N   -6.746444   3.413104  -
1.462128  
2   C   -6.025898   2.384604  -
0.939311  
3   C   -4.650563   2.631046  -
0.476450  
4   C   -3.828871   1.520400   
0.078290  
5   C   -2.493787   1.735771   
0.489325  
6   C   -1.725360   0.682511   
1.003891  
7   C   -2.289160  -0.599583   
1.130742  
8   C   -3.612445  -0.825079   
0.722849  
9   C   -4.395574   0.228818   
0.197441  
10   C   -5.807715   0.000963  -
0.229770  
11   C   -6.596751   1.102190  -
0.839991  
12   C   -7.916128   0.915403  -
1.319366  
13   C   -8.625361   2.003303  -
1.837171  
14   C   -8.017857   3.253290  -
1.903286  
15   O   -4.183933   3.798913  -
0.562132  
16   O   -6.343634  -1.126714  -
0.058571  
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17   O   -8.560640  -0.342858  -
1.251351  
18   C   -8.299091  -0.987496  -
2.513990  
19   O   -1.908182   3.017856   
0.388142  
20   O   -4.146324  -2.127898   
0.843207  
21   C   -0.333348   0.978904   
1.477457  
22   C   -1.486295  -1.758382   
1.644179  
23   O   -1.001988  -2.537586   
0.537810  
24   C    0.475365  -0.290713   
1.607479  
25   C   -0.312598  -1.263582   
2.454618  
26   C    1.808130   0.043000   
2.275338  
27   C    2.756649  -1.146120   
2.293216  
28   O    2.365288   1.027521   
1.667593  
29   O    0.687155  -0.853392   
0.299439  
30   C   -0.887833  -3.870732   
1.059820  
31   O   -2.155093  -4.508905   
0.998188  
32   C    0.116515  -4.656307   
0.219918  
33   C   -0.443600  -4.874479  -
1.186944  
34   C   -1.805712  -5.577000  -
1.137901  
35   C   -2.757306  -4.754051  -
0.264038  
36   O   -1.658408  -6.909665  -
0.606348  
37   C   -4.090451  -5.455763  -
0.082407  
38   N    0.503743  -5.654104  -
1.986315  
  
Cite ArgusLab as: 
*****************  
ArgusLab 4.0  
Mark A. Thompson  
Planaria Software LLC, Seattle, WA.  
http://www.arguslab.com  
Journal Citations for this Calculation  
**************************************  
Thompson, M. A., Zerner M. C.  
J. Am. Chem. Soc., 113, 8210, (1991(  
Mark A. Thompson, Eric D. Glendening,  
and David Feller J. Phys. Chem. 98,  
10465-10476 ,)1994(  
Mark A. Thompson, and Gregory K. Schenter  
J. Phys. Chem. 99, 6374-6386, (1995(  
Mark A. Thompson, J. Phys. Chem. 100,  
14492-14507 ,)1996(  
 168
  
AM1 reference:s 
***************  
Michael J. S. Dewar, Eve G. Zoebisch  
Eamonn F. Healy, and James J. P. Stewart  
JACS, 107, 3902-3909, (1985(  
*************************************************************  
Constructing Chemical System(s(  
Basis Set  
***********  
basis functions : 152  
shells          : 76  
primitives      : 456  
Memory for Main Chemical System  
Max. number 2-ele. ints. = 70908  
Memory Requirements (bytes(  
*****************************  
                                    Core   3434672  
Scratch      376960  
System charge                          0.000000 
 *****Integrals*****   
AM1 two-center two-electron integrals  
MNDO-type Two-electron integrals: elapsed time 0 sec.  
elapsed time 0 sec.  
Coulomb integrals for semi-empirical  
elapsed time 0 sec.  
One-center exchange integrals for semi-empirical  
elapsed time 0 sec.  
Total number of 2-ele integrals 70901  
Dipole length integrals  
elapsed time 0 sec.  
Integrals elapsed time 0 sec 
 
 *****SCF*****   
Core repulsion    1668.93 au  
Calculating one electron matrix 
Diagonalizing starting one-ele. matrix  
Performing SCF  
  
Cycle        Energy (au)          Difference  
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**********************************************  
1        -                                   30.586048  
2          1.913171571               32.4992  
3         59.541621349               57.6284  
4         74.123760932               14.5821  
5         92.696718838                18.573  
6        113.403950778               20.7072  
7         94.018878643              -19.3851  
8        119.432349398               25.4135  
9        100.468484959              -18.9639  
10        121.793940614               21.3255  
11        101.986751464              -19.8072  
12        125.817657225               23.8309  
13        104.923198669              -20.8945  
14        128.839167858                23.916  
15        123.627255529              -5.21191  
16        131.855068142               8.22781  
17        152.968506219               21.1134  
18        156.262502292                 3.294  
19        228.266866946               72.0044  
20        202.592054749              -25.6748  
21        229.457632886               26.8656  
22        208.297690734              -21.1599  
23        229.317422248               21.0197  
24        208.301385663               -21.016  
25        229.317312878               21.0159  
26        208.301388742              -21.0159  
27        229.317312773               21.0159  
28        208.301388745              -21.0159  
29        229.317312773               21.0159  
30        208.301388745              -21.0159  
31        229.317312773               21.0159  
32        208.301388745              -21.0159  
33        229.317312773               21.0159  
34        208.301388745              -21.0159  
35        229.317312773               21.0159  
36        208.301388745              -21.0159  
37        229.317312773               21.0159  
38        208.301388745              -21.0159  
39        229.317312773               21.0159  
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40        208.301388745              -21.0159  
41        229.317312773               21.0159  
42        208.301388745              -21.0159  
43        229.317312773               21.0159  
44        208.301388745              -21.0159  
45        229.317312773               21.0159  
46        208.301388745              -21.0159  
47        229.317312773               21.0159  
48        208.301388745              -21.0159  
49        229.317312773               21.0159  
50        208.301388745              -21.0159  
51        229.317312773               21.0159  
52        208.301388745              -21.0159  
53        229.317312773               21.0159  
54        208.301388745              -21.0159  
55        229.317312773               21.0159  
56        208.301388745              -21.0159  
57        229.317312773               21.0159  
58        208.301388745              -21.0159  
59        229.317312773               21.0159  
60        208.301388745              -21.0159  
61        229.317312773               21.0159  
62        208.301388745              -21.0159  
63        229.317312773               21.0159  
64        208.301388745              -21.0159  
65        229.317312773               21.0159  
66        208.301388745              -21.0159  
67        229.317312773               21.0159  
68        208.301388745              -21.0159  
69        229.317312773               21.0159  
70        208.301388745              -21.0159  
71        229.317312773               21.0159  
72        208.301388745              -21.0159  
73        229.317312773               21.0159  
74        208.301388745              -21.0159  
75        229.317312773               21.0159  
76        208.301388745              -21.0159  
77        229.317312773               21.0159  
78        208.301388745              -21.0159  
79        229.317312773               21.0159  
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80        208.301388745              -21.0159  
81        229.317312773               21.0159  
82        208.301388745              -21.0159  
83        229.317312773               21.0159  
84        208.301388745              -21.0159  
85        229.317312773               21.0159  
86        208.301388745              -21.0159  
87        229.317312773               21.0159  
88        208.301388745              -21.0159  
89        229.317312773               21.0159  
90        208.301388745              -21.0159  
91        229.317312773               21.0159  
92        208.301388745              -21.0159  
93        229.317312773               21.0159  
94        208.301388745              -21.0159  
95        229.317312773               21.0159  
96        208.301388745              -21.0159  
97        229.317312773               21.0159  
98        208.301388745              -21.0159  
99        229.317312773               21.0159  
100        208.301388745              -21.0159  
101        229.317312773               21.0159  
102        208.301388745              -21.0159  
103        229.317312773               21.0159  
104        208.301388745              -21.0159  
105        229.317312773               21.0159  
106        208.301388745              -21.0159  
107        229.317312773               21.0159  
108        208.301388745              -21.0159  
109        229.317312773               21.0159  
110        208.301388745              -21.0159  
111        229.317312773               21.0159  
112        208.301388745              -21.0159  
113        229.317312773               21.0159  
114        208.301388745              -21.0159  
115        229.317312773               21.0159  
116        208.301388745              -21.0159  
117        229.317312773               21.0159  
118        208.301388745              -21.0159  
119        229.317312773               21.0159  
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120        208.301388745              -21.0159  
121        229.317312773               21.0159  
122        208.301388745              -21.0159  
123        229.317312773               21.0159  
124        208.301388745              -21.0159  
125        229.317312773               21.0159  
126        208.301388745              -21.0159  
127        229.317312773               21.0159  
128        208.301388745              -21.0159  
129        229.317312773               21.0159  
130        208.301388745              -21.0159  
131        229.317312773               21.0159  
132        208.301388745              -21.0159  
133        229.317312773               21.0159  
134        208.301388745              -21.0159  
135        229.317312773               21.0159  
136        208.301388745              -21.0159  
137        229.317312773               21.0159  
138        208.301388745              -21.0159  
139        229.317312773               21.0159  
140        208.301388745              -21.0159  
141        229.317312773               21.0159  
142        208.301388745              -21.0159  
143        229.317312773               21.0159  
144        208.301388745              -21.0159  
145        229.317312773               21.0159  
146        208.301388745              -21.0159  
147        229.317312773               21.0159  
148        208.301388745              -21.0159  
149        229.317312773               21.0159  
150        208.301388745              -21.0159  
151        229.317312773               21.0159  
152        208.301388745              -21.0159  
153        229.317312773               21.0159  
154        208.301388745              -21.0159  
155        229.317312773               21.0159  
156        208.301388745              -21.0159  
157        229.317312773               21.0159  
158        208.301388745              -21.0159  
159        229.317312773               21.0159  
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160        208.301388745              -21.0159  
161        229.317312773               21.0159  
162        208.301388745              -21.0159  
163        229.317312773               21.0159  
164        208.301388745              -21.0159  
165        229.317312773               21.0159  
166        208.301388745              -21.0159  
167        229.317312773               21.0159  
168        208.301388745              -21.0159  
169        229.317312773               21.0159  
170        208.301388745              -21.0159  
171        229.317312773               21.0159  
172        208.301388745              -21.0159  
173        229.317312773               21.0159  
174        208.301388745              -21.0159  
175        229.317312773               21.0159  
176        208.301388745              -21.0159  
177        229.317312773               21.0159  
178        208.301388745              -21.0159  
179        229.317312773               21.0159  
180        208.301388745              -21.0159  
181        229.317312773               21.0159  
182        208.301388745              -21.0159  
183        229.317312773               21.0159  
184        208.301388745              -21.0159  
185        229.317312773               21.0159  
186        208.301388745              -21.0159  
187        229.317312773               21.0159  
188        208.301388745              -21.0159  
189        229.317312773               21.0159  
190        208.301388745              -21.0159  
191        229.317312773               21.0159  
192        208.301388745              -21.0159  
193        229.317312773               21.0159  
194        208.301388745              -21.0159  
195        229.317312773               21.0159  
196        208.301388745              -21.0159  
197        229.317312773               21.0159  
198        208.301388745              -21.0159  
199        229.317312773               21.0159  
 174
200        208.301388745              -21.0159  
  
Maximum number of iterations reached: SCF NOT CONVERGE  
 
Writing final SCF to disk  
Final SCF Energy =  208.3013887455 au  
Final SCF Energy =     130711.2128 kcal/mol  
Saving the final SCF to the restart file C:\Documents and 
Settings\XPPRESP3\mohamed osman\N1DAU.restartscf  
 
SCF elapsed time 1 min. 43 sec.  
  
 *****Properties*****   
Ground state properties  
*****************************  
 *****Heat of Formation*****   
290640.1800 kcal/mol  
Atomic spin densities  
**********************  
1    N    0.0000  
2    C    0.0000  
3    C    0.0000  
4    C    0.0000  
5    C    0.0000  
6    C    0.0000  
7    C    0.0000  
8    C    0.0000  
9    C    0.0000  
10    C    0.0000  
11    C    0.0000  
12    C    0.0000  
13    C    0.0000  
14    C    0.0000  
15    O    0.0000  
16    O    0.0000  
17    O    0.0000  
18    C    0.0000  
19    O    0.0000  
20    O    0.0000  
21    C    0.0000  
22    C    0.0000  
23    O    0.0000  
24    C    0.0000  
25    C    0.0000  
26    C    0.0000  
27    C    0.0000  
28    O    0.0000  
29    O    0.0000  
30    C    0.0000  
31    O    0.0000  
32    C    0.0000  
33    C    0.0000  
34    C    0.0000  
35    C    0.0000  
36    O    0.0000  
37    C    0.0000  
38    N    0.0000  
S2 operator  
***********  
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exact                 0.000000  
calculated           -0.000000  
Ground State Dipole (debye(  
X             Y             Z          length  
1700.72851501  -1335.11569063  348.14693931  2190.02686753  
Properties elapsed time 0 sec.  
  
Total Elapsed Time 1 min. 43  
